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ABSTRACT OF THE DISSERTATION 
SAB CONCENTRATION DETERMINES THE CHEMOTHERAPEUTIC EFFICACY 
IN GYNECOLOGICAL CANCER 
by 
Iru Paudel 
Florida International University, 2018 
Miami, Florida 
Professor Jeremy W. Chambers, Major Professor 
 
The American Cancer Society predicts there will be 110,070 new cases and 32,120 deaths 
due to gynecological malignancies in 2018. A major contributing factor to the high 
mortality associated with gynecological cancers is the recurrence of treatment-resistant 
tumors. Ovarian cancer (OC) remains the most lethal gynecological malignancy, yet the 
mechanisms responsible for regulating tumor resistance and vulnerability are largely 
unknown or undruggable. Therefore, the goal of this research is to identify mechanisms 
responsible for therapeutic resistance in gynecological cancers and discover innovative 
approaches to circumvent these molecular alterations. Our efforts began in OC where 
secondary analysis of gene expression data from OC studies revealed that Sab, an outer 
mitochondrial membrane (OMM) scaffold protein, was down-regulated in OC tumors 
compared to normal tissue controls. Our previous studies demonstrate that Sab-mediated 
OMM signaling induces cell death in cervical cancer.  In the current study, we found that 
Sab concentrations corresponded to chemoresponsiveness in a panel of OC cells; wherein, 
OC cells with low Sab levels were chemoresistant. Dynamic BH3 profiling revealed that 
 vii 
cells with high Sab expression were primed for apoptosis. Furthermore, over-expression of 
Sab in chemoresistant cells enhanced apoptotic priming and restored cellular vulnerability 
to cisplatin/paclitaxel treatment. Additionally, an examination of treatment-resistant 
metastatic uterine cancer (UC) cells were found to have low Sab concentrations compared 
to vulnerable primary site-derived UC cells. Ectopic expression of Sab in chemoresistant 
UC cells enhanced the susceptibility towards megestrol acetate and BH3-mimetic ABT-
737.  To exploit the relationship between Sab concentrations and chemo-responsiveness in 
gynecological cancer cells, we developed a high-throughput screening assay to detect Sab 
levels in chemo-resistant OC cells. In collaboration with the Torrey Pines Institute for 
molecular studies, we have identified compounds that can increase Sab levels in resistant 
OC cells. The identified compounds improved the effectiveness of cisplatin/paclitaxel 
therapy. We propose that Sab may be a prognostic marker to discern personalized 
treatments for gynecological cancer patients. Furthermore, pharmacologically enhancing 
Sab-mediated signaling may increase the efficacy of chemotherapeutic agents, which 
would mean lower doses that would limit toxic side-effects. 
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Chapter 1 
 
LITERATURE REVIEW
 2 
 
Gynecological cancer 
Five different types of cancer arise within the reproductive organs of women are termed 
together as gynecological cancer. These include cervical, ovarian, uterine, vaginal and 
vulval cancers. Each gynecological malignancy is uniquely characterized by different 
diagnostic signatures, symptoms, and pathogenesis (CDC). The projected statistics for 
gynecological cancer for 2018 is enlisted in table 1.1 [1]. Ovarian cancer is the most lethal 
gynecological malignancy [2], and we will focus mostly on it. 
1. Ovarian Cancer 
1.1. OC Statistics: Ovarian cancer (OC) is the gynecological malignancy with the greatest 
mortality. OC accounts for approximately 4% of all cancer in the women and is the seventh 
most common cancer worldwide [2]. In the United States, according to American Cancer 
Society (ACS), the estimated number of new cases of OC in 2017 was 22,440, and the 
estimated number of deaths was 14,080. The overall five-year survival rate for OC is 46.5% 
(2007-2013). In a woman’s lifetime, the risk of developing an invasive form of OC is 1 in 
79, and the resulting risk of death is 1 in 109 [2]. These statistics demonstrate gravity 
associated with OC and the demand for better treatment. 
Table 1.1: Gynecological cancer statistics  
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1.2. Clinical Stages of OC: For effective treatment, OC is divided into different stages based 
on how far it has spread and what organs are affected in patients. It is called the FIGO 
(Federation of Gynecological Oncologists) system.  
A. Stage 1: The cancer is confined to the ovaries (primary site tumors). 
B. Stage 2: Cancerous cells have gone beyond ovaries, it has spread to the pelvis 
and sometimes even to the abdomen. 
C. Stage 3: Cancer has crossed the pelvis and spread to the abdominal cavity 
D. Stage 4: Cancer has spread to distant organs like liver and lungs. 
The staging may also be classified as local (referred as stage 1 and confined to primary 
sites), regional (spread to regional lymph nodes), distant (cancer has metastasized) and 
unknown. Approximately,14.8% of OC are diagnosed at the local stage, and the five-year 
survival for these patients is 92.5%. However, 60% of women in the United States are 
diagnosed with late-stage OC. More than half of the patients diagnosed with late-stage OC 
will relapse within 18 months after initial therapy [3]. 
1.3. Types of OC: OC is classified into three types based on the etiology of the malignancy: 
epithelial ovarian cancer (EOC), germline ovarian cancer and stromal cell ovarian cancer 
[4]. EOC is the most common and highly heterogeneous form of ovarian cancer [4]. 
Histologically EOC can be further divided into different subtypes; the four most common 
includes Serous, Endometroid, Mucinous and Clear Cell carcinoma [5]. Histological 
classification of OC is based on the tumor cell origin and morphology [6]. 
1.3.1. Serous ovarian carcinoma (SOC):  Serous carcinomas are considered to develop from 
ovarian surface epithelium or inclusion cysts [7]. SOC comprise most ovarian carcinomas 
and are further classified into low-grade and high-grade. Low-grade carcinomas are less 
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common than high-grade. The high grade and low-grade carcinomas are characterized by 
different underlying pathogeneses, molecular events, behavior and prognosis [8]. These 
two are distinguished based on morphology, the degree of nuclear atypia (abnormal 
appearance of cell nuclei), and the amount of mitotic activity. Low-grade serous 
carcinomas have mild to moderate nuclear atypia with less than 12 mitoses per 10 high-
power field images. High-grade have, in contrast, nuclear atypia greater than 12 mitoses 
per 10 high-power field images [8]. In both grades of serous carcinomas, diverse cellular 
architectural patterns, such as nested, papillary, glandular, cribriform, solid and single can 
be present. Laminated psammoma bodies are usually present in both tumor types [8]. 
1.3.2.Mucinous ovarian carcinomas (MOC): These are the less common type of ovarian 
carcinomas, only 5-10% of EOC [9]. Mucinous carcinomas are of so-called intestinal or 
enteric subtype with cystic unilocular neoplasm with a thin space wall and filled with 
watery mucinous fluid. MOCs are confined to the ovary at diagnosis. They have solid and 
necrotic areas which histologically may be borderline or malignant  [10]. MOCs have the 
worst prognosis and poor response to chemotherapy compared to other subtypes [11]. 
1.3.3.Endometroid ovarian carcinoma: Endometroid carcinomas have been reported to 
develop from endometriotic tissues [12]. Endometroid carcinomas are commonly 
characterized by an epithelium composed of single layer of large polygonal cells with 
abundant eosinophils and large hyperchromatic, smudged nuclei [10,12]. Advanced 
endometroid carcinoma normally responds to platinum-taxane combination treatment. 
However, the relapse rate is high with poor prognosis [13]. 
1.2.4.Clear cell carcinoma: This is a rare epithelial ovarian carcinoma which makes less 
than 10% of EOC [10,12]. They are characterized by a clear peg-shaped cell with abundant 
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cytoplasm. The cells can be observed either alone or in combination [10]. Clear cell 
carcinomas are usually chemoresistant malignancies with a poor prognosis [14]. 
1.4. Common OC features: Cancers cells are typified by the occurrence of ten traits, 
which are termed hallmarks of cancer. OC hallmarks include the capabilities for sustaining 
proliferative signaling, resisting cell death, evading growth suppressors, activating 
invasion and metastasis, enabling replicative immortality, inducing angiogenesis, avoiding 
immune destruction, tumor-promoting inflammation, genome instability, and mutation and 
deregulating cellular energetics [15]. These features allow cancer cells to survive, 
proliferate, and disseminate. In addition to these hallmarks, tumors have other 
characteristics like evading immune destruction, the presence of genomic instability and 
mutation, and reprogramming of energy metabolism. Somatic mutations in the ovarian 
tumors, which can activate downstream pathways; for example, mutations in the BRAF 
proto-oncogene can engage mitogen-activated protein kinase (MAPK) signaling pathways. 
Alterations in MAPK pathways are observed during cancer progression. Inhibition of the 
c-Jun N-terminal Kinase (JNK)-induced apoptotic death is one of the mechanisms 
developed during OC [16]. Tumors have a complex environmental dynamics including the 
presence of heterogeneous cell populations. This includes the cells that make up the tumor 
and those in the surrounding tumor microenvironment, wherein both areas play a 
significant role in tumor development and progression. Normal cells, including immune 
cells, may contribute to tumorigenesis by providing various growth factors to tumors [15]. 
The cell types and tumor microenvironment are crucial to the development and outcomes 
of individual tumors including tumor size and therapeutic resistance. 
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The hallmarks of cancer are present in OC, and these hallmarks represent potential, enticing 
targets for OC drug discovery. Metastasis is one crucial hallmark, which accounts for the 
high morbidity and mortality by OC because the spread of the tumor beyond ovaries 
increases the difficulty of treating cancer [17]. There are two prevailing reasons behind the 
absence of an effective treatment for OC: late diagnosis and resistance to available 
therapeutic approaches [3]. Complicating the difficulties in treating OC is the fact that the 
origins and pathogeneses of OCs are poorly understood.  There are numerous treatment 
options available for the attempted management of OC; however, each one has its benefits 
and drawbacks. For example, radiation targets specifically the cancer cells; however, it 
damages the DNA of cells instead of killing cells while chemotherapy is given to entire 
body and kills cancer as well as other dividing cells. The most prominent problem with OC 
treatment is its relapse or recurrence because of the return of the disease following 
treatment is typified by the presence of highly resistant tumor cells. One important cause 
of characteristic of these resistant cells is their ability to withstand a variety of cell death 
mechanisms. The heterogeneous cell population and absence of a prevailing cell death 
pathway are evidence of the urgent need for novel and aggressive therapies for OC [17]. 
1.5. OC chemotherapy mechanisms of action and the involvement of JNK signaling 
The standard of care for OC patients is the combination of surgery and radio/chemotherapy 
[18]. Surgery removes the local tumor mass (or those that are visible) [19], and surgery 
may be followed by a chemotherapeutic regimen comprised of a platinum-based 
compound, such as cisplatin, and a taxane, like paclitaxel [17]. Based on individual 
responses to chemotherapy, OC patients are classified into platinum-sensitive (recurs after 
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six months of treatment), platinum-resistant (recurs within six months after treatment) and 
platinum-refractory (recurs during treatment) [17].  
Platinum compounds, like cisplatin and carboplatin, form active species by aqueous 
hydrolysis(i.e., these compounds react with water and form reactive species). These species 
can interact with DNA, RNA, and proteins. Most of the cytotoxic effects of platinum 
compounds result from the formation of DNA inter-stand and intra-stand crosslinks 
because these disturb DNA replication. Consequently, the cell engages repair processes 
such as nucleotide-excision repair (NER) and mismatch repair (MMR) [20]. NER solely 
repairs the damage, whereas MMR can induce apoptosis in addition to repair. It has been 
observed that in response to cisplatin, MMR-related signaling pathways; specifically, c-
Abl protein tyrosine kinase and JNK are activated. In the cells lacking MMR, both 
signaling pathways are not initiated [21]. This evidence suggests that JNK is involved in 
cisplatin-induced cell death. Further studies reveal that sustained activation of JNK 
pathway by cisplatin occurs in the OC cell line 2008, while in its cisplatin-resistant clone 
2008c13 did not display JNK activation [22]. This suggests that a failure to robustly induce 
apoptotic signaling may be a contributing factor to platinum resistance in OC. 
Taxols act by binding to -tubulin of microtubules causing microtubule stabilization, 
leading to cell cycle arrest (specifically arresting cells at G2-M) and ultimately apoptosis 
[23]. Paclitaxel regulates MAPK signaling and promotes phosphorylation of Bcl-2 and 
dephosphorylation of Bad triggering apoptosis [24] Additional research suggests that 
paclitaxel promotes apoptosis in OC cells. Woo et al., demonstrate that JNK activity 
contributes to paclitaxel-induced apoptosis [25]. Further, the Ras-related nuclear protein 
(Ran) impairs JNK-mediated phosphorylation in U373MG cells preventing the 
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phosphorylation of downstream pro-apoptotic Bcl-2 proteins and induction of apoptosis 
[25]. Additionally,  Lee and colleagues show that JNK is phosphorylated after paclitaxel 
exposure in a dose-dependent manner before cell death [26]. These studies collectively 
fundamentally implicate JNK in chemotherapy-induced apoptosis in OC cells. 
2. Uterine/Endometrial Cancer 
Uterine or endometrial cancer is the fourth most common cancer in the United States. 
Endometrial cancer is the most commonly diagnosed gynecological malignancy. ACS 
estimates 63,230 new cases and 11,350 death from the cancer of uterine body in 2018. The 
5-year survival for uterine cancer is 82% [1]. It is the sixth most common cause of cancer 
death among women in the USA [2]. The most common treatment approach for 
endometrial cancer is surgery [27], and it has been found to be effective for tumors confined 
to the uterus [28]. However, surgery alone cannot treat advanced or recurrent endometrial 
cancer. A combination of radiotherapy with platinum-based chemotherapy is employed for 
progression-free survival in endometrial cancer [29]. 
3. Cervical Cancer 
Cervical cancer is caused by the development of cancer in the uterine cervix. ACS 
estimates 13,240 new cases and 4,170 deaths from the cancer of the cervix in 2018. 
Cervical cancer is the second leading cause of cancer death in women aged 20 to 39 years 
[1]. The prognosis of the cervical cancer patient with an advanced or metastatic 
malignancies is poor. A common form of treatment is surgery followed by cisplatin or 
carboplatin. Cisplatin-paclitaxel combination may be an improved chemotherapeutic 
modality for advanced cervical cancer [30]. Bevacizumab is a humanized vascular 
endothelial growth factor (VEGF)- neutralizing antibody, and the addition of bevacizumab 
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to combination chemotherapy increases disease-free survival in cases of advanced or 
metastasized cervical cancer [31]. 
4. c-Jun N-terminal kinase (JNK) 
Mitogen-activated protein kinases (MAPKs) are critical modulators of numerous cellular 
processes, namely proliferation, differentiation and apoptosis [32]. JNK is a member of the 
MAPK superfamily and is an effector kinase. JNK has a profound impact on cellular 
viability, as it is a critical regulator of apoptosis. JNK is a serine/threonine (Ser/Thr) protein 
kinase that modulates cell survival pathways by targeting transcription factors and other 
non-nuclear substrates [32-34]. JNK activation and function is regulated by phosphorelay 
cascade (Figure 1.1). JNK activation occurs in response to both extracellular and 
intracellular stimuli, which may influence JNK function in a cell and stress-dependent 
manner by activating specific MKKKs. These MAPKKKs, in turn, activate two MAPKKs, 
MKK7 and MKK4.  MKK7 and MKK4 phosphorylate JNK on threonine 183 (Thr183) and 
tyrosine 185 (Tyr185) of the activation loop respectively [32,34]. Although 
phosphorylation of both sites is required for full activation, it is suggested that Thr183 is 
the critical residue and Tyr185 gives fine tuning in TNF-α induced JNK activation [35]. 
Active JNK then phosphorylates downstream substrates, such as c-Jun, ATF-2, c-Myc, 
p53, and Bcl-2 proteins; this protein alteration determines the biological outcomes of 
specific stimuli [32,33,36].  
The role of JNK in apoptosis is well-established [32,37], and JNK-mediated apoptosis has 
been observed in numbers of stresses including anisomycin, dexamethasone, phorbol ester, 
acetaminophen-induced liver injury, DNA damaging agents, paclitaxel and in disease 
models of cardiac stress, cerebral ischemia, and aging [26,38-44]. JNK-mediated apoptosis 
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was first identified in rat PC-12 pheochromocytoma cells following nerve growth factor 
(NGF) withdrawal. This apoptotic cell death was suppressed by inhibition of JNK pathway 
by using dominant negative form of the JNK substrate c-jun.  
 
Figure 1.1: JNK phosphorylation and activation occurs in response to the activation of 
upstream kinases, MKK and MKKK. In response to different signals, the upstream kinase 
MKKK gets phosphorylated, which phosphorylates MKK7 and MKK4. MKK7/4 activation causes 
the phosphorylation of JNK.  JNK activation can lead to nuclear-JNK or mitochondrial-JNK 
signaling depending on the signal and cell type. 
 
Further, constitutively active mitogen-activated protein kinase kinase kinase 1 (MEKK1) 
induced apoptosis, implicating JNK as a pro-apoptotic kinase [45]. Additionally, genetic 
ablation of JNK prevents apoptosis as well. Hippocampal neurons in JNK3-/- mice were 
resistant to kainic acid-induced apoptosis [46]. Suppression of cell death in response to 
ultra-violet light and anisomycin in JNK1-/- JNK2-/- and MKK4-/- MKK7-/- mouse embryonic 
fibroblasts (MEFs) also demonstrate the significance of JNK in apoptosis [35,47]. It was 
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shown that the absence of JNK prevented the release of cytochrome c from the 
mitochondria, in JNK1-/- JNK2-/- MEF following UV exposure; while cytochrome c release 
was observed in WT-MEF (wild-type). Again demonstrating JNK as an important 
component of the mitochondria-mediated apoptosis [47]. Recently, the interaction of JNK 
with mitochondrial scaffold protein Sab (or SH3-binding protein 5 – SH3BP5)  during 
stress was revealed to have a significant impact on apoptosis; the association of JNK with 
Sab promotes JNK-mediated phosphorylation of anti-apoptotic protein Bcl-2 on Ser-70. 
JNK phosphorylation of Bcl-2 leads to emigration of the protein from the outer 
mitochondrial membrane (OMM) ultimately promoting apoptosis [48]. 
Despite an abundance of data implicating JNK in apoptosis, other studies suggest JNK 
signaling may have pro-survival functions. JNK can facilitate IL-3-mediated survival of 
hematopoietic pro-B FL5.12 cells [49]. JNK generates this survival response by 
phosphorylating and inactivating pro-apoptotic protein Bad at Thr-201; inhibition of JNK 
caused an increase in IL-3 withdrawal-induced apoptosis. Meanwhile, expression of a 
constitutively active MEKK1 suppressed cell death [49]. Sabapathy et al., have shown both 
the pro-apoptotic and anti-apoptotic role of JNK in the development of fetal brain using 
JNK1-/- JNK2-/- double knockout fetuses. JNK1 and JNK2 positively regulate apoptosis in 
hindbrain region at E9.25 (embryonic day); whereas, there was a decrease in apoptosis in 
the double-knockout animals. The overall effect of the double-knockout is defective neural 
morphogenesis and defective neural tube closure [50]. Inhibition of cell proliferation and 
inhibition of cell cycle progression was observed in cultured KB-3 human cells with JNK 
inhibitor (SP600125), and JNK-specific anti-sense oligonucleotides, supported the role of 
JNK in cellular proliferation [51]. Thus, JNK activity can be a pro-apoptotic and a pro-
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survival kinase, depending on the stress, physiologic conditions, localization, and 
potentially the activity of distinct JNK isoforms. 
The involvement of mitochondrial JNK signaling in improving the chemotherapeutic 
efficacy in gynecological cancer was observed following low-dose sub-chronic 
administration of LY294002 in HeLa cells (cervical cancer) [52]. The prolonged exposure 
of HeLa cells to LY294002 increases phospho-JNK (active kinase) on the mitochondria of 
HeLa cells [52]. Blocking the accumulation of JNK on mitochondria was found to reduce 
the sensitivity of HeLa cells towards common chemotherapeutic agents [52]. 
Mitochondrial JNK also regulates mitochondria-mediated intrinsic apoptosis by regulating 
Bcl-2 family of proteins [53]. These studies demonstrate that mitochondrial JNK may be a 
crucial driver of apoptosis in cancer cells.  
5. Bcl-2 superfamily of proteins 
B-cell lymphoma-2 (Bcl-2) family of proteins includes both pro-survival and pro-apoptotic 
proteins with a profound impact on cell death and survival. This family of proteins has four 
domains BH1, BH2, BH3 and BH4; and subfamilies are identified by the specific domains 
that are present within the proteins (Figure 1.2). Anti-apoptotic or pro-survival Bcl-2 
proteins have all four BH domains and include, Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bcl-B, Bfl-
1/A1. Pro-apoptotic Bcl-2 proteins are further divided into pro-apoptotic BH3 only proteins 
and multi-domain proteins. BH3 only pro-apoptotic proteins include Bid, Bad, Bim, Bmf, 
Bik, Hrk/DP5, Blk, Nip3, BNip3/Nix, Puma, Noxa. These proteins assist the executor 
proteins in apoptosis and sequester anti-apoptotic proteins (Figure 1.3). Bid and Bim act as 
major ‘direct activators’ which are responsible for the induction of activation of Bax and 
Bak via their BH3 domain whereas Bad and Puma are also called sensitizers or de-
 13 
repressors, because of their ability to bind anti-apoptotic protein [54,55]. Multi-domain 
proteins have BH1, BH2, and BH3 domains. These are executor apoptotic proteins and are 
also called effectors, which include Bax, Bak, and lesser known protein Bok [56,57]. 
Bax and Bak’s oligomerization leads to MOMP (mitochondrial outer membrane 
permeabilization), pore formation and release of cytochrome c and other factors into the 
cytoplasm. This ultimately starts the cell death process by activating apoptotic protease 
activating factor-1 (APAF-1) which further stimulates caspases [58]. 
  
 
Figure 1.2: Bcl-2 family of proteins with specific domains. Anti-apoptotic proteins have all four 
domains (BH1, BH2, BH3 and BH4), whereas BH-3 only pro-apoptotic have BH3 domain, and 
effector proteins have three domains (BH1, BH2, and BH3). 
 
5.1. Interaction between Bcl-2 proteins 
Bcl-2 family is classified into two groups, folded globular and intrinsically unstructured 
proteins (IUPs). Globular proteins, which include antiapoptotic and effector protein, share 
a core structure of the protein called ‘Bcl-2 core’. The first study of the structure of these 
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proteins was done in Bcl-xL, which is a 20KD globular protein, using NMR based 
spectroscopy and X-ray crystallography[59]. Three-dimensional structure of ‘Bcl-2 core’ 
contains seven or eight amphipathic alpha helices, surrounding central helix, α5 and α6. 
Both helices are highly hydrophobic and are flanked by α3 and α4 on one side and α1 and 
α2 on the other. This hydrophobic groove is termed as BC groove. The BH4 (conserved α1 
positioned along α6) domain stabilizes BH1-BH3 regions. BC groove and α1/α6 makes up 
the ‘Bcl-2 core’[60,61].  
The hydrophobic groove is the interaction site of anti-apoptotic proteins and BH3 domain 
of both the effector and BH3 only proteins, which was first observed between Bcl-xL and 
Bak. This interaction was detected by co-immunoprecipitation and two-hybrid interaction 
in the yeast; which was supported by NMR spectroscopy between Bcl-xL/Bak peptide 
complexes. Heterodimerization was observed, which was because of electrostatic and 
hydrophobic interaction between these two proteins [56]. Mutation on BH3 domain led to 
the termination of this interaction which suggests that there is conserved amino acid in the 
BH3 domain. 
The BH3 domain consists of between 9 and 16 amino acids, of which seven were found to 
by core amino acids by phylogenetic studies. The sequence is LXXXXGDE, where X is 
any amino acid [62]. Recently, a 13-residue consensus motif has been proposed based on 
structural studies and sequence analysis. The consensus motif is 
Ф1ΣXXФ2XXФ3Σ’DZФ4г; where Ф represents a hydrophobic residue (Ф2 is often 
leucine), Σ is a small residue (G, A, S), Z is usually an acidic residue and г is a hydrophilic 
residue [63]. The most conserved residues are leucine and aspartic acid residues which 
have an important role in interaction with the anti-apoptotic protein. The leucine residue is 
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buried in the protein-protein interface and packs against the conserved residue of anti-
apoptotic protein whereas aspartate forms ionic interaction with conserved arginine in the 
BH1 domain of pro-survival protein [56,64]. Other binding interactions like Vander Waals, 
hydrophobic and hydrophilic interaction play equally important role [63]. 
As different BH3 proteins have diverse amino acids in their BH3 domains, this could be 
affecting their binding preference for anti-apoptotic proteins. In vitro analysis was 
performed using recombinant anti-apoptotic proteins and synthetic BH3 peptides of the 
BH3 only protein to determine the binding specificity of this BH3 only proteins. This 
revealed that there is preference shown by BH3 domains for binding anti-apoptotic proteins 
[65]. Among eight BH3 peptides, BIM and Puma had the affinity for all the anti-apoptotic 
Bcl-2 proteins whereas others were specific. It could be said that the observed selectivity 
was relying on the BH3 motif; any mutational change could change the specificity easily 
[66]. 
  5.2. Bax activation 
While there are many BH3-only proteins having the ability to bind to anti-apoptotic 
proteins, only few can bind to effector pro-apoptotic proteins. Activators BH3 proteins, 
Bim and Bid, can induce oligomerization of Bax and Bak, OMMP formation and 
cytochrome c release [67]. 
Bid also has the affinity for anti-apoptotic Bcl-2 and Bcl-xL. There are two different 
theories for activation of Bax by Bid. Bid can either directly activate full-length Bax or t-
Bid, a cleaved form of Bid activates Bax differently. t-Bid has been described as the direct 
activator of Bax. However, the exact mechanism of Bax activation was not clear. Bid can 
be cleaved by caspase 8 forming t-Bid, which is unable to interact with full-length Bax or 
 16 
Bcl-xL in solution [68]. Following cleavage, N-terminus Bid (N-Bid) remains attached 
with C-terminus Bid (C-Bid), forming BH3 domain. In the presence of lipid bilayer; 
mimicking OMM, C-Bid inserts into the membrane, while the N-Bid remains in the 
solution.  Once in the membrane, it can recruit Bax into the membrane, which was shown 
by fluorescence resonance energy transfer (FRET) [68]. This emphasizes the importance 
of lipid membrane for Bax activation. tBID also can cause an allosteric conformational 
change of Bak followed by its homo-oligomerization and the release of cytochrome c [69].   
To understand the mechanism of Bax activation by Bid, the α-helix of Bid was stabilized 
by a chemical modification called ‘hydrocarbon stapling’ [70]. The C terminal α-helix 9 of 
Bax is embedded into the hydrophobic groove, making it problematic for BH3 protein 
binding; as this is the site where BH3 domain binds to the anti-apoptotic protein [71]. With 
the modification of BH3 Bid helix, it could bind to the groove by displacing intramolecular 
Bax α-helix. This led to the conformational change of Bax and cytochrome c release was 
observed in both in vitro and in vivo experiments. A similar result was observed with the 
modification of Bim peptide. However, modified Bad BH3 didn’t show any ability to bind 
Bax [70]. According to the NMR studies, Bax interaction with Bim causes the 
conformational change in α-helix 1 & 2, from closed to an open conformation which causes 
the release of α-helix 9 hydrophobic grooves exposing the groove for BH3 binding [72].  
5.3. Bcl-2 proteins: The individual member of the Bcl-2 family will be discussed further 
below.  
5.3.1. Bcl-2: B-cell lymphoma-2 (Bcl-2) is a 26kD anti-apoptotic protein. Bcl-2 is a 
membrane-associated protein embedded in the endoplasmic reticulum, the nuclear 
envelope, and the outer mitochondrial membrane [73]. Bcl-2 can be modified by several 
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kinases and phosphatases, and these modifications play significant roles in cellular 
survival/death [36].  
 
 
Figure 1.3: BH3 only proteins have multiple roles. They can neutralize the pro-survival proteins 
causing the release of Bax and Bak or directly activate effector proteins by a conformational change 
of Bax and Bak. Both events lead to the translocation of Bax to OMM, oligomerization with 
mitochondria located Bak, which eventually causes OMM permeabilization, the release of 
cytochrome c and initiation of apoptosis.  
 
The microtubule damaging agent, paclitaxel induces phosphorylation of Bcl-2 in 
unstructured loop regions where residues Ser70, Ser87, and Thr69 were phosphorylated in 
Jurkat-Bcl-2 cells [36]. This is further supported by other observations where deletion of 
Bcl-2 loop regions completely blocked paclitaxel-induced apoptosis [74,75]. Mutations of 
these sites enhance the anti-apoptotic function of Bcl-2 [36]. Ser-70 is the principal site of 
phosphorylation of Bcl-2 during various stress conditions, including paclitaxel, vinblastine, 
and anisomycin [48,76,77]. This phosphorylation was found to be mediated by JNK [36]. 
Ser-70 phosphorylation suppresses the pro-survival function of Bcl-2, and mutation in this 
site improves the anti-apoptotic function of Bcl-2 indicating the importance of this site in 
Bcl-2 function [36]. In contrast, same site phosphorylation could lead to inhibition of cell 
death pathway. JNK-mediated Ser-70 phosphorylation was found to enhance cell survival 
during various stress conditions including IL-3 withdrawal and a low dose of okadaic 
treatment in murine wild-type [78].  
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With the treatment of paclitaxel, the active form of JNK (Phospho-Thr-Tyr) and 
phosphorylated Bcl-2 (Ser-70) were found in the mitochondria of HeLa (cervical cancer) 
and MCF-7 (breast cancer) cells. This was also observed in cell-free mitochondria when 
treated with cytosolic activated JNK, which was extracted from HeLa cell treated with 
paclitaxel. Preincubation of a cytosolic extract from paclitaxel-treated HeLa cells with 
CEP11004, a proposed JNK inhibitor, did not show any phosphorylation of Bcl-2 [79]. 
Conversely, Park et al. have shown the regulation of JNK1 activity by Bcl-2 protein. 
Apoptosis is activated in N18TG neuroglioma cells in response to various apoptotic 
stresses. However, in N18TG cells expressing Bcl-2 (N18 cells transfected with Bcl-2) 
were resistant to etoposide, staurosporine, anisomycin, and UV mediated cell death. It was 
found that Bcl-2 inhibits the activation of MEKK1, the upstream activator of JNK signaling 
pathway [80]. Expression of JNK1 in N18/ Bcl-2 cells neutralized or counteracted the anti-
apoptotic effect of Bcl-2; making N18/Bcl-2 cells as sensitive as the control cells [80]. Bcl-
2 was also shown to inhibit the activation of JNK in response to nerve growth factor 
withdrawal in PC12 cells [81]. These observations suggest that JNK1 and Bcl-2 protein 
can regulate each other depending on the cellular context. 
5.3.2. Bcl-xL: B-cell lymphoma extra-large (Bcl-xL) is an anti-apoptotic transmembrane 
protein present in the mitochondria. Bcl-xL is a 20kD globular protein and was the first 
protein of the family in which structural detail was studied [82]. Bcl-xL can inhibit the 
formation of OMMP and release of cytochrome c. Even though many cell lines express 
both Bcl-2 and Bcl-xL, an inverse association in the expression pattern of these two 
proteins have been found in thirty-four cell lines derived from colon, breast, ovary, central 
nervous system, and renal cancers [83].  
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Petros and colleagues have suggested that the characteristic feature of Bcl-xL and Bcl-2 to 
heterodimerize with Bax, Bak, and other BH3 only proteins keeps the apoptotic balance of 
the cells [84]. Letai and colleagues proposed that the antiapoptotic protein binds to the BH3 
domain of activator protein and sequesters them before they could activate Bax and Bak 
[85]. 
In response to ionizing radiation, Kharbanda et al. have shown the translocation of JNK to 
mitochondria in U-937 (lymphoma) cells, using fluorescence image analyzer, microscopy, 
and immunoblotting. At mitochondria, JNK was found to interact with Bcl-xL, which was 
shown by a co-localization assay.  JNK phosphorylates Bcl-xL on Threonine-47 (Thr-47) 
and Threonine 115 (Thr-115) in U-937 cells [86]. Further, the effect of tetradecanoyl 
phorbol-13-acetate (TPA) on JNK and Bcl-xL was studied on U-937 cells, where no 
significant effect of Bcl-xL was found on the JNK translocation to mitochondria; however, 
TPA-induced the interaction of JNK and Bcl-xL. Overexpression of Bcl-xL mutated at 
sites of JNK phosphorylation (T47A and T115A) caused a substantial decrease in the 
release of cytochrome c and apoptosis compared to the overexpression of normal Bcl-xL; 
signifying the importance of these two sites in Bcl-xL function [40]. JNK was also found 
to phosphorylate Bcl-xL in 293T cells [86]. JNK mediated phosphorylation in Ser-62, 
within the unstructured loop region of Bcl-xL was observed in response to taxol or 2-
methoxyestradiol in DU145 human prostate cancer cells [87]. 
Phosphorylation of Bcl-2 and Bcl-xL by JNK has been observed in KB-3 sarcoma cells 
following treatment with vinblastine. When JNK-1 and JNK-2 expression were inhibited 
using antisense oligonucleotides, there was a decrease in the phosphorylation of Bcl-2 by 
85% and Bcl-xl by 65% [76]. Similarly, Du et al. have shown phosphorylation of Bcl-2 
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and Bcl-xL with the treatment of vinblastine in KB-3 carcinomas. Even though the 
phosphorylation of both proteins was shown to be dependent on the same kinase, they were 
not able to identify the kinase responsible. They showed that there was no effect in 
phosphorylation event with the use of JNK, ERK and CDK inhibitors [88]. Taken together, 
JNK has a significant role in post-translational modification of pro-survival proteins Bcl-2 
and Bcl-xL resulting in different outcomes. 
5.3.3. Mcl-1: Myeloid cell leukemia-1 (Mcl-1) is a 40kD pro-survival Bcl-2 protein, 
expressed in many cell types [61]. Mcl-1 is regulated at the transcriptional, translational 
and post-translational level [89,90]. Mcl-1 has an important role in proliferating cells and 
early embryonic development [91]. Mcl-1 contributes to pro-survival function by 
inhibiting the formation of OMMP and release of cytochrome c, which is done either by 
inactivating Bax and Bak or sequestering the BH3 only activator protein Bim [61].  
Mcl-1 is regulated by phosphorylation at various sites. Enhancement of the antiapoptotic 
function of Mcl-1 occurs when it is phosphorylated at Ser-64 in a cell-cycle-dependent 
manner by CDK1, CDK2, and JNK1. Instead of affecting the Mcl-1 turnover, Ser-64 
phosphorylation enhances the binding of Mcl-1 to pro-apoptotic Bcl-2 protein. The 
requirement of Ser64 phosphorylation of Mcl-1 in TNF-related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis was shown in KMCH cholangiocarcinoma cell by silencing 
endogenous Mcl-1 and transfecting with S64A, S64E and wild-type Mcl-1. Cells with 
silenced Mcl-1 and S64A were quite sensitive to TRAIL while S64E, which mimics 
phosphorylation, and wild-type were resistant [92].  
JNK facilitates the UV-mediated degradation of Mcl-1. In wild-type fibroblasts, there was 
a significant decrease of Mcl-1 while there was no change in JNK1-/-, JNK2-/- fibroblasts. 
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This degradation of Mcl-1 occurs via the GSK-3 mediated proteasomal pathway. JNK 
phosphorylates Mcl-1 at Thr-163 and primes Mcl-1 for GSK3 phosphorylation. GSK3 
phosphorylates Mcl-1 at Ser-159 leading to its ubiquitination and degradation [90]. Mcl-1 
half-life and turn-over rate are regulated by the proteasomal degradation pathway [93,94]. 
Phosphorylation of Ser-121 and Thr-163 in Mcl-1 by JNK has shown opposing effects in 
two different cell lines. In hepatocytes, it stabilizes Mcl-1 whereas, in endothelial cells, it 
causes a reduction in the anti-apoptotic effect of Mcl-1 mediated by oxidative damage 
[61,95,96]. JNK signaling pathway is involved in phosphorylation of Mcl-1, which could 
enhance its pro-survival function or inhibit its pro-survival function and initiate the 
degradation of the protein. 
5.3.4. Bim/ Bmf: Bcl-2 interacting mediator of cell death (Bim) and the closely related 
Bim-related molecule (Bmf) are BH3-only pro-apoptotic proteins that are normally 
sequestered by binding to motor complexes. Transcriptional and post-translational 
regulation plays an important role in their apoptotic activity [58]. Bim exists in three 
isoforms produced as a result of alternative splicing; BimS (short isoform), BimL (long 
isoform) and BimEL (extra-long isoform) [97]. BimL and BimEL are present in normal 
cells while BimS is transiently present in cells undergoing apoptosis. The presence of short 
peptide motif (DKSTQTP) in BimL and BimEL mediates their binding to Dynein motor 
complex via dynein light chain (DLC1); whereas, BimS doesn’t have this motif and can 
potently show apoptotic activity [98]. Bmf also contains a similar motif (DKATQTLSP) 
that binds to DLC2, a component of the myosin V motor complex [98]. 
The apoptotic activity of Bim is sequestered by binding of this protein to DLC1 of dynein 
motor complex under normal condition. However, with the exposure to UV radiation, Bim 
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gets detached from the DLC1 and is activated because of the phosphorylation caused by 
JNK at Ser-44, Thr-56, and Ser-58 [58]. JNK mediated phosphorylation of Bim was 
observed both in vivo and in vitro. Exposure to UV caused an increase in phosphorylation 
of BimL in cells labeled with 32Pphosphate [58]. It was also observed that Thr-56 
phosphorylation inhibits the binding of BimL to DLC1 and increases apoptotic activity 
[58]. TRAIL facilitated JNK mediated phosphorylation of Bim and caused Fas-induced 
liver damage. JNK and Bim deficient thymocytes were protected against TRAIL-mediated 
Fas-induced damage [99]. 
Bim is involved in neuronal apoptosis under trophic factor withdrawal. Induction of Bim 
is considered a hallmark of neuronal apoptosis. Potassium withdrawal in cerebral granule 
neurons caused a five-fold increase in mRNA levels of Bim. However, with the use of 
CEP-1347, the mRNA level of these BH3-only proteins were not increased to that level 
even in the absence of potassium. CEP-1347 is a mixed lineage kinase inhibitor which 
blocks c-Jun phosphorylation and inhibits activation under trophic factor withdrawal. The 
mRNA level of Bim was upregulated by 2.8 folds. This shows that inhibiting JNK pathway 
reduces the induction of Bim mRNA by ~55%. A similar trend was observed in 
sympathetic neurons during nerve growth factor (NGF) deprivation [100]. However, 
Putcha et al. have shown that JNK is not required for BIM induction in NGF-deprived 
superior cervical ganglions. They observed that JNK signaling pathway activation is not 
required for NGF-deprivation induced Bim-EL expression in sympathetic neurons. They 
suggest two pathways for apoptotic cell death of NGF deprived neurons; one caused by 
activation of JNK pathway and another by induction of Bim and Dp5 BH3 only proteins. 
Both of them act upstream of Bax activation, so both of these pathways are required for 
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NGF deprived neuronal apoptosis which acts in parallel [101]. Activation of JNK pathway 
is required for, but not sufficient for, Bim-mediated death in NGF deprived neuronal 
apoptosis. 
Bmf, which is a related protein to Bim is also regulated by JNK, and the phosphorylation 
site is the same (Thr56 and Ser58) as Bim, which is conserved in Bmf. Bmf is detached 
from DLC2 when phosphorylated by JNK. JNK deficient and Bim deficient thymocytes 
show a similar deficiency in apoptosis [58]. 
5.3.5. DP5/Hrk: Death protein 5/ harakiri (DP5, Hrk) is a BH3 only apoptotic protein 
involved mostly in neuronal apoptosis [102,103]. DP5 was originally identified in rat 
sympathetic neurons, during screening for genes induced after nerve growth factor (NGF) 
withdrawal [104]. Hrk is a human DP5 homolog, which interacts specifically with Bcl-2 
and Bcl-xL [105]. Harris et al. have shown DP5 induced neuronal apoptosis to be Bax 
dependent [100]. Thus, it can be suggested that like other BH3 only protein, Hrk promotes 
apoptosis either by neutralizing anti-apoptotic proteins or activating Bax.  
The DP5 gene is transcriptionally regulated by JNK. This is mediated via phosphorylation 
of c-Jun by JNK. It was observed that DP5/Hrk was upregulated with potassium 
deprivation in cerebellar granule neurons (CGNs) [102]. DIV7 cells were cultured in 
25mM or 5mM KCl containing media for different times. The increase in phospho-JNK 
was observed followed by phospho-c-Jun which was further followed by an increase in 
DP5 in the cells grown in 5mM KCl. Inhibition of JNK using SP600125 resulted in a 
decrease in DP5 by 62%, showing that the JNK pathway is involved in transcription 
regulation of DP5 under potassium deprivation [102]. Polyglutamine- repeat expansion in 
the androgen receptor (PolyQ-AR) induces neurotoxicity which results in 
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neurodegeneration and apoptosis in various disorders. This apoptotic cell death was found 
to be mediated by Hrk, regulated by JNK via c-Jun [106]. 
JNK is also involved in Hrk manipulation during ceramide-mediated mitochondrial 
dysfunction, as evident by the release of cytochrome c and a decrease in OMMP in human 
corneal stromal fibroblasts (HCSF) [107]. JNK plays a significant role in neuronal 
apoptosis by regulation of Bim/Bmf and DP5/Hrk proteins. 
5.3.6. PUMA: The p53-upregulated modulator of apoptosis (PUMA), identified as a target 
of p53 is a pro-apoptotic member of the Bcl-2 family of proteins [108]. It is localized to 
mitochondria with a hydrophobic groove on its C-terminal domain [108,109]. PUMA binds 
to anti-apoptotic proteins via the BH3 domain and activates the induction of apoptosis 
[108]. PUMA is transcriptionally regulated mostly by p53 (tumor suppressor gene); there 
are few observations showing regulation of PUMA by JNK. 
Palmitate-induced PUMA expression was found to be JNK-dependent. In Huh-7 
(hepatocarcinoma) cells treated with palmitate, an increase in JNK phosphorylation and 
PUMA mRNA leading to lipoapoptosis was observed. Whereas, SP600125 caused 
significant decrease in JNK phosphorylation and 70% decrease in PUMA mRNA and 
protein level even with the treatment of palmitate [110]. PUMA was found to be involved 
in apoptosis of cerebral granule neurons under potassium withdrawal. JNK was involved 
in the induction of PUMA mRNA and increase in PUMA protein. A decrease in PUMA 
protein was observed with the use of SP600125 [111].  
5.3.7. Bad: Bcl-2 associated death promoter (Bad) is a pro-apoptotic protein involved in 
initiating the apoptotic pathway. Once activated, it can form a heterodimer with anti-
apoptotic proteins (Bcl-2 and Bcl-xL) and prevent them from inhibiting apoptosis [54,112]. 
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Phosphorylation at different sites determines the activity of Bad. Phosphorylation of Bad 
at Ser-136 or Ser-112 or both by survival factors causes the binding and sequestration of 
the 14-3-3 protein, whereas phosphorylation at Ser-128 on 14-3-3 promotes the release of 
Bad [113-115]. 
In contrast, JNK is found to be inhibiting apoptosis by phosphorylation of pro-apoptotic 
protein Bad in IL-3 mediated hematopoietic cells (FL5.12) [49,116]. Unphosphorylated 
Bad heterodimerizes with Bcl-xL at a non-membrane site causing inactivation of this 
antiapoptotic protein. Whereas phosphorylated Bad binds to 14-3-3, causing the 
sequestration of Bad in the cytosol in hematopoietic pro-B FL5.12 cells [113]. IL-3 
mediated phosphorylation of Bad by JNK occurs at the Thr-201 residue. This 
phosphorylation was found to reduce the association of Bad with Bcl-xL. The importance 
of the Thr-201 residue of Bad in JNK mediated cell survival was shown by the generation 
of a mutant, which under IL-3 withdrawal could show higher apoptotic activity compared 
to wild type [49]. JNK mediated phosphorylation of Bad results in a commitment to either 
death or survival under different contexts. 
5.3.8. Bax and Bak: Bcl-2 associated X- protein is a cardinal member of the Bcl-2 family. 
Bax regulates the critical balance between life and death [117]. Bax is predominantly a 
cytosolic protein, which translocates to mitochondria by various modifications including 
stress. Another reason is a conformational change in Bax with the interaction of BH3 
proteins like BID and Bim, which causes its insertion into the mitochondrial membrane 
[117]. Bax heterodimerizes with B-cell associated killer protein (Bak) present on 
mitochondrial membrane, leading to oligomerization of Bax and Bak and initiates pore 
formation in the outer mitochondrial membrane [118].  
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Bax protein is sequestered in the cytoplasm by various mechanisms; one of which is 
binding of Bax by 14-3-3, a cytoplasmic anchor protein [119]. Under stress, Bax 
dissociates from 14-3-3 and translocates to mitochondria. JNK plays a significant role 
during this translocation process, which was shown in COS-1 cells treated with anisomycin 
or staurosporine. It was also shown that SP600125 or JNK binding peptide (JBP) prevented 
Bax translocation. JNK phosphorylation of 14-3-3 ζ at Ser-184 and 14-3-3 σ at Ser-186 
causes the dissociation of Bax. This phosphorylation was found both in vitro and in vivo in 
HTC116 (colon carcinoma) cells following anisomycin treatment [120]. Another stress 
shows the phosphorylation of Bax on Thr-167 by JNK and p38 kinase in response to 
treatment with staurosporine, UV light, and H2O2 in HepG2, human hepatoma cell line. 
They suggest that this phosphorylation causes the conformational change in Bax which 
leads to the translocation of Bax to mitochondrion [118]. JNK induced apoptosis requires 
Bax and Bak, which was shown in Bax/Bak double knock out MEFs. Apoptosis was 
observed with the activation of JNK in WTMEFs whereas there was no apoptosis in DKO 
MEFs [121]. JNK favors apoptosis by direct modification of Bax or modification of anchor 
protein ultimately resulting in translocation of Bax to mitochondria. 
6. Mitochondrial permeabilization 
Mitochondria are comprised of two membranes, the inner mitochondrial membrane (IMM) 
and the outer mitochondrial membrane (OMM). In the space between these two membranes 
(dubbed the intermembrane space), cytochrome c and various other factors are found [122]. 
Executor apoptotic proteins, Bax which are present in the cytosol of the normal cells 
translocate to the OMM when activated. Similarly Bak is constitutively targeted to the 
mitochondria after activation [55].  The activation of Bax and Bak occurs either by direct 
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activators or by other proteins or non-protein factors, like mild heat, high pH and detergents 
[55]. Due to the change in the structure, these proteins homo-oligomerize leading to the 
formation of proteolipid pores in the OMM; OMM permeabilization occurs after a critical 
number beyond the capacity of recovery has occurred. OMMP is considered the point of 
no return and is the crucial event in programmed cell death [64,123]. This leads to the 
release of cytochrome c, SMAC/DIABLO, endonuclease G, apoptosis-inducing factor 
(AIF), adenylate kinase, Ser protease OMI, deafness dystonia protein (DDP) and OPA1, 
some of which are also involved in caspase-independent cell death [65,122].  
7. Mitochondrial priming and BH3 profiling 
Apoptosis is a complex process regulated by several proteins; the intrinsic apoptotic 
pathway is mostly regulated by Bcl-2 proteins. As mentioned before, this group of proteins 
contains many members, making it difficult to analyze the complex pattern of interaction 
of individual proteins. However, Letai group developed a mechanism to find the ultimate 
result of this interaction. Cells are usually classified as dead or alive; they termed a third 
term called ‘primed for death’ [124]. Priming determines the dependence of cells on anti-
apoptotic proteins for survival [125]. In response to death signaling received, these ‘primed 
cells’ have pro-apoptotic proteins sequestered by anti-apoptotic Bcl-2 proteins. 
Mitochondrial priming is used to reveal the degree of proximity to death.  It correlates with 
the clinical response to chemotherapy. It can be used to characterize patients’ tissue into 
chemo-resistant and chemo-sensitive [126].  
The Letai group developed a technique to measure priming called BH3-profiling. BH3-
profiling is proposed to measure mitochondrial priming in patients to guide a personalized 
selection of the best chemotherapeutic regimen for a patient. BH3-profiling not only 
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determines if the tumor cells are primed for death, but it can also determine which anti-
apoptotic proteins promote the survival of resistant samples [124,127]. Letai group have 
developed different ways of BH3-profiling. In this technique, mitochondria are isolated 
and treated with a panel of BH3-peptides and as a measure of the formation of OMMP 
release of cytochrome c or change in MMP is assessed. A fluorescent-associated cell 
sorting (FACS) for the measurement of MMP or cytochrome c can be utilized. However, 
a plate-based assay is commonly used for homogeneous cell population whereas FACS can 
be used in heterogeneous cell population [125]. 
Using B-cell lymphoma as a model, the Letai group classified cancer cell into three classes. 
Class A has suppression of pro-apoptotic activator BH3 proteins, Class B has lost Bax and 
Bak, effector Bcl-2 protein and Class C has high expression of anti-apoptotic Bcl-2 protein. 
Further class C cells which were sensitive to ABT-737, a BH3-mimetics, the anti-apoptotic 
protein particularly responsible for survival was identified [127]. This method can be used 
to find the dependency of on anti-apoptotic protein for survival. For example, a tumor it 
could be dependent on either Bcl-2 or Mcl-1 and Bcl-2 antagonists ABT-263 or ABT-199 
could be used in that patient [125]. This classification helps in determining the 
chemotherapeutic drug that will work best in the patient. 
8. SH3BP5 (Sab)  
Sab (also called SH3 binding protein 5 or SH3BP5) was first identified as a novel molecule 
binding to SH3-domain of Bruton’s tyrosine kinase (Btk) using protein interaction cloning 
method [128]. Sab is a scaffold protein present on the OMM [129]. Sab has three 
interaction motifs; kinase interaction motifs (KIM-1 and KIM-2) and SH3-binding motif 
[130,131]. A yeast-two hybrid screening method showed that C-terminus of Sab binds to 
 29 
JNK [130]. C-terminus also has potential phosphorylation sites that can be assigned to 
MAPKs. The C-terminus is present on the outside of the mitochondria facing cytoplasm 
while N-terminal lies in between inner and outer membrane coil-like structure similar to 
myosin heavy chain [131]. Sab has been shown to facilitate pro-apoptotic signaling events 
in response to cytotoxic stress. One of the major known interacting partners of Sab is JNK; 
the interaction between these two have been shown to be involved in mitochondrial 
dysfunction and cell death in few studies. However, other mechanisms regulating Sab is 
not known yet. 
8.1. Sab and JNK interaction 
Sustained activation of JNK leads to its translocation to mitochondria [48,129]. The 
interaction between JNK and Sab was found to ‘prime the mitochondria’ for JNK signaling 
in the presence of 25m of anisomycin for 30 minutes. It was observed that interaction of 
Sab with JNK results in initiation of the apoptotic pathway which occurs via KIM-1 motif. 
While inhibition of Mito-JNK signaling which was mediated by Sab, no mitochondrial 
dysfunction was observed [48]. It was shown that JNK-Sab interaction leads to 
phosphorylation of the anti-apoptotic protein Bcl-2, which leads to its emigration from 
mitochondria and favors the accumulation of pro-apoptotic BH3 only proteins [48]. The 
interaction between Sab and JNK leads to inhibition of respiration, increased reactive 
oxygen species (ROS) which further endures JNK activation and causes cell death 
[48,52,132,133]. JNK-Sab interaction leading to cell death has been observed in different 
disease models, which are inhibited by inhibiting JNK-Sab interaction or silencing of Sab. 
Acetaminophen or tumor-necrosis factor-induced liver injury requires JNK-Sab interaction 
[129]. In addition to this, the JNK-Sab nexus is involved in palmitic acid-induced 
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hepatocyte lipotoxicity, tunicamycin ER-stress induced apoptosis [134,135] This 
highlights the importance of the JNK interaction with scaffold protein Sab for causing 
mitochondria-mediated cell death. 
The potential for the levels of Sab on the OMM to indicate the robustness of apoptotic 
induction was first illustrated by sub-chronic administration of LY294002 in HeLa cells 
[52]. Increasing Sab-levels by subchronic exposure to LY294002 could enhance the 
efficacy of cisplatin and paclitaxel in HeLa cells. While silencing of Sab or inhibition of  
JNK-Sab interaction did not increase the efficacy of these agents but rather promoted 
resistance [52]. We suggest that this technique of increasing Mito-JNK signaling by 
increasing Sab could be used to restore or enhance apoptosis in drug-resistant cancer cells. 
9. Conclusion 
Few investigations have examined the involvement of Mito-JNK in chemotherapeutic-
induced death in OC cells; even though, a broad inhibition of JNK reveals a contribution 
to cisplatin- and paclitaxel-mediated apoptosis. There is even less information regarding 
the role of Sab in chemotherapeutic responses. The Chambers and Kaplowitz groups’ 
collective research demonstrates the importance of Sab in mediating toxic JNK signaling 
events under different stress conditions. Increasing Sab concentration increases Mito-JNK 
signaling and consequently the potential to induce apoptosis through the manipulation of 
Bcl-2 proteins; however, the molecular mechanisms relating chemotherapeutic efficacy 
and Sab concentration have not been explored in gynecological cancers. This endeavor will 
be the subject of my dissertation research.  
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CHAPTER 2 
HYPOTHESIS AND RATIONALE 
  
 48 
1. Problem Statement 
Gynecological cancer mortality can be attributed to the presence of recurrent, highly 
metastatic, and resistant disease [1]. Unfortunately, the molecular mechanisms responsible 
for the resistance to conventional therapies are not thoroughly defined. Because of this 
knowledge gap, treatment-resistant gynecological cancers are responsible for diminished 
survival in late-stage ovarian and uterine cancer patients [2]. Thus, until the mechanisms 
driving therapeutic resistance are defined, effective therapies for advanced gynecological 
cancers will likely remain elusive. Therefore, it is the goal of this research to identify and 
characterize molecular events responsible for therapeutic resistance in gynecological 
cancers. By elucidating these events, one anticipates that new treatments targeting these 
specific molecular alterations can be developed to reestablish cell death induction in many 
difficult to treat tumors. 
2. Hypothesis and Rationale  
The inability of tumor cells to induce cell death mechanisms is a hallmark of cancer [3]. A 
recent study demonstrated that treatment with a chemosensitizer (LY294002) altered cell 
death signaling on the mitochondrial surface, the site for induction of apoptosis [4]. Sub-
chronic, low-dose treatment with LY294002 increased the concentration of the outer 
mitochondrial scaffold protein Sab. Because the concentration of scaffold proteins dictate 
the biological outcomes of signaling pathways at discrete subcellular locales [5, 6], one 
could propose that increased Sab levels on mitochondria would correspond to enhanced c-
Jun N-terminal Kinase (JNK) signaling on the organelle. Indeed, chemosensitization did 
increase the drug-induced translocation of JNK to mitochondria and lowered the threshold 
for apoptosis in a Sab-dependent manner [4]. Based on this study and other relevant 
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literature (See Chapter 1), the over-arching hypothesis of this project is that decreased Sab 
expression in gynecological cancers is in part responsible for chemotherapeutic resistance 
in late-stage disease. Furthermore, therapeutic strategies aimed at elevating the local 
concentrations of Sab on mitochondria may represent useful approaches to restore cell 
death induction in treatment-resistant gynecological tumors. The rationale for this research 
is once approaches are found to restore apoptotic pathways in gynecological tumors 
efficacious treatments can eliminate the disease resulting in increased patient survival and 
improve quality of life. 
3. Project Aims 
To investigate the hypothesis, and accomplish the research goal, the approach for this 
project is to understand the role of mitochondrial signaling in drug resistance for 
gynecological cancers and develop an approach to restore mitochondrial JNK signaling 
and induction of apoptosis in tumor cells. For this purpose, the following specific aims are 
proposed. 
a. Identify the role of Sab in mitochondrial JNK signaling and mitochondrial priming 
in gynecological cancers. 
b. Identify and characterize compounds that increase Sab concentrations in treatment-
resistant gynecological cancer cells. 
 
4. Chapter Abstracts 
The project has resulted in three submitted manuscripts, which will comprise Chapters 3, 
4, and 5 of the dissertation. To preview these chapters, the abstracts from these 
manuscripts/chapters appear below: 
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Chapter 3 - Sab Concentrations Indicate Chemotherapeutic Susceptibility in 
Ovarian Cancer Cell Lines 
The occurrence of chemotherapy-resistant tumors makes ovarian cancer (OC) the most 
lethal gynecological malignancy. While many factors may contribute to chemoresistance 
in OC, the mechanisms responsible for regulating tumor vulnerability are under 
investigation. Our analysis of gene expression data from OC studies revealed that Sab, a 
mitochondrial outer membrane (OMM) scaffold protein, was down-regulated in OC 
patients. Our previous studies demonstrate that Sab-mediated signaling on the OMM 
induces cell death suggesting that this apoptotic pathway may be diminished in OC.  In the 
current study, we examined Sab expression in a panel of OC cell lines and found that the 
magnitude of Sab expression correlated to chemo-responsiveness; wherein, OC cells with 
high Sab concentrations were vulnerable to chemotherapy, while cells with low Sab levels 
were chemoresistant. The Sab levels were reflected by a complementary amount of the c-
Jun N-terminal kinase (JNK) on the OMM in response to cytotoxic stress. Dynamic BH3 
profiling and examination of Bcl-2 and BH3-only protein concentrations revealed that cells 
with high Sab expression were primed for apoptosis, as determined by the decrease in pro-
survival Bcl-2 proteins and an increase in pro-apoptotic BH3-only proteins on 
mitochondria. Furthermore, over-expression of Sab in chemoresistant cells enhanced 
apoptotic priming and restored cellular vulnerability to a combination treatment of cisplatin 
and paclitaxel. Contrariwise, inhibiting Sab-mediated signaling or silencing Sab expression 
in a chemosensitive cell line resulted in decreased apoptotic priming and increased 
resistance to cisplatin/paclitaxel treatment. We propose that Sab may be a prognostic 
biomarker to discern personalized treatments for OC patients. 
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Chapter 4 – Sab Concentrations Indicate Chemotherapeutic Susceptibility in 
Uterine Cancer Cell Lines 
Metastatic uterine cancer (UC) has a 5-year survival less than 8%. This mortality is 
associated with treatment resistance in metastatic UC cells. There is an urgent need to 
identify the mechanisms contributing to resistance in UC patients with metastatic disease 
to improve the patient survival. Mitochondria control cell death responses, yet cancer cells 
can develop mechanisms to avoid apoptosis and evade therapeutic approaches. We propose 
communication between the cell and mitochondria becomes altered during metastasis, and 
metastatic UC cells have mitochondria that can no longer process cell death signals. To 
address if mitochondrial-cell communication was altered during metastasis, we compared 
a human cell line derived from a primary site tumor (SK-UT-1) and another isolated from 
a metastatic site (AN-3-Ca). Analysis of the signaling proteins on the surface of the 
mitochondria in these two cell lines revealed that a scaffold protein, Sab, was down-
regulated in metastatic AN-3-Ca cells compared to SK-UT-1. Our previous research 
demonstrated that elevated levels of Sab induced mitochondrial dysfunction and apoptosis, 
ultimately enhancing chemo-responsiveness in gynecological tumors. We examined the 
apoptotic potential of SK-UT-1 and AN-3-Ca cells by measuring the levels of pro-survival 
Bcl-2 proteins and pro-death BH-3 only proteins. Our results indicate that metastatic AN-
3-Ca cells had considerably higher levels of Bcl-2 proteins, while SK-UT-1 cells had 
higher levels of BH-3 only proteins. We found that AN-3-Ca cells were more resistant to 
taxane and platinum treatment than SK-UT-1 cells. To determine if diminished Sab-
mediated signaling played a role chemo-resistance, we ectopically expressed Sab in AN-
3-Ca cells. Elevating Sab levels in AN-3-Ca cells rescued chemo-responsiveness by 
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decreasing Bcl-2 protein levels and increasing BH-3 only protein concentrations. We 
surmise that Sab-mediated signaling plays a critical role in treatment responsiveness in UC 
and that inhibiting Sab expression is a critical event in metastasis and chemo-resistance. 
 
Chapter 5 - A high-throughput Assay to Screen for Compounds Elevating Sab 
Concentrations in Chemoresistant Human Ovarian Cancer Cells. 
Ovarian cancer (OC) is the most lethal gynecological malignancy. OC mortality is 
associated with the high rate of recurrence, which stands at approximately 80%. 
Recurrence is typified by the presence of treatment-resistant cells; consequently, 
conventional therapies, including chemotherapy, are often ineffective. Therefore, it is 
imperative to find novel therapeutic options to eliminate treatment-resistant OC cells. We 
propose that targeting mitochondrial-cell communication in resistant OC cells will increase 
their susceptibility to established chemotherapies. Previous studies from our lab 
demonstrate that increasing the concentration of the outer mitochondrial scaffold protein 
Sab sensitizes OC cells to paclitaxel by inducing apoptotic priming. These studies suggest 
that increasing Sab levels in OC will induce a pre-apoptotic state and sensitize the tumor 
cells to conventional chemotherapies, thus rendering resistant OC cells sensitive. We have 
developed a high-throughput assay, an in-cell western (ICW), to detect changes in Sab 
protein concentrations following chemical exposures. The ICW approach was developed 
in HEK-293 cells and validated using Sab silencing and overexpression. A trail screen of 
known compounds found that mitochondrial toxins were the most potent enhancers of Sab 
levels, while antioxidants were the greatest suppressors of Sab levels. The ICW assay was 
re-optimized in SK-OV-3 cells (z- score of 0.81), a chemoresistant cell line.  The Sab ICW 
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was co-stained with the TO-PRO-3 DNA stain for normalization and as an index of 
viability. We screened a scaffold-ranking and positional-scanning library (provided by the 
Torrey Pines Institute for Molecular Studies) to identify novel compounds that increase 
Sab expression in OC cells. Fifty (50) chemical scaffolds were screened for SK-OV-3 cells. 
Scaffolds selected for further testing increased Sab expression greater than 30% and 
demonstrated minimal toxicity in SK-OV-3 cells. Using this method we have identified six 
candidate scaffolds. Individual compounds derived from this scaffold are currently being 
evaluated to identify the best compounds for OC studies. We predict that this approach will 
identify novel drugs that will improve OC treatment and mortality. 
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Chapter 3 
SAB CONCENTRATIONS INDICATE CHEMOTHERAPEUTIC 
SUSCEPTIBILITY IN OVARIAN CANCER CELL LINES.
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1. Introduction 
Ovarian cancer (OC) is the most lethal gynecological malignancy [1]. While the overall 5-
year survival for OC is approximately 45%, 60% of OC patients suffer from the metastatic 
disease, which has a survival rate of nearly 28%; whereas, locally detected OC cases have 
a 92% survival rate [2].  The high mortality associated with OC is attributed to a 
combination of poor detection and an extremely high recurrence rate (~80%) [3]. Recurrent 
OC is typified by the presence of treatment-resistant tumor cells [4]. Specifically, OC 
patients are often characterized by their relative responsiveness to platinum-based drugs, 
which are commonly used chemotherapy agents for OC [4, 5]. Patients are classified as 
platinum-sensitive (recurrence after six months), platinum-resistant (recurrence in less than 
six months) or platinum-refractory (recurrence during or upon completion of 
chemotherapy) [6], and this patient stratification is used, in part, to determine treatment 
options. In fact, the front-line treatment of paclitaxel and a platinum agent, such as 
cisplatin, only provides a modest improvement in survival among OC patients [7, 8]. Thus, 
the molecular mechanisms driving chemoresistance need to be defined and targeted to 
enhance treatment responsiveness in OC patients. To date, many factors have been 
implicated and targeted in platinum-resistant/refractory OC to improve therapeutic 
efficacy. These include angiogenesis [9, 10], perturbations in cellular signal transduction 
[11-15], DNA maintenance and repair machinery [7, 16], folate metabolism [17, 18], and 
mitochondrial physiology [19-21]. 
Recent research has demonstrated that changes in the apoptotic potential (ability to induce 
cell death) is altered in advanced OC patients [22, 23]. Specifically, a decrease in the 
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relative abundance of pro-apoptotic BH3-only proteins is linked to chemoresistance in OC. 
BH3-only proteins (Bad, Bid, Bik, Bim, Noxa, and Puma) are members of the Bcl-2 
superfamily of proteins and facilitate apoptosis by sequestering pro-survival Bcl-2 proteins 
or enhancing mitochondrial outer membrane permeabilization (OMMP) by catalyzing the 
assembly of Bax-Bak pores [24, 25]. Because of the association among BH3-only proteins, 
apoptosis, and chemo-responsiveness, BH3 profiling, a reproducible, high-throughput 
assessment of BH3-only protein levels, has been proposed to be an index for chemo-
responsiveness in solid tumors, including OC tumors [26-28]. Recent BH3 profiling efforts 
have found that indeed OC cells with high levels of BH3-only proteins were sensitive to 
chemotherapy [22, 23]. Moreover, increasing BH3-only protein concentrations, emulating 
BH3-only functions with chemical mimetics (ABT-737), and inhibiting pro-survival Bcl-
2 proteins have been found to enhance chemotherapeutic efficacy in resistant OC cells [23, 
24, 29]. However, the precise molecular mechanisms controlling the relative levels of BH3-
only proteins on mitochondria in OC are currently being investigated and may represent 
new therapeutic and prognostic targets. 
The outer mitochondrial membrane (OMM) is the interface between mitochondria and the 
rest of the cell. The OMM is not only the primary site of signal integration for mitochondria 
[30], but the OMM is also the location of Bcl-2 superfamily proteins, including several 
BH3-only proteins [31, 32]. Signaling complexes on the OMM may influence many 
aspects of mitochondrial physiology, including the recruitment, function, and retention of 
BH3-only proteins. Previously, we found that the OMM scaffold protein Sab organized 
pro-apoptotic signaling cascades in response to cytotoxic stress [33-35]. Specifically, the 
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c-Jun N-terminal kinase (JNK) translocated to the mitochondria and interacted with Sab in 
human cervical cancer (HeLa) cells treated with anisomycin [34]. Selective inhibition of 
the JNK-Sab interaction using a small, cell-permeable peptide (Tat-SabKIM1) prevented 
JNK-induced apoptotic events such as phosphorylation and emigration of Bcl-2 from the 
OMM [33]. Recently, we reported that sub-chronic treatment of HeLa cells with a chemo-
sensitizer, LY294002, increased Sab expression and chemosensitivity towards cisplatin 
and paclitaxel, two drugs commonly used in combination to treat OC [35]. In general, 
enhanced Sab-mediated signaling may increase the sensitivity of cells to toxic stress [36], 
including OC tumors. However, we have yet to determine the precise molecular 
mechanisms by which Sab-mediated signaling may reduce chemoresistance. 
In our current study, we examined the role of Sab-mediated signaling in OC chemo-
responsiveness. Analysis of gene expression data from six, independent OC patient studies 
shows that Sab expression is reduced more than five-fold on average across 970 OC 
samples when compared to normal tissue. Profiling four commercially available OC cell 
lines revealed that cells with high Sab expression are sensitive to common chemotherapy 
agents and that Sab levels reflect the concentrations of BH3-only proteins on mitochondria. 
Additionally, over-expression of Sab in the chemoresistant SK-OV-3 cell line increased 
BH3-only protein levels and chemosensitivity to cisplatin and paclitaxel treatment. 
Conversely, inhibition of Sab-mediated signaling in a chemosensitive cell line, PA-1, was 
sufficient to enhance chemoresistance to paclitaxel and cisplatin. Our studies demonstrate 
that manipulation of OMM signaling, such as increasing Sab-mediated signaling events, 
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may be a useful strategy to determine viable, personalized treatment options for OC 
patients.  
2. Experimental procedures 
Materials: Cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). Human Ovarian Epithelium Cells were obtained from ScienCell Research 
Laboratories (Carlsbad, CA). Chemotherapeutic agents ABT-737, carboplatin, cisplatin, 
docetaxel, doxorubicin, etoposide, and paclitaxel were purchased from Sigma-Aldrich (St. 
Louis, MO). Antibodies were purchased from vendors as listed below. General laboratory 
supplies were purchased from Fisher Scientific (Pittsburgh, PA). 
Gene Expression Analysis: Secondary data analysis was performed to determine the 
relative levels of Sab expression in normal and OC tissue samples. The expression of Sab 
(SH3-binding protein 5; SH3BP5) was examined using the Oncomine database 
(http://www.oncomine.org) in March 2017 [37]. By querying six datasets available for OC 
that included Sab as part of past studies [38-43], we compared experimental data for normal 
tissue and OC samples. The data were compiled from across six independent studies, which 
contained a total of 41 normal tissue samples and 970 OC samples (1,011 samples in total). 
The data were presented as medians with error bars with limits of the 90th and 10th 
percentiles. All of the OC samples were from surgically removed primary site tumors 
(summarized in Table 1). 
Cell Culture: OC cell lines CaOV-3 (HTB-75), PA-1 (CRL-1572), SW-626 (HTB-78), and 
SK-OV-3 (HTB-77) cells were cultured according to the suppliers instructions in 
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Dulbecco's Minimal Essential Medium (DMEM), Eagle’s Minimal Essential Medium 
(EMEM), Lebovitz L15 medium, and McCoy’s 5a medium, respectively.  Each medium 
was supplemented with 10% fetal bovine serum (FBS), 1,000 U/mL penicillin, 100mg/mL 
streptomycin, and 5g/mL plasmocin. For experiments, cells between passages 3 and 20 
were used. To account for media-induced effects, cells were also adapted to DMEM and 
analyzed as described below. Human ovarian epithelium cells were cultured under normal 
cell culture conditions on poly-L-lysine-coated plates according to manufacturer’s 
instructions using Ovarian Epithelial Cell Medium (ScienCell Research Laboratories) for 
no more than five passages. 
Immunoblotting: To isolate proteins from cells for analysis, cells were plated at 2.5x105 
cells/well in six-well plates and 60-mm dishes. Following treatment, cells were lysed, and 
proteins were harvested as previously described. Briefly, cells were washed twice in 
phosphate buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM 
KH2PO4) and lysed in radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH 
8.0, 150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 
1mM phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase 
Inhibitor Cocktails (Thermo Scientific). Cells were incubated while gently rocking at 4°C 
for five minutes, and then transferred to a sterile microcentrifuge tube. After two minutes 
on ice, cell disruption was completed using sonication. The lysate was cleared by 
centrifuging at 14,000 × g for 15 minutes. Supernatant protein concentrations were 
measured using the Pierce BCA Assay kit. Proteins (25g) were resolved by SDS-PAGE 
and transferred onto low-fluorescence PVDF membranes. Membranes were placed in 
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blocking buffer comprised of PBS with 5% bovine serum albumin (BSA) and incubated 
for one hour at room temperature. The membranes were incubated in PBS containing 0.1% 
Tween 20 (PBST) and 5% BSA in the presence of primary antibodies overnight (4oC) while 
gently rocking.  Primary antibodies specific for Sab (Novus Biologicals, H00009467-
M01), Phospho-JNK (Thr183/Tyr185, Cell Signaling Technology (CST), 4668), JNK (Cell 
Signaling Technology, 9252), Phospho-c-Jun (Ser73, CST, 3270), c-Jun (CST, 9165), 
Phospho-Bcl-2 (Ser70) (CST, 2827), Bcl-2 (CST, 2870), Bcl-xL (CST, 2764), Mcl-1 (CST, 
5453), Bad (CST, 9239), Bik (CST, 4592), Bim (CST, 2933), Bid (CST, 2002), PUMA 
(CST, 12450), Bax (CST, 5023), Bak (CST, 12105)Actin (CST, 4970), α-tubulin (CST, 
2144), COX-IV (CST, 4850), GAPDH (CST, 5174), Calnexin (CST, 2679), Histone H3 
(CST, 4499), TOM20 (Abcam, ab115746), TIMM23 (Abcam, ab116329), and PEX19 
(Abcam, ab137072) were used at dilutions of 1:1000. Membranes were washed three times 
for five minutes in PBST and were incubated with secondary antibodies in the appropriate 
blocking buffer at a ratio of 1:20,000 for one hour at RT gently rocking. The following 
secondary antibodies were used in the experiments below: IRDye 680RD goat anti-rabbit 
(926-32211) and IRDye 800CW goat anti-mouse (926-68070) (Licor Biosciences). 
Membranes were again washed three times for five minutes in PBST. Membranes were 
analyzed using fluorescence detection using the Odyssey CLx near infrared scanner (Licor 
Biosciences). The corresponding bands on the immunoblots were quantified and 
normalized using the Image Studio 2.0 software (Licor Biosciences). The fluorescence of 
specific bands of interest was divided by the fluorescence of the loading control band to 
equilibrate signal strength and loading. The resulting signal was then normalized by 
dividing the signals from treated samples by untreated controls for each experiment. 
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Cell-based IC50s of Chemotherapeutic Agents: To determine the relative chemo-sensitivity 
of the OC cell lines, cells were treated with increasing concentrations (generally 0-100M) 
of drugs approved for the treatment of OC. Cells were plated at 1.5x104 cells per well in 
black-walled, clear bottom plates (Perkin Elmer) and grown overnight. The cells were then 
treated with chemotherapeutic agents for 48 hours. The cells were washed three times with 
PBS and fixed in 4% paraformaldehyde/PBS. The cells were then stained with 5M TO-
PRO-3 for 45 minutes at RT [35, 36]. The cells were then washed three times in Hank’s 
Buffered Saline Solution (HBSS). The plate was imaged using the Odyssey CLx scanner 
(Licor Biosciences) and analyzed using the Image Studio 2.0 software (Licor Biosciences). 
The IC50s were then calculated using the GraphPad Prism7© software. 
Mitochondrial Isolation: To determine the relative abundance of proteins located on or 
within mitochondria, we isolated mitochondria as described in our previous work [33, 36]. 
Mitochondrial preparations with greater than 75% purity were used for our studies. 
Mitochondria purity was determined by immunoblotting for proteins from other subcellular 
compartments. For protein analyses, a total of 50g protein was loaded for each 
mitochondrial sample. 
JNK Activity Assay: We have previously used a luciferase-based kinase activity assay 
(Promega’s Kinase-Glo Assay) to determine cellular JNK activity [33, 63]. In this study, 
mitochondria were isolated from each cell type, and the organelles were lysed using a 
native lysis buffer (25mM Tris-HCl [pH 7.5], 150mM NaCl, 1mM EGTA, 1mM EDTA, 
1% TritonX-100) supplemented with protease and phosphatase inhibitors (Halt Cocktails 
– Thermo Fisher Scientific). Next, the mitochondrial lysate was placed in JNK activity 
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buffer (25mM HEPES, pH 7.4, 10mM MgCl2, 2mM dithiothreitol (DTT), 1mg/mL BSA, 
and 1µM ATP). Then, 1µM of peptide substrate: either c-Jun (1-79) peptide, recombinant 
Sab polypeptide (335-435), or mutant Sab polypeptide (335-435) with mutated JNK 
binding sites to prevent kinase docking (SabKIM1/2L-A(335-435)) was added. Sab peptides 
were expressed and purified as previously described [33, 64]. As a control for JNK activity, 
specific lysates were pretreated fifteen minutes with 10M SR-3306 (Tocris) to inhibit 
JNK. The assays were incubated for one hour at 30oC, and the reaction was stopped by the 
addition of 50mM EDTA. The reaction was combined with an equivalent volume of 
Kinase-Glo reagent and incubated at room temperature for ten minutes. Luminescence was 
measured on the BioTek Synergy H1 microplate reader with 500ms integration. ATP 
concentrations were determined by interpolating results onto an ATP standard curve 
acquired during each kinase reaction replicate. The data are reported as mean relative 
luminescence and normalized to protein concentration (mg) with error bars representing 
one standard deviation of the mean. 
Apoptotic Priming Assay: To examine the potential for OC cell lines to induce apoptosis, 
we employed dynamic BH3-profiling, a high-throughput technique to predict the 
responsiveness of tumors to therapy [23, 26, 29, 65]. First, 2.0x104 cells were used for the 
analysis of each cell line. The cells were trypsinized and dispersed into single cell 
suspensions, as determined by microscopy, in Trehalose Experiment Buffer (T-EB, 
300mM Trehalose, 10mM HEPES-KOH (pH 7.7), 80mM KCl, 1mM EGTA, 1mM EDTA, 
0.1% BSA, and 5mM succinate) at four times the final density. Bim BH3-peptide 
(MRPEIWIAQELRRIGDEFNA) was prepared as ten distinct concentrations over a three 
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log margin ranging in concentrations from 0.01mM to 100mM to determine the optimal 
conditions of the assay. A concentration of 500nM was determined to be the optimal 
concentration of Bim BH3 assays in HeLa cells and later used for our profiling of OC cell 
lines. Next, 15L of  Bim BH3-peptide was placed in a black 384-well plate (Nunc 
262260). One volume (7.5L) of the cell suspension was combined with one volume 
(7.5L) of  JC-1/Digitonin Mastermix (4mM JC-1, 40g/mL oligomycin, 20mM -
mercaptoethanol, and 0.02% digitonin in T-EB). The cells were permeabilized for 10 
minutes at room temperature. The 15L of cell/dye solution was then added to the Bim 
BH3-peptide in the respective well of the 384-well plate. When completed, the plate was 
placed inside a BioTek Synergy H1 plate reader and shaken for 15 seconds. The 
fluorescence was then monitored at 590nM (excitation 545nM; with 20nM bandwidths) 
every five minutes for 120 minutes. As a positive control for complete depolarization, cells 
were treated with 3M Carbonyl-cyanide-p-trifluoro-methoxy-phenylhydrazone (FCCP) 
and 250nM valinomycin. For each biological replicate, experimental conditions were 
performed in replicates of five for each cell line; experiments with a standard deviation of 
less than 10% were used for our analysis. The percent priming (% priming) was found by 
subtracting the mean maximum depolarization (FCCP/Valinomycin) from the mean 
depolarization from Bim BH3-peptide treatment across replicates. The change in priming 
(% priming) refers to the difference in priming between non-treated, and Bim BH3-
peptide-treated cells [22].  
Mitochondrial outer membrane permeabilization: To evaluate the integrity of the OMM, 
we chose to quantify the amount of cytosolic cytochrome c [36]. Extra-mitochondrial 
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cytochrome c concentrations were assessed using immunoblotting of subcellular fractions 
(mitochondria and S100 (cytosol)). Briefly, 5x107 cells were grown in two 150-mm dishes. 
The cells were resuspended in 800L of ice-cold homogenization buffer (250 mM sucrose, 
20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 
pH 7.4 and Halt protease inhibitor cocktail). The cells were homogenized and centrifuged 
(750xg, 10 minutes, 4oC) to remove nuclei and intact cells. The supernatant was 
centrifuged (10,000xg, 10 minutes, 4oC). The resulting supernatant was transferred to a 
new tube, and the pellet (or mitochondria-containing fraction) was resuspended in 
homogenization buffer. The supernatant was centrifuged at 100,00xg (4oC) for 60 minutes 
yielding the cytosolic fraction. Finally, 50g of protein was resolved by SDS-PAGE, and 
cytochrome c was detected by immunoblotting as described above.  
Manipulation of Sab-mediated signaling: We transiently transfected SK-OV-3 (a low Sab 
expressing OC line) with plasmids designed to express Sab (pLOC:Sab), red fluorescent 
protein (RFP; pLOC:RFP), or a Sab mutant lacking MAPK binding motifs (SabKIM-2L/A; 
pLOC: SabKIM-2L/A) [35, 36] to evaluate the impact of increased Sab levels. Plasmid DNA 
and FugeneHD (Promega) were combined in Optimem (Invitrogen) at a ratio of 1:3 and 
incubated for 15 minutes at RT before addition to culture. Eight hours after the addition of 
the transfection complex to media, the media was exchanged. Protein levels were assessed 
at 72 hours post-transfection. For drug-related studies, chemotherapeutic agents were 
added at 48 hours post-transfection, and cell viability was measured at 96 hours post-
transfection (48 hours after drug). 
To reduce Sab-mediated signaling in a high Sab-expressing OC cell line (PA-1), we used 
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peptide-based inhibition of protein-protein interactions on Sab as described in our prior 
studies. Cells were treated with up to 10M of Tat-SabKIM1 (a cell-permeable, inhibitory 
peptide) [33], scrambled control peptide (Tat-Scramble), or a variant of Tat-SabKIM1 
lacking the intact MAPK binding site (Tat-SabKIM1L/A). Cells were plated as described 
above and then treated with peptide for thirty minutes before drug treatment. 
To decrease Sab expression, PA-1 cells were transiently transfected with pLKO.1 plasmids 
containing shRNAs either a luciferase-specific shRNA (control) or a shRNA for Sab that 
demonstrated over 85% silencing in 72 hours (Supplemental Figure 3). Ectopic expression 
of a shRNA-resistant form of Sab (previously described in [35]) was used to rescue Sab 
levels in PA-1 cells silencing Sab. Briefly, 1.5x104 cells were plated in a 96-well plate, or 
1.5x105 cells were plated a day before transfection in 35-mm dishes for experiments. 
Plasmids were mixed with FugeneHD (Promega) at a 3:1 ratio per manufacturer’s 
recommendations and added to cells for up to 72 hours. Protein levels were determined by 
immunoblotting as described above.  
Cell Viability: To determine the extent of cell death, we utilized two methods: 1) Annexin-
V with propidium iodide (PI) analyzed by fluorescent microscopy and 2) Caspase 3/7 
fluorescent activity assay [66-68]. For the Annexin-V/PI assays (Cayman Chemical), 
1.5x104 cells were plated in a black-walled optically-clear bottom 96-well plate (Nunc), 
and the cells were treated with the chemotherapy agents as described above. The plate was 
centrifuged at 400xg for five minutes, and the media was removed. The cells were then 
placed in 100L of Binding Buffer; the plate was centrifuged again (400xg, 5 minutes) and 
the buffer was removed. The cells were then incubated in 50mL of Annexin-FITC/PI 
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solution for ten minutes at room temperature, and the solution was removed following 
centrifugation (400xg, 5 minutes). The cells were placed in 100L of HBSS, and the cells 
were imaged by fluorescent microscopy using the Applied Precision DeltaVision Elite 
Imaging System. Images were analyzed by counting cells stained only with unstained, 
Annexin-V-FITC stained (early apoptosis), and double labeled, Annexin-V/PI stained cells 
(late apoptosis).  As a positive control, cells were treated with 1M staurosporine (STS) to 
induce significant cell death at 24 hours. Images were assembled using Adobe Photoshop. 
For the cell-based caspase 3/7 activity assay, cells were grown in a clear 96-well plate as 
described for the Annexin-V/PI assay. The plate was centrifuged (400xg) for five minutes, 
and the supernatant was removed. The cells were placed in 150L of PBS and centrifuged 
(400xg for 5 minutes). After removing the buffer, the cells were placed in 100L of PBS 
supplemented with 1% TritonX-100 to lyse the cells. After thirty minutes of incubation on 
a room temperature orbital shaker, the plate was centrifuged at 800xg for ten minutes, and 
90L of the cleared lysate was transferred to a black 96-well plate. Next, either 10L of 
PBS or 10L of a caspase inhibitor (Ac-DEVD-CHO; 10M) was added to the lysate. 
Then, 100L of caspase substrate Ac-DEVD-AMC (100M) in PBS supplemented with 
20mM DTT was added to the well. The assay was incubated at 37oC for thirty minutes, 
and fluorescence was measured (excitation: 488nm; emission: 535nm) using the BioTek 
Synergy H1 plate reader. Each assay was performed in triplicate for each condition for a 
minimum of four biological replicates. Data are presented as mean relative fluorescent 
units. 
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Biological Replicates and Statistics: A minimum of five biological replicates were used for 
cell-based studies, while a minimum of six experimental replicates was evaluated for 
biochemical, fluorescence, and other measurements. To determine statistical significance, 
the Mann-Whitney test was employed for significance between treatments. Statistical 
significance is indicated by an asterisk in figures in which the p-value is less than 0.05. 
Data are displayed as means with error bars representing plus and minus one standard 
deviation of the mean.  
3. Results 
3.1. Sab expression is reduced in OC. Our previous study in HeLa cells demonstrated 
that increasing the concentration of Sab on the OMM enhanced the sensitivity towards 
cisplatin and paclitaxel [35]. Because OC is typified by the presence of tumor cells resistant 
to platinum drugs, such as cisplatin, we wanted to determine if Sab expression may be 
altered in OC patients. To determine if Sab expression was changed in OC, we queried the 
Oncomine database [37] for Sab expression in OC samples and normal ovarian tissue. 
Examination of six independent studies (Table 1) found that Sab levels were reduced on 
average ~5.5-fold (2.19-fold in log2 scale) in primary site OC tumors when compared to 
normal tissue [38-43]. We plotted the medians, 90th percentile values, and 10th percentile 
values for each study in Figure 1. This analysis of 970 OC samples had a p-value less than 
0.001 indicating a difference in Sab expression, at least at the mRNA level, between the 
normal tissue and OC tumors (Table 3.1)
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Table 3.1: Summary of Ovarian Cancer Expression Studies and Observed Changes in Sab Expression. 
The data presented in the table was obtained from the Oncomine repository and statistically reexamined for Sab (SH3BP5) 
expression. *The number of samples from each study were added to arrive at the total numbers used for our evaluation. The 
mean fold changes were generated by averaging the fold changes from the studies. ** The types of OC were provided by the 
studies; multiple types were used in the Hendrix and Lu studies, and we did not segregate the data based on type. In both studies, 
the types were clear cell adenocarcinoma, serous adenocarcinoma, endometrioid adenocarcinoma, and mucinous 
adenocarcinoma.
STUDY 
TOTAL 
SAMPLES 
CANCER 
SAMPLES 
NORMAL 
SAMPLES 
OVARIAN 
CANCER 
TYPES** 
NORMAL 
TISSUE 
GENES 
ANALYZED 
HUMAN 
GENOME 
ARRAY(S) 
LOG2 
FOLD 
CHANGE 
AVG. 
FOLD 
CHANGE 
P REF. 
ABID 16 12 4 
Serous 
Carcinoma 
Ovary 8,603 
U95A-
Av2 
-2.331 -5.032 0.003 (38) 
BONOME 195 185 10 
Ovarian 
Carcinoma 
Ovarian 
Surface 
Epitheliu
m 
12,624 U133A -3.776 -13.699 
7.18
E-9 
(39) 
HENDRIX 103 99 4 
Multiple** 
 
Ovary 12,624 U133A -1.446 -2.725 
1.43
E-5 
(40) 
LU 50 45 5 Multiple** 
Ovarian 
Surface 
Epitheliu
m 
17,572 
U95A-
Av2 
U95B 
U95C 
U95D 
U95E 
-1.285 -2.437 0.067 (41) 
TCGA 594 586 8 
Ovarian 
Serous 
Cystadenocar
cinoma 
Ovary 12,624 U113A -1.684 -3.213 
1.17
E-7 
(42) 
YOSHIHARA 53 43 10 
Ovarian 
Serous 
Adenocarcino
ma 
Peritoneu
m 
16,724 
Agilent 
1A Oligo 
v2 
-2.619 -6.143 
2.10
E-9 
(43) 
TOTALS/MEANS* 1,011 970 41     -2.190 -5.542   
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FIGURE 3.1: Summary of Sab expression levels in six OC gene expression studies. 
Six studies were identified in the Oncomine repository that matched our criteria of a 2-fold 
decrease in Sab expression and a p-value less than 10-4. The critical data of these studies 
can be found in Table 1. We plotted the median value for Sab expression in normal tissue 
(black circles) and ovarian cancer samples (gray squares) for each study, and the error bars 
represent the 90th and 10th percentiles for each study. An asterisk (*) is used to indicate 
studies with a p-value <0.005. 
 
3.2. Ovarian cancer cell lines have distinct levels of Sab expression and mitochondrial 
JNK signaling. To determine if the diminished Sab expression in the patient OC samples 
affects chemosensitivity, we assessed Sab protein levels in OC cell lines. First, we 
measured Sab expression in four commercially-available OC cell lines, Caov-3, PA-1, SK-
OV-3, and SW-626; human ovarian epithelial cells were used as a normal tissue control. 
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Immunoblot analysis of Sab reveals that Caov-3 and SK-OV-3 lines have lower levels of 
Sab than that of ovary epithelial cells. Caov-3 and SK-OV-3 had 33% and 48% less 
expression, respectively (Figure 3.2A and 3.2B). Meanwhile, the expression of Sab was 
significantly elevated in PA-1 and SW-626 cells (Figure 3.2A, top panel); PA-1 had an 
average increased Sab expression of 6.7-fold that of ovarian epithelial cells, SW-626 was 
4.2-fold higher (Figure 3.2A and 3.2B). -Tubulin was used as a cellular loading control 
(Figure 3.2A, middle panel), while COX-IV was used as a control for mitochondrial 
density (Figure 3.2A, bottom panel). Ponceau S staining of membranes was used to 
normalize protein levels among cell types (Figure 3.2A). The results of four 
immunoblotting experiments were quantified and normalized to Ponceau S in Figure 3.2B. 
To evaluate if the differences in Sab protein levels among the four cell lines occurred on 
the OMM or elsewhere in the cell, we performed subcellular fractionation to isolate 
mitochondria and other subcellular compartments [33-35]. Immunoblotting of subcellular 
fractions reveals that Sab is exclusively in the mitochondrial fraction for each of the four 
OC cell lines as compared to nuclear, cytosolic, and microsomal fractions (Figure 3.2C). 
We were unable to detect Sab at substantial levels in the ER, cytosolic or nuclear 
preparations (Figure 3.2C). Furthermore, the relative purity of each compartment fraction 
was assessed by monitoring the levels of nuclear (Histone H3), ER (Calnexin), lysosomal 
(LAMP2), and peroxisomal (PEX19) contamination in the mitochondrial isolates (Figure 
3.2C). Only preparations with greater than 80% purity were used in our analysis. The 
relative levels of Sab were quantified and presented in Figure 3.2D. To examine if the 
relative Sab levels in the OC cells reflected mitochondrial JNK levels, we performed an 
immunoblot for JNK. JNK was not detected in any of the OC cell lines under normal 
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culture conditions (Figure 3.2E). Equivalent mitochondrial loading and OMM loading in 
each sample was assessed by the signal intensity of COX-IV and TOM20, respectively, 
(Figure 3.2E). Because previous research has indicated that mitochondrial translocation of 
JNK is dependent upon activation, we treated each of the four OC lines with 1M 
staurosporine (STS) for 45 minutes and measured phosphorylated (active) JNK 
(Thr183/Tyr185) levels in mitochondrial extracts. Upon treatment with 1M STS, 
phospho-JNK levels on mitochondria increased in all four cell lines (Figure 3.2E); this was 
reflected by an increase in the amount of total JNK in the mitochondrial isolates (Figure 
3.2E). The amount of JNK localized on mitochondria of SK-OV-3 and Caov-3 cells were 
62% and 47% less of the amount of JNK on the mitochondria of PA-1 cells (Figure 3.2E; 
top panel). Also, SW-626 mitochondrial JNK levels were 21% less than JNK on PA-1 
mitochondria (Figure 3.2E). Immunoblot analysis of whole cell extracts demonstrates that 
there was no significant difference in JNK expression among the four OC cell types (Figure 
3.2E; bottom panel), suggesting that the amount of JNK on mitochondria was dependent 
upon the concentrations of Sab. As observed in our previous studies only the higher 
molecular weight (54kDa) JNK band was present on mitochondria (Figure 3.2E; top panel); 
accordingly, this band cross-reacted with the phospho-JNK-specific antibody in 
mitochondrial preps from each of the four OC cell lines (Figure 3.2E, top panel).
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FIGURE 3.2: The levels of Sab differ among OC cell lines and correspond to stress-
induced mitochondrial JNK recruitment. (A) OC cell lines were grown under normal 
cell culture conditions to ~80% confluency. The cells were lysed, and the proteins were 
resolved by SDS-PAGE. Immunoblotting was performed to determine the relative 
abundance of Sab with a-Tubulin and COX-IV serving as cellular and mitochondrial 
loading controls. Ponceau staining of membranes was used to quantify the immunoblotting 
results. (B) Quantification of Sab abundance from whole cell lysates in Figure 2A. (C) 
Mitochondrial isolates were prepared from the four OC cell lines and assessed for the levels 
of Sab by western blot analysis. TOM20 was used as an outer mitochondrial loading 
control, while the relative contamination of other cellular compartments was assessed by 
monitoring the levels of Calnexin (ER), Histone H3 (nucleus), PEX-19 (peroxisomes), and 
LAMP2 (lysosomes). (D) The levels of Sab for each OC cell line were normalized to 
mitochondria abundance (TOM20 levels) and quantified for seven independent biological 
replicates. (E) The relative abundance of activated JNK on mitochondria was assessed in 
the presence and absence of stress. The top panel examines the relative levels of total JNK 
(JNK), activated JNK (P-JNK), with respect to Sab on mitochondria isolated from 
untreated OC cells. The bottom panel shows the same proteins following treatment with 
1mM staurosporine (STS) for 45 minutes. TOM20 was used as a mitochondrial loading 
control for both panels. (F) In vitro kinase activity assays for JNK were performed on 
mitochondria using either a c-Jun (1-79) or a Sab (335-435) peptide containing JNK 
phosphorylation sites. Additionally, a Sab-peptide lacking JNK binding residues 
(SabKIM1/2L-A(335-435) was used as a negative control substrate. SR-3306 (500nM), a 
potent JNK inhibitor, was used to impair JNK activity during cellular stress and prevent 
JNK translocation to mitochondria. An asterisk (*) is used to indicate studies with a p-
value <0.01 with respect to controls; meanwhile a double asterisk (**) is used to demark 
differences between cell types and distinct treatments. Data are plotted as means and error 
bars represent the standard deviation among at least three biological replicates. 
To determine if JNK present on mitochondria following STS treatment was indeed active, 
we lysed mitochondria isolated from each of the four OC cell lines in non-denaturing 
conditions and then measured JNK activity towards c-Jun and Sab peptides as well as a 
Sab mutant peptide (SabKIM1/2L-A(335-435)) incapable of binding JNK. Following exposure 
to 1M STS, JNK activity increased on mitochondria from all four cell lines (Figure 3.2F). 
However, JNK activity with respect to c-Jun and Sab peptides was increased over 10-fold 
in PA-1 and SW-626 cells, while only a 2.5 and 3.5-fold increase in activity was observed 
in SK-OV-3 and Caov-3 cells, respectively (Figure 3.2F). No kinase activity was observed 
with the SabKIM1/2L-A(335-435) peptide (Figure 3.2F). The activity could be attributed to 
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JNK as the introduction of 500nM JNK specific inhibitor SR-3306 prevented kinase 
activity in the assay. Quantitation of western blot analyses can be found in Supplemental 
Figure 3.2.  This reinforces previous observations that imply JNK activation is required for 
mitochondrial translocation.  
To determine if JNK translocation was specific to STS, we treated cells with 25M 
anisomycin for 30 minutes and measured mitochondrial JNK levels and activity. JNK 
levels increased in all four OC cell lines, with greater amounts of JNK present on the 
mitochondria of PA-1 and SW-626 compared to SK-OV-3 and Caov-3 (Supplemental 
Figure 3). The JNK species on mitochondria cross-reacted with the phospho-specific JNK 
antibody (Supplemental Figure 3). Similarly, the activity of JNK towards c-Jun and Sab 
peptides in the mitochondrial fractions was greater in PA-1 and SW-626 cell compared to 
SK-OV-3 and Caov-3 (Supplemental Figure 3). SR-3306 was used to demonstrate that 
JNK was the kinase responsible for the activity. Taken together, these results demonstrate 
that Sab concentrations on the OMM of OC cells may dictate the local magnitude of JNK 
signaling. 
3.3. OC cell lines with low Sab levels are resistant to chemotherapy agents: Because 
mitochondrial JNK signaling on Sab is linked to apoptosis [33, 44-49], we measured the 
chemosensitivity of the four OC cell lines to determine if Sab levels correlated to chemo-
responsiveness. Using common and clinically relevant chemotherapeutic agents and OC-
toxic regimens (Table 3.2), we assessed the potency of each with TO-PRO-3 staining and 
near-infrared imaging (Supplemental Figure 4). The data presented in Table 3.2 
summarizes the chemicals and IC50 values for each of the cells lines. SK-OV-3 and Caov-
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3 consistently had higher IC50 values than PA-1 and SW-626 cells. We also examined the 
potency of paclitaxel/cisplatin treatment, an approach employed for resistant and refractory 
tumors [5]. Similarly, SK-OV-3 cells and Caov-3 cells had considerably greater cellular 
viability as assessed by TO-PRO-3  
Table 3.2: Cell-based IC50 Values (M) for Chemotherapeutic Agents in OC Cell 
Lines. 
Note: IC50 values are presented as means plus or minus one standard deviation of the mean. 
The IC50s were determined using TO-PRO-3 staining and were confirmed by cell death 
assays. For each assay, each dose over the range of 10nM to 1mM was performed in 
quadruplet including the 0.01% DMF control. The means and standard deviations were 
based on a minimum of three biological replicates.  
 
 
CHEMOTHERAPY CAOV-3 PA-1 SK-OV-3 SW-626 
PACLITAXEL  9.7   0.11   13.7   0.57   
DOCETAXEL 0.45   <0.01  1.22   0.01   
DOXORUBICIN 0.41   0.04   0.5   0.11   
ETOPOSIDE 28.9   0.13   10.9   8.1   
CARBOPLATIN 48   1.9   65   5.8   
CISPLATIN 34.5   0.79   60.2   3.2   
ABT-263 189   0.96   215   3.2   
ABT-727 8.9   0.09   15   0.47   
OBATOCLAX 1.4   0.07   0.6   0.09  
TW-37 1.69   0.1   0.8   0.4  
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fluorescence following cisplatin/paclitaxel treatment when compared to PA-1 and SW-626 
cells (Figure 3.3). Specifically, SK-OV-3 and Caov-3 had IC50 values greater than 10-fold 
higher than PA-1 and SW-626 when treated with ABT-737, ABL-263, TW-37, and 
Obatoclax mesylate (Table 2). To determine if Sab levels correlated to the cellular 
sensitivities towards chemotherapeutic agents, we derived the Pearson’s coefficient with 
respect to Sab levels (from Figure 3.2A) in the cell lines (Supplemental Figure 5). As 
presented in Table 3.2, across the four OC cell lines, Sab levels were strongly correlated to 
chemo sensitivity. The correlation curves and one-sided Pearson’s coefficients can be 
found in Supplemental Figure 5 for each drug presented in Table 3.2.  
 
FIGURE 3.3: Cisplatin/Paclitaxel treatment affects OC 
cell lines differently. (A) TO-PRO-3 staining was used to 
assess the viability of OC cell types following treatment 
with vehicle (0.1% DMSO) or a combination of 0.25M 
cisplatin and 0.1M paclitaxel for 72 hours. A 
representative experiment with duplicates of each 
treatment is shown to illustrate the technique. (B) The 
quantified results of the cell viability are shown for each 
OC cell line. The vehicle is the left bar, while the right bar 
represents the relative fluorescence of cells treated with 
cisplatin and paclitaxel. An asterisk (*) is used to indicate 
studies with a p-value <0.01. Data are plotted as means and 
error bars represent the standard deviation among at least 
three biological replicates. 
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3.4. OC cell mitochondria with high Sab expression are primed for apoptosis. Because 
of the Sab-mediated JNK signaling is linked to Bcl-2 levels on mitochondria [33, 45, 49], 
we measured the apoptotic potential in the four OC cell lines. To examine the extent of 
apoptotic priming in each of the cancer cell lines, we first performed dynamic BH3 
profiling [22, 27, 29] to assess the relative extent of priming. The addition of Bim BH3 
peptide caused a rapid depolarization of mitochondrial membrane potential in all four OC 
cell lines; however, the loss of JC-1 fluorescence was slower in  SK-OV-3 cells than PA-1 
(Figure 3.4A). Additionally, the PA-1 and SW-626 cells with higher levels of Sab 
expression were found to have a greater percent depolarization than Caov-3 and SK-OV-3 
cells that have relatively low Sab levels (Figure 3.4B). Consequently, the PA-1 and SW-
626 cells had a greater change in priming (%Priming) compared to Caov-3 and SK-OV-
3 cells (Figure 3.4C). Next, we verified the results of the dynamic BH3 profiling by 
measuring the cytosolic levels of cytochrome c by immunodetection within cytoplasmic 
subcellular fractions in the presence and absence of 500nM Bim-BH3 peptide (Figure 
3.4D; quantified in 3.4E). The extent of cytochrome c present in the cytosol of OC cell 
lines was modest compared to cells treated with 1M STS for two hours (Figure 3.4D and 
3.4E). OC cells with low Sab expression (Caov-3 and SK-OV-3) had decreased 
cytochrome c release into the cytosol compared to cells with higher Sab expression, PA-1, 
and SW-626. To examine if the loss of mitochondrial membrane integrity was indeed due 
to apoptotic priming, the relative levels of Bcl-2 proteins (Bcl-2, Bcl-xL, and Mcl-1), BH3-
only proteins (Bid, Bik, Bim, Bad, and Puma), and pro-apoptotic proteins (Bax and Bak) 
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were measured (Figure 3.4F). The quantified data presented in Supplemental Figure 7 
indicate that PA-1 and SW-626 cells have higher levels of pro-apoptotic BH3-only proteins 
than Caov-3 and SK-OV-3 cells, which have higher levels of pro-survival Bcl-2 proteins. 
This may indicate that ovarian cancer cells with elevated Sab-expression cells may be 
primed for apoptosis.  
3.5. Ectopic expression of Sab induces apoptotic priming. To directly determine if Sab-
mediated signaling contributes to apoptotic priming in ovarian cancer cell lines, we 
ectopically expressed either RFP, Sab, or a Sab mutant incapable of binding JNK (SabKIM1L-
A) [35] (Figure 3.5A) in chemoresistant SK-OV-3 cells over the course of 72 hours (Figure 
3.5B). By 72 hours, Sab was expressed five to seven-fold higher than SK-OV-3 cells that 
are expressing RFP or mock-transfected cells (Figure 3.5B; quantified in Figure 3.5C). 
Dynamic BH3 profiling reveals that SK-OV-3 cells expressing Sab have a greater percent 
depolarization and change in depolarization compared to mock-transfected and RFP- 
expressing cells (Figure 3.5D), an effect that was not observed in cells expressing SabKIM1L-
A (Figure 3.5D). Furthermore, analysis of cytosolic cytochrome c reveals that compared to 
mock transfected and RFP-expressing SK-OV-3 cells, Sab expressing SK-OV-3 cells have 
increased cytosolic cytochrome c (Figure 3.5E). This increase is not observed in SabKIM1L-
A-expressing SK-OV-3 cells (Figure 3.5E). Additionally, the mitochondrial levels of Bcl-2 
family proteins were assessed (Figure 3.5F). Ectopic expression of Sab in SK-OV-3 cells 
changed the relative abundance of Bcl-2 and BH3-only proteins on mitochondria when 
compared to mock transfected, RFP-expressing, and SabKIM1L-A-expressing cells (Figure 
3.5G; quantified in Figure 3.5H). 
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FIGURE 3.4: OC cells with high Sab expression are primed for apoptosis and 
chemosensitive. (A) Dynamic BH3 profiling was used to evaluate the extent of mitochondrial 
priming between PA-1 cells with high Sab expression and SK-OV-3 cells with low Sab levels. 
Cells were treated with vehicle (0.1% DMSO) or 500nM BIM BH3-only peptide and JC-1 
fluorescence was monitored. FCCP/Valinomycin was used to depolarize mitochondria in this 
assay. (B) The percent depolarization and (2) the change relative priming (%Priming) were 
calculated based on the dynamic BH3 profiling for each of the OC cell lines. An asterisk (*) is 
used to indicate studies with a p-value <0.01. (D) The abundance of cytosolic cytochrome c 
was measured using western blot analysis of cytosolic fractions taken from OC cells in the 
absence (top panel) and presence of 500nM BIM peptide (bottom panel). GAPDH was used as 
a cytosolic loading control. The relative fluorescence of cytosolic cytochrome c was quantified 
(right panel). An asterisk (*) is used to indicate studies with a p-value <0.01. (E) Pro-survival 
Bcl-2 protein levels were monitored on isolated mitochondria from each of the four OC cells 
lines; specifically, Bcl-2, Bcl-xL, and Mcl-1 levels were measured, while TOM20 served as a 
mitochondrial loading control. (F) Pro-apoptotic protein levels on mitochondrial were 
measured by western blot analysis. Bim, Bad, Bak, and Bax were detected on isolated 
mitochondria from the OC cell lines and COX-IV was used as a mitochondrial loading control. 
Data are plotted as means and error bars represent the standard deviation among at least three 
biological replicates. 
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FIGURE 3.5: Artificially elevating Sab expression in resistant OC cells increases 
vulnerability to chemotherapy. (A) A schematic representation of Sab showing the two 
leucine residues in the KIM1 motif necessary for JNK binding. The bottom panel shows a Sab-
variant (SabKIM1(L-A)) generated by site-directed mutagenesis that lacks the leucine residues 
required for JNK binding. (B) Ectopic expression of Sab and SabKIM1(L-A) in chemoresistant 
SK-OV-3 cells was assessed using western blot analysis with TOM20 and Tubulin as loading 
controls for mitochondria and whole cell respectively. (C) The relative levels of activated JNK 
(P-JNK) and total JNK (JNK) on mitochondria (top panel) and in whole cell lysates (bottom 
panel) were assessed in SK-OV-3 cells following 45 minutes of 1M STS treatment. (D) 
Dynamic BH3 profiling of SK-OV-3 cells with and without ectopic expression of Sab was 
performed in the presence of vehicle or 500nM BIM peptide, and treatment with 
FCCP/Valinomycin was used as a depolarization control. (E) The %Depolarization and (F) 
%Priming were calculated from the BH3 profiling for SK-OV-3 cells expressing either RFP, 
Sab, or SabKIM1(L-A). An asterisk (*) is used to indicate studies with a p-value <0.01. (G) 
Western blot analysis was used to assess the relative abundance of pro-survival (left panel) and 
pro-apoptotic (right panel) in SK-OV-3 cells expressing either RFP, Sab, or SabKIM1(L-A). Data 
are plotted as means and error bars represent the standard deviation among at least three 
biological replicates. 
3.6. Increasing Sab expression sensitizes SK-OV-3 cells to chemotherapies. Because Sab 
levels may affect apoptotic priming, and we previously demonstrated that increasing Sab 
sensitizes HeLa cells to toxic agents [35], we examined whether ectopic expression of Sab 
enhanced the chemo-responsiveness of resistant SK-OV-3 cells towards cisplatin/paclitaxel 
treatment. To assess cell death in mock-transfected SK-OV-3 cells, cells transfected with an 
empty vector, or cells expressing either Sab or SabKIM1L-A, we utilized microscopic analysis of 
Annexin V and PI staining (Figure 3.6A). Compared to mock-transfected cells and empty 
vector cells, Sab-expressing SK-OV-3 cells had a considerable increase in the number of 
apoptotic cells in the presence of 25M cisplatin and 10M paclitaxel after 72 hours (Figure 
3.6B). Specifically, these cells had a marked rise in the number of late apoptotic cells (those 
cells stained with both Annexin V and PI – Figure 3.5B). SK-OV-3 cells expressing the 
MAPK-binding deficient mutant, SabKIM1L-A, did not differ from mock-transfected and RFP 
expressing SK-OV-3 cells (Figure 3.6B). To complement the microscopic analysis, we 
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performed an assay to detect caspase 3 and 7 activity in the cells exposed to 25M cisplatin 
and 10M paclitaxel. Mock-transfected and empty vector transfected cells had little caspase 
activation following treatment with cisplatin and paclitaxel (Figure 3.6C); conversely, Sab-
expressing cells had a substantial increase in caspase activity in the presence of 
chemotherapeutic agents, which was comparable to SK-OV-3 cells treated with 1M of STS 
for 24 hours (Figure 3.6C). Again, expression of SabKIM1L-A in SK-OV-3 cells did not alter 
caspase activity levels in response to 25M cisplatin and 10M paclitaxel treatment (Figure 
3.6C). To determine if Sab-mediated signaling was involved in cisplatin and paclitaxel-induced 
death in sensitive cell lines, such as PA-1, we incubated PA-1 with increasing amounts of either 
Tat-Scramble or Tat-SabKIM1 and measured the extent of cell death following treatment with 
0.25M cisplatin and 0.10M paclitaxel (Figure 3.6D). Inhibition of Sab-mediated signaling 
with the Tat-SabKIM1 peptide prevented PA-1 cell death following cisplatin and paclitaxel 
administration when compared to untreated and cells treated with Tat-Scramble peptide 
(Figure 3.6D). PA-1 cells treated with a mutant Sab peptide, Tat-SabKIM1L-A, which cannot bind 
MAPKs did not differ from cells treated with the Tat-Scramble peptide (Figure 3.6D). Again, 
we verified the induction of apoptosis in PA-1 cells following 0.25M cisplatin and 0.10M 
paclitaxel treatment by using a caspase activity (Figure 3.6E). PA-1 cells treated with 1M 
Tat-SabKIM1 peptide had decreased caspase activity following treatment with chemotherapy 
agents as compared to cells treated with 1M Tat-Scramble or Tat-SabKIM1L-A (Figure 3.6E). 
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FIGURE 3.6: Inhibiting Sab-mediated signaling in sensitive OC cells enhances resistance. 
(A) Fluorescent microscopy of a TUNEL assay performed on SK-OV-3 cells treated with 
vehicle (0.1% DMSO) or 1M STS for 2 hours. Cells were stained with DAPI for total cell 
number, while Annexin V and PI staining were used to detect early and late apoptosis 
respectively. (B) The TUNEL assays were scored by counting the fluorescent cells in a field 
of view, and based on fluorescence SK-OV-3 cells expressing either RFP, Sab, or SabKIM1(L-A) 
were assessed for apoptosis levels in the presence and absence of 25M cisplatin and 10M 
paclitaxel after 72 hours. (C) Caspase assays were performed using cell lysates obtained from 
SK-OV-3 cells expressing RFP, Sab, or SabKIM1(L-A) that were exposed to 1% DMSO, 
Cisplatin/Paclitaxel for 72 hours, or 1M STS for 24 hours. (D) Chemosensitive PA-1 cells 
with high Sab expression were surveyed for apoptosis using TUNEL assays in the presence 
and absence of 0.25M cisplatin and 0.1M paclitaxel after 72 hours in the presence of 
increasing concentrations of Tat-Scramble, Tat-SabKIM1, or Tat-SabKIM1(L-A) peptides. Both 
early and late apoptotic cells were scored in these experiments. (E) Caspase assays were used 
to assess the extent of apoptosis induced in PA-1 cells treated with cisplatin/paclitaxel and 
1M of either Tat-Scramble, Tat-SabKIM1, or Tat-SabKIM1(L-A) peptides. STS was used as a 
positive control for apoptosis. (F) To selectively impair Sab-mediated signaling in 
chemosensitive PA-1 cells, we used shRNA-mediated gene silencing of Sab. Luciferase-
specific shRNAs were used as a negative control, while two Sab-specific shRNAs were used. 
Additionally, a version of Sab resistant to shRNA #1 was expressed in PA-1 cells treated with 
San shRNA #1 as a rescue control. (G) The levels of Sab were assessed by western blot analysis 
using COX-IV as a mitochondrial loading control and tubulin as a cellular loading control. (H) 
A TUNEL assay was performed to assess the levels of apoptosis in cells treated with Luc or 
Sab shRNAs and compared to a Sab rescue in PA-1 cells. (I) Caspase assays were employed 
to indicate the level of apoptosis in the PA-1 cells treated with shRNAs. An asterisk (*) is used 
to indicate studies with a p-value <0.01. A double asterisk (**) is used to demark differences 
between cell types and distinct treatments. Data are plotted as means and error bars represent 
the standard deviation among at least three biological replicates. 
To confirm that the inhibition of apoptosis observed with the Tat-SabKIM1 peptide was due to 
loss of Sab-mediated signaling, we silenced Sab expression in PA-1 cells using shRNAs 
specific for Sab (Figure 3.6F; quantified in Figure 3.6G).  Cell death induction was restored in 
Sab-deficient PA-1 cells by ectopic expression of a shRNA-resistant Sab construct (Figure 
3.6F and 3.6H) [35]. Additionally, silencing Sab expression in PA-1 cells impaired caspase 
activation when compared to cells expressing a control shRNA (Figure 3.6I), and expression 
of a shRNA-resistant Sab restore caspase activity following 0.25M cisplatin and 0.10M
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paclitaxel treatment. Taken together, these results suggest that Sab facilitates signaling 
necessary to induce apoptosis in OC cells.          
4.Discussion 
Mitochondrial JNK signaling on the OMM scaffold protein Sab has been shown to be an 
instrumental event in the induction of mitochondria-induced cell death; furthermore, 
altering the concentration of Sab-mediated JNK signaling has been shown to affect 
chemosensitivity in tissues (brain and heart) and cancer cells. In our current study, we 
extend these observations by demonstrating that chemoresistant cancer cells have 
diminished Sab expression compared to normal tissue, and restoring or enhancing Sab 
levels on the OMM is critical to reestablishing proper apoptotic signaling in OC cell lines. 
Our analysis of six independent OC transcriptome analyses [38-43] found that Sab mRNA 
levels were reduced over 5-fold when compared to normal tissues (Figure 3.1, Table 3.1). 
Previous studies have demonstrated in various tissues and cell lines that diminished Sab-
mediated signaling prevents apoptosis [33, 36, 47, 48, 50, 51]. To date, there are no 
published reports regarding the transcriptional regulation of Sab. It stands to reason that 
the decreased reliance on mitochondrial health status and the suppression of apoptotic 
mechanisms in cancer cells [19] may be partly responsible for the reduction in Sab 
expression. Indeed, we recently described that JNK-deficient murine embryonic fibroblasts 
(MEFs) had a significant decrease in Sab on the OMM compared to wild-type MEFs [35]. 
In our opinion, this would suggest that perturbations in signal transduction pathways, 
specifically those responsible for apoptosis, may be instrumental to the diminished Sab 
levels in OC. 
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Intriguingly, one OC patient from The Cancer Genome Atlas repository [42] had a Sab-
overexpression phenotype; however, the genomic sequence of Sab from this patient 
possessed premature termination site, which truncated the protein at residue 379 (Sab is 
normally 455 amino acids in length). The loss of the C-terminal portion removes the two 
kinase interaction motifs (KIMs) responsible for mitochondrial MAPK signaling. Without 
the KIMs, it is unlikely that this Sab variant would have any impact on apoptotic induction, 
as previous studies have demonstrated that mutation of the KIMs that disrupt MAPK 
binding prevent the induction of cell death. 
We demonstrated that the relative levels of Sab correlate to chemo-responsiveness in OC 
cells. Over-expression of Sab improved the chemosensitivity of resistant SK-OV-3 cells; 
meanwhile, inhibiting Sab-mediated signaling with the Tat-SabKIM1 peptide or silencing 
Sab expression increased chemoresistance in vulnerable PA-1 cells (Figure 3.2 and 3.5). 
These effects were mediated by the relative levels of JNK on mitochondria. JNK signaling 
has long been implicated in apoptotic responses [52]. JNK signaling can contribute to 
apoptosis through the combination of nuclear and cytosolic/mitochondrial mechanisms.  
The primary mitochondrial alteration facilitated by Sab-mediated JNK signaling in OC 
cells was the change in Bcl-2/BH3-only proteins at mitochondria (Figure 3 and 4). Previous 
research establishes this possibility, as JNK can directly phosphorylate Bcl-2 and BH3-
only proteins affecting their functions and localizations [53]. We observed a marked 
decrease in mitochondrial Bcl-2 levels, an event previously noted in breast cancer cells 
treated with paclitaxel [54, 55]. Following stress, such as chemotherapy, JNK can 
phosphorylate Bcl-2 on Ser70 inducing its migration from the OMM [33, 56]. Furthermore, 
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JNK can impair Bcl-xL activity by phosphorylating Thr47 and Thr115 [45].  Enhancing 
the amount of Sab on the OMM would increase the concentration of activated JNK that 
could modify Bcl-2 proteins and hasten the impairment of anti-apoptotic mechanisms on 
mitochondria. 
JNK can directly phosphorylate BH3-only proteins and increase their pro-apoptotic 
potential. During UV-induced apoptosis JNK has been shown to phosphorylate Bim and 
Bmf [24, 56, 57]. This phosphorylation causes Bim and Bmf to dissociate from dynein and 
myosin V motor complexes and activate Bax and Bak to initiate apoptosis. Furthermore, 
phosphorylation of Bim by JNK can complement JNK’s phosphorylation of Bcl-2 and Bcl-
xL because Bim can bind and neutralize Bcl-2 and Bcl-xL to promote apoptosis as well. 
Additionally, JNK can phosphorylate Bad on Ser128, which promotes apoptosis [58]. Bad, 
similar to Bim, can promote apoptosis by inhibiting Bcl-2 proteins. JNK can improve Bad 
activity by phosphorylating 14-3-3, which causes the release of Bad from the scaffold 
[59]. JNK can also affect the BH3-only proteins of the extrinsic pathway of apoptosis at 
the mitochondrial level. JNK can induce the cleavage of Bid, thereby elevating the levels 
of t-Bid, which will, in turn, activate Bax and Bak [60, 61]. During TNF--evoked 
apoptosis in HeLa cells, JNK activity induces a caspase 8-dependent cleavage of Bid that 
produces the product jBid that promotes the release of Smac/DIABLO [62]. In addition to 
the direct modulation of Bcl-2 function, mitochondrial JNK signaling facilitated by Sab 
would also enhance the activity of BH-3 only proteins contributing to apoptosis in OC cells 
treated with chemotherapy. 
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We have previously demonstrated that increasing Sab levels in mammalian cells can 
increase the vulnerability towards toxic agents. First, we demonstrated that the sub-chronic 
exposure to the chemosensitizer LY294002 increased Sab levels on the OMM, which led 
to an increase in mitochondrial JNK signaling and induction of apoptosis [35]. This data 
combined with our current study would suggest that increasing Sab levels would be a useful 
technique to improve chemo-responsiveness in cancer cells. However, we have recently 
reported that elevated Sab levels in the heart can increase the risk for cardiotoxicity 
following chemotherapy [36]. We show that artificially enhancing Sab in cardiomyocyte 
cell lines sensitized the cells to imatinib [14]. One may anticipate that targeted methods to 
selectively up-regulate Sab expression in OC tumors may be a safer approach to sensitize 
cancer cells than that of widespread Sab increase in the body. 
We propose that Sab levels may be utilized better as a prognostic biomarker to guide the 
selection and magnitude of therapy for OC patients. Specifically, low Sab concentrations 
in a tumor biopsy or resection may suggest a more rigorous therapeutic regimen; whereby, 
high Sab levels may allow for a less ambitious and toxic approach to treating patients. 
Nonetheless, cancer, especially OC, are complex conditions and Sab concentrations may 
need to be considered in the cellular context of the tumor for choosing the most efficacious 
therapeutic approach. Because little is known regarding the regulation of Sab expression, 
future studies in our group will be focused on understanding the molecular mechanisms 
responsible for controlling Sab levels on the OMM. 
Our current study reinforces the important role that scaffold proteins play in regulating the 
cell signaling responses, especially how scaffold proteins, such as Sab, can influence the 
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magnitude and outcomes at specific subcellular sites within cells. We demonstrate that 
increasing the concentration of a specific OMM scaffold protein can enhance signaling 
pathways on mitochondria and alter organelle and cellular physiology. Specifically, we 
have demonstrated that increasing Sab levels in OC cells increases mitochondrial JNK 
signaling and apoptotic priming, which enhances the vulnerability of OC cells to 
chemotherapy agents. Moreover, we uncovered that Sab levels are decreased in OC patient 
samples, and restoring Sab levels in OC cells with low Sab expression enhances chemo-
responsiveness. Thus, assessing Sab expression in the context of genetic and histological 
testing, including dynamic BH3 profiling may be a useful prognostic tool for OC. 
References 
1 Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: 
A Cancer Journal for Clinicians. 55, 74-108 
2 Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M. J. (2008) Cancer 
Statistics, 2008. CA: A Cancer Journal for Clinicians. 58, 71-96 
3 Ledermann , J., Harter , P., Gourley , C., Friedlander , M., Vergote , I., Rustin , G., Scott , 
C., Meier , W., Shapira-Frommer , R., Safra , T., Matei , D., Macpherson , E., Watkins , 
C., Carmichael , J. and Matulonis , U. (2012) Olaparib Maintenance Therapy in Platinum-
Sensitive Relapsed Ovarian Cancer. New England Journal of Medicine. 366, 1382-1392 
4 Gore, M. E., Fryatt, I., Wiltshaw, E. and Dawson, T. (1990) Treatment of relapsed 
carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these 
compounds. Gynecologic Oncology. 36, 207-211 
5 Sandercock, J., Parmar, M. K. B., Torri, V. and Qian, W. (2002) First-line treatment for 
advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer. 87, 815-824 
92 
 
6 Yap, T. A., Carden, C. P. and Kaye, S. B. (2009) Beyond chemotherapy: targeted therapies 
in ovarian cancer. Nat Rev Cancer. 9, 167-181 
7 Placido, S. D., Scambia, G., Vagno, G. D., Naglieri, E., Lombardi, A. V., Biamonte, R., 
Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., Matteis, A. d., Gasparini, G., 
Valerio, M. R., Danese, S., Perrone, F., Lauria, R., Laurentiis, M. D., Greggi, S., Gallo, C. 
and Pignata, S. (2004) Topotecan Compared With No Therapy After Response to Surgery 
and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in 
Ovarian Cancer (MITO-1) Randomized Study. Journal of Clinical Oncology. 22, 2635-
2642 
8 Bookman, M. A., Greer, B. E. and Ozols, R. F. (2003) Optimal therapy of advanced ovarian 
cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on 
GOG0 182-ICON5. International Journal of Gynecological Cancer. 13, 735-740 
9 Spannuth, W. A., Sood, A. K. and Coleman, R. L. (2008) Angiogenesis as a strategic target 
for ovarian cancer therapy. Nat Clin Prac Oncol. 5, 194-204 
10 Mesiano, S., Ferrara, N. and Jaffe, R. B. (1998) Role of Vascular Endothelial Growth 
Factor in Ovarian Cancer. The American Journal of Pathology. 153, 1249-1256 
11 Matei, D., Emerson, R. E., Lai, Y. C., Baldridge, L. A., Rao, J., Yiannoutsos, C. and 
Donner, D. D. (2005) Autocrine activation of PDGFR[alpha] promotes the progression of 
ovarian cancer. Oncogene. 25, 2060-2069 
12 Matei, D., Chang, D. D. and Jeng, M.-H. (2004) Imatinib Mesylate (Gleevec) Inhibits 
Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth 
Factor Receptor α and Akt Inactivation. Clinical Cancer Research. 10, 681-690 
13 Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I. and Boyd, 
J. (2005) Frequent Mutation of the <em>PIK3CA</em> Gene in Ovarian and Breast 
Cancers. Clinical Cancer Research. 11, 2875-2878 
14 Obata, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix-Trench, G., Thomas, E. 
J. and Campbell, I. G. (1998) Frequent PTEN/MMAC Mutations in Endometrioid but not 
Serous or Mucinous Epithelial Ovarian Tumors. Cancer Research. 58, 2095-2097 
15 Wiener, J. R., Windham, T. C., Estrella, V. C., Parikh, N. U., Thall, P. F., Deavers, M. T., 
Bast, R. C., Mills, G. B. and Gallick, G. E. (2003) Activated Src Protein Tyrosine Kinase 
93 
 
Is Overexpressed in Late-Stage Human Ovarian Cancers. Gynecologic Oncology. 88, 73-
79 
16 Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., 
Meuth, M., Curtin, N. J. and Helleday, T. (2005) Specific killing of BRCA2-deficient 
tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434, 913-917 
17 Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. 
L. and Hartmann, L. C. (2008) Folate receptor alpha as a tumor target in epithelial ovarian 
cancer. Gynecologic Oncology. 108, 619-626 
18 Gibbs, D. D., Theti, D. S., Wood, N., Green, M., Raynaud, F., Valenti, M., Forster, M. D., 
Mitchell, F., Bavetsias, V., Henderson, E. and Jackman, A. L. (2005) BGC 945, a Novel 
Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–
Overexpressing Tumors. Cancer Research. 65, 11721-11728 
19 Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell. 
144, 646-674 
20 Chappell, N. P., Teng, P.-n., Hood, B. L., Wang, G., Darcy, K. M., Hamilton, C. A., 
Maxwell, G. L. and Conrads, T. P. (2012) Mitochondrial Proteomic Analysis of Cisplatin 
Resistance in Ovarian Cancer. Journal of Proteome Research. 11, 4605-4614 
21 Ara, G., Kusumoto, T., Korbut, T. T., Cullere-Luengo, F. and Teicher, B. A. (1994) 
<em>cis</em>-Diamminedichloroplatinum(II) Resistant Human Tumor Cell Lines Are 
Collaterally Sensitive to PtCl<sub>4</sub>(Rh-123)<sub>2</sub>: Evidence for 
Mitochondrial Involvement. Cancer Research. 54, 1497-1502 
22 Montero, J., Sarosiek, Kristopher A., DeAngelo, Joseph D., Maertens, O., Ryan, J., Ercan, 
D., Piao, H., Horowitz, Neil S., Berkowitz, Ross S., Matulonis, U., Jänne, Pasi A., Amrein, 
Philip C., Cichowski, K., Drapkin, R. and Letai, A. (2015) Drug-Induced Death Signaling 
Strategy Rapidly Predicts Cancer Response to Chemotherapy. Cell. 160, 977-989 
23 Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. 
G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., Mitsiades, C. S., Matulonis, U. 
A., Drapkin, R., Stone, R., DeAngelo, D. J., McConkey, D. J., Sallan, S. E., Silverman, L., 
Hirsch, M. S., Carrasco, D. R. and Letai, A. (2011) Pretreatment Mitochondrial Priming 
Correlates with Clinical Response to Cytotoxic Chemotherapy. Science. 334, 1129-1133 
94 
 
24 Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S. and Korsmeyer, S. 
J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, 
serving as prototype cancer therapeutics. Cancer Cell. 2, 183-192 
25 Shamas-Din, A., Brahmbhatt, H., Leber, B. and Andrews, D. W. (2011) BH3-only proteins: 
Orchestrators of apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Cell 
Research. 1813, 508-520 
26 Ryan, J. A., Brunelle, J. K. and Letai, A. (2010) Heightened mitochondrial priming is the 
basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proceedings of the 
National Academy of Sciences. 107, 12895-12900 
27 Ryan, J. and Letai, A. (2013) BH3 profiling in whole cells by fluorimeter or FACS. 
Methods. 61, 156-164 
28 Letai, A. G. (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. 
Nat Rev Cancer. 8, 121-132 
29 Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A. 
and Letai, A. (2006) Mitochondria primed by death signals determine cellular addiction to 
antiapoptotic BCL-2 family members. Cancer Cell. 9, 351-365 
30 Chandel, N. S. (2014) Mitochondria as signaling organelles. BMC Biology. 12, 34 
31 Bender, T. and Martinou, J.-C. (2013) Where Killers Meet—Permeabilization of the Outer 
Mitochondrial Membrane during Apoptosis. Cold Spring Harbor Perspectives in Biology. 
5 
32 Brunelle, J. K. and Letai, A. (2009) Control of mitochondrial apoptosis by the Bcl-2 family. 
J Cell Sci. 122, 437-441 
33 Chambers, J. W., Cherry, L., Laughlin, J. D., Figuera-Losada, M. and Lograsso, P. V. 
(2011) Selective inhibition of mitochondrial JNK signaling achieved using peptide 
mimicry of the Sab kinase interacting motif-1 (KIM1). ACS Chem Biol. 6, 808-818 
34 Chambers, J. W. and LoGrasso, P. V. (2011) Mitochondrial c-Jun N-terminal kinase (JNK) 
signaling initiates physiological changes resulting in amplification of reactive oxygen 
species generation. J Biol Chem. 286, 16052-16062 
95 
 
35 Chambers, T. P., Portalatin, G. M., Paudel, I., Robbins, C. J. and Chambers, J. W. (2015) 
Sub-chronic administration of LY294002 sensitizes cervical cancer cells to chemotherapy 
by enhancing mitochondrial JNK signaling. Biochem Biophys Res Commun. 463, 538-544 
36 Chambers, T. P., Santiesteban, L., Gomez, D. and Chambers, J. W. (2017) Sab mediates 
mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity. 
Toxicology. 382, 24-35 
37 Rhodes, D. R., Kalyana-Sundaram, S., Mahavisno, V., Varambally, R., Yu, J., Briggs, B. 
B., Barrette, T. R., Anstet, M. J., Kincead-Beal, C., Kulkarni, P., Varambally, S., Ghosh, 
D. and Chinnaiyan, A. M. (2007) Oncomine 3.0: genes, pathways, and networks in a 
collection of 18,000 cancer gene expression profiles. Neoplasia. 9, 166-180 
38 Adib, T. R., Henderson, S., Perrett, C., Hewitt, D., Bourmpoulia, D., Ledermann, J. and 
Boshoff, C. (2004) Predicting biomarkers for ovarian cancer using gene-expression 
microarrays. Br J Cancer. 90, 686-692 
39 Bonome, T., Levine, D. A., Shih, J., Randonovich, M., Pise-Masison, C. A., Bogomolniy, 
F., Ozbun, L., Brady, J., Barrett, J. C., Boyd, J. and Birrer, M. J. (2008) A Gene Signature 
Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer. Cancer 
Research. 68, 5478-5486 
40 Hendrix, N. D., Wu, R., Kuick, R., Schwartz, D. R., Fearon, E. R. and Cho, K. R. (2006) 
Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt 
Signaling in Ovarian Endometrioid Adenocarcinomas. Cancer Research. 66, 1354-1362 
41 Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., 
Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., Smith, D., Hartmann, L., Fishman, D., 
Berchuck, A., Schmandt, R., Whitaker, R., Gershenson, D. M., Mills, G. B. and Bast, R. 
C. (2004) Selection of Potential Markers for Epithelial Ovarian Cancer with Gene 
Expression Arrays and Recursive Descent Partition Analysis. Clinical Cancer Research. 
10, 3291-3300 
42 Network, T. C. G. A. R. (2011) Integrated genomic analyses of ovarian carcinoma. Nature. 
474, 609-615 
43 Yoshihara, K., Tajima, A., Komata, D., Yamamoto, T., Kodama, S., Fujiwara, H., Suzuki, 
M., Onishi, Y., Hatae, M., Sueyoshi, K., Fujiwara, H., Kudo, Y., Inoue, I. and Tanaka, K. 
(2009) Gene expression profiling of advanced-stage serous ovarian cancers distinguishes 
96 
 
novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Science. 
100, 1421-1428 
44 Aoki, H., Kang, P. M., Hampe, J., Yoshimura, K., Noma, T., Matsuzaki, M. and Izumo, S. 
(2002) Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase 
in adult cardiac myocytes. J Biol Chem. 277, 10244-10250 
45 Kharbanda, S., Saxena, S., Yoshida, K., Pandey, P., Kaneki, M., Wang, Q., Cheng, K., 
Chen, Y. N., Campbell, A., Sudha, T., Yuan, Z. M., Narula, J., Weichselbaum, R., Nalin, 
C. and Kufe, D. (2000) Translocation of SAPK/JNK to mitochondria and interaction with 
Bcl-x(L) in response to DNA damage. J Biol Chem. 275, 322-327 
46 Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Munshi, N., 
Kharbanda, S. and Anderson, K. C. (2003) JNK-dependent release of mitochondrial 
protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 278, 
17593-17596 
47 Nijboer, C. H., Bonestroo, H. J., Zijlstra, J., Kavelaars, A. and Heijnen, C. J. (2013) 
Mitochondrial JNK phosphorylation as a novel therapeutic target to inhibit 
neuroinflammation and apoptosis after neonatal ischemic brain damage. Neurobiol Dis. 54, 
432-444 
48 Win, S., Than, T. A., Min, R. W. M., Aghajan, M. and Kaplowitz, N. (2016) c-Jun N-
terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent 
pathway leading to inactivation of intramitochondrial Src. Hepatology. 63, 1987-2003 
49 Schroeter, H., Boyd, C. S., Ahmed, R., Spencer, J. P., Duncan, R. F., Rice-Evans, C. and 
Cadenas, E. (2003) c-Jun N-terminal kinase (JNK)-mediated modulation of brain 
mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent 
apoptosis. Biochem J. 372, 359-369 
50 Win, S., Than, T. A., Fernandez-Checa, J. C. and Kaplowitz, N. (2014) JNK interaction 
with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death. 
Cell Death Dis. 5, e989 
51 Win, S., Than, T. A., Han, D., Petrovic, L. M. and Kaplowitz, N. (2011) c-Jun N-terminal 
kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor 
(TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem. 286, 35071-
35078 
97 
 
52 Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, D., Jones, 
S. N., Flavell, R. A. and Davis, R. J. (2000) Requirement of JNK for Stress- Induced 
Activation of the Cytochrome c-Mediated Death Pathway. Science. 288, 870-874 
53 Dhanasekaran, D. N. and Reddy, E. P. (2008) JNK signaling in apoptosis. Oncogene. 27, 
6245-6251 
54 Srivastava, R. K., Mi, Q.-S., Hardwick, J. M. and Longo, D. L. (1999) Deletion of the loop 
region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proceedings of the 
National Academy of Sciences. 96, 3775-3780 
55 Yamamoto, K., Ichijo, H. and Korsmeyer, S. J. (1999) BCL-2 Is Phosphorylated and 
Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at 
G2/M. Molecular and Cellular Biology. 19, 8469-8478 
56 Lei, K., Nimnual, A., Zong, W. X., Kennedy, N. J., Flavell, R. A., Thompson, C. B., Bar-
Sagi, D. and Davis, R. J. (2002) The Bax subfamily of Bcl2-related proteins is essential for 
apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol. 22, 4929-
4942 
57 Marani, M., Tenev, T., Hancock, D., Downward, J. and Lemoine, N. R. (2002) 
Identification of Novel Isoforms of the BH3 Domain Protein Bim Which Directly Activate 
Bax To Trigger Apoptosis. Molecular and Cellular Biology. 22, 3577-3589 
58 Donovan, N., Becker, E. B. E., Konishi, Y. and Bonni, A. (2002) JNK Phosphorylation 
and Activation of BAD Couples the Stress-activated Signaling Pathway to the Cell Death 
Machinery. Journal of Biological Chemistry. 277, 40944-40949 
59 Tsuruta, F., Sunayama, J., Mori, Y., Hattori, S., Shimizu, S., Tsujimoto, Y., Yoshioka, K., 
Masuyama, N. and Gotoh, Y. (2004) JNK promotes Bax translocation to mitochondria 
through phosphorylation of 14‐3‐3 proteins. The EMBO Journal. 23, 1889-1899 
60 Sarosiek, Kristopher A., Chi, X., Bachman, John A., Sims, Joshua J., Montero, J., Patel, 
L., Flanagan, A., Andrews, David W., Sorger, P. and Letai, A. (2013) BID Preferentially 
Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy 
Response. Molecular Cell. 51, 751-765 
98 
 
61 Madesh, M., Antonsson, B., Srinivasula, S. M., Alnemri, E. S. and Hajnóczky, G. (2002) 
Rapid Kinetics of tBid-induced Cytochrome c and Smac/DIABLO Release and 
Mitochondrial Depolarization. Journal of Biological Chemistry. 277, 5651-5659 
62 Deng, Y., Ren, X., Yang, L., Lin, Y. and Wu, X. (2003) A JNK-Dependent Pathway Is 
Required for TNFα-Induced Apoptosis. Cell. 115, 61-70 
63 Chambers, J. W., Pachori, A., Howard, S., Ganno, M., Hansen, D., Jr., Kamenecka, T., 
Song, X., Duckett, D., Chen, W., Ling, Y. Y., Cherry, L., Cameron, M. D., Lin, L., Ruiz, 
C. H. and Lograsso, P. (2011) Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors 
Protect Dopaminergic Neurons in a Model of Parkinson's Disease. ACS Chem Neurosci. 
2, 198-206 
64 Laughlin, John D., Nwachukwu, Jerome C., Figuera-Losada, M., Cherry, L., Nettles, 
Kendall W. and LoGrasso, Philip V. (2012) Structural Mechanisms of Allostery and 
Autoinhibition in JNK Family Kinases. Structure. 20, 2174-2184 
65 Vo, T. T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., Deangelo, D. J., 
Frattini, M. G. and Letai, A. (2012) Relative mitochondrial priming of myeloblasts and 
normal HSCs determines chemotherapeutic success in AML. Cell. 151, 344-355 
66 Allen, R. T., Hunter Iii, W. J. and Agrawal, D. K. (1997) Morphological and biochemical 
characterization and analysis of apoptosis. Journal of Pharmacological and Toxicological 
Methods. 37, 215-228 
67 Anuradha, C. D., Kanno, S. and Hirano, S. (2001) Oxidative damage to mitochondria is a 
preliminary step to caspase-3 activation in fluoride-induced apoptosis in HL-60 cells. Free 
Radical Biology and Medicine. 31, 367-373 
68 Kluck, R. M., Bossy-Wetzel, E., Green, D. R. and Newmeyer, D. D. (1997) The release of 
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 
275 
99 
 
 
 
 
 
 
Chapter 5 
SAB CONCENTRATIONS INDICATE CHEMOTHERAPEUTIC 
SUSCEPTIBILITY IN UTERINE CANCER CELLS 
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1. Introduction 
Uterine cancer (UC), the most common gynecological cancer in developed countries [1], 
is a malignancy of the uterus that commonly arises in the endometrium as adenocarcinoma 
[2]. There are approximately 55,000 new cases of UC each year, which accounts for ~3.3% 
of new cancer cases and the prevalence of UC is increasing [1]. UC patients have an 81.7% 
5-year survival rate; accordingly, the UC survival rate drops to 16.9% for metastatic disease 
[3]. Treatment options for uterine cancer include surgery with radiotherapy and 
chemotherapy [4, 5]. Because of the favorable survival rate, the underlying causes of 
treatment resistance in UC have not been extensively investigated. However, metastatic 
UC is typified by treatment resistance [6]; specifically, there is substantial chemo-
resistance toward megestrol acetate, the approved drug for treatment of UC [7]. 
Additionally, UC is often a disease of older women, whereby, most UC diagnoses are made 
between the ages of 45 and 75 years of age [8]. Thus, safer therapeutic alternatives may 
need to be considered due to the increased likelihood of toxic off-target effects in older 
patients [8]. Consequently, understanding the molecular mechanisms driving UC 
oncogenesis and resistance will be instrumental in developing rational therapies targeting 
unique aspects of UC pathophysiology to develop more efficacious and safer UC 
treatments. 
Mitochondria are highly integrated organelles that regulate a myriad of cellular processes 
including cell death [9]. Paramount to mitochondrial apoptotic events are the Bcl-2 family 
of proteins, which control the cell death potential of mitochondria [10]. BH3-only proteins, 
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members of the Bcl-2 family, facilitate apoptotic programming by sequestering the pro-
survival Bcl-2 proteins and mediating the formation of the Bax-Bak pore [11]. The 
formation of the Bax-Bak pore causes mitochondrial outer membrane permeabilization 
(OMMP), which allows for the release of pro-apoptotic components from the mitochondria 
(i.e. cytochrome c, endonuclease G, etc.) [12, 13]. Recently, studies have demonstrated that 
the levels of BH3-only proteins correlate to chemo-responsiveness [14-19]; wherein, high 
BH3-only levels conferred chemo-sensitivity due to elevated OMMP, while low BH3-only 
levels corresponded to chemo-resistance in vitro and in vivo [20-24]. Further, chemical 
induction of BH3-only proteins in chemo-resistant cells improved the chemo-
responsiveness of several cancer cell types [18, 20]. However, the mechanism responsible 
for enhanced BH3-only levels in certain cancers remains elusive. 
Recently, we demonstrated that the chemosensitizer LY294002 [25] altered mitochondrial 
signaling to enhance the effectiveness of radiotherapy and chemotherapeutic agents [25-
27]. In cervical cancer cells (HeLa cells), administration of low-dose LY294002 increased 
the concentration of a mitochondrial scaffold protein Sab, which facilitated chemo-
sensitization [28]. Previously, Sab-mediated signaling events have been linked to 
mitochondrial dysfunction and the induction of apoptosis in numerous cell types and under 
a myriad of conditions [29-34]. Sab facilitates c-Jun N-terminal Kinase (JNK) signaling on 
the outer mitochondrial membrane (OMM) [29, 35, 36]. Specifically, activated JNK 
isoforms can interact with one of two kinase interaction motifs (KIM1/2) neat the C-
terminus of Sab, and ablation of essential residues in the KIM binding sites or use of KIM-
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motif mimicry can prevent JNK translocation to mitochondria along with subsequent 
organelle dysfunction and apoptosis [28, 29, 35-37]. Mitochondrial JNK signaling induces 
apoptosis through the manipulation of Bcl-2 family proteins via posttranslational 
modifications [29, 38-43]. The magnitude of local JNK signaling on Bcl-2 proteins in 
tumors determines the capacity of individual cells to induce apoptosis [44, 45]. 
Furthermore, chemotherapeutic agents have been shown to be potent inducers of 
mitochondrial JNK signaling events [28, 40, 46, 47]. Based on these studies, enhancing 
JNK signaling on mitochondria could be a means to improve therapeutic responsiveness in 
UC patients.  
Because the abundance of scaffold proteins at specific subcellular sites dictate the 
biological outcomes of signaling events [48-50], the goal of the current study is to 
determine if changes in Sab concentrations affect mitochondrial physiology and the 
induction of apoptosis in UC cells. To investigate this possibility, we performed secondary 
data analysis of existing gene expression studies from patients with UC. After observing 
that Sab levels were reduced in UC patient samples with advanced and recurring disease, 
we assessed mitochondrial physiology in a metastatic-derived (AN-3-Ca) and a primary 
site-derived (SKUT-1) cell line. We found that Sab-levels were increased in the primary 
site line compared to the metastatic line. This difference was reflected by the resistance of 
An-3-Ca cells to common chemotherapeutic agents. The AN-3-Ca resistance to 
chemotherapy was mitigated by overexpressing Sab in the cells; contrariwise, silencing 
Sab in chemosensitive SKUT-1 cells promote resistance to chemotherapy agents. After 
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observing this evidence, these results suggest that alteration of Sab expression in late-stage 
UC may be responsible for chemoresistance.  
2. Materials and methods 
Gene Expression Analysis: Secondary data analysis was performed to determine the 
relative levels of Sab expression in UC. The expression of Sab (SH3-binding protein 5; 
SH3BP5) was examined using the Oncomine database (http://www.oncomine.org) in 
October 2017 [51]. By querying available endometrial cancer datasets that included Sab, 
we compared experimental data from normal and malignant tissue. The data were compiled 
across the independent studies. Data are presented as mean fold changes between 
endometrial cancer and control samples or distinct types of endometrial cancers. 
Materials: AN-3-Ca (HTB-111) and SKUT-1 (HTB-114) cells were obtained from 
American Type Culture Collection (Manassas, VA), and metabolic testing reagents were 
acquired from Seahorse Biosciences (Boston, MA). Antibodies were procured from Cell 
Signaling Technologies (Danvers, MA) unless indicated otherwise. Chemotherapeutic 
agents and general laboratory supplies were purchased from Fisher Scientific (Pittsburgh, 
PA) unless alternatively noted below. Near-infrared detection reagents were purchased 
from Li-Cor Biosciences. 
Cell Culture: AN-3-Ca and SKUT-1 cells were grown in Eagle Minimum Essential 
Medium (EMEM) supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin, 
10g/mL streptomycin, and 5g/mL plasmocin (Invivogen). The cells were cultured at 
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37C under humidity with 5% CO2. The cells were counted using the TC10 counter 
(BioRad) in the presence of Trypan blue. 
Determining IC50 for drugs: To examine the relative effectiveness of drugs towards a 
particular cell line, we calculated IC50 for drugs in AN-3-Ca and SKUT-1 cells [28]. Cells 
were plated in a black-walled 96-well plate at a density of 2.0x105 cells per well and grown 
overnight. We tested common and existing chemotherapeutic agents for UC; this group of 
compounds included megestrol acetate, ABT-737, cisplatin, doxorubicin, mitomycin C, 
and paclitaxel. The cells were treated with increasing concentrations of the drug (ranging 
from 0.1nM to 100M on a log10 scale) for 72 hours and were then washed, fixed, and 
stained with TO-PRO-3 for 45 minutes at room temperature. The plate was imaged using 
the Odyssey CLx imager (Li-Cor Biosciences), the fluorescence of each well was 
determined using the ImageStudio 2.0 software (Li-Cor Biosciences), and IC50s were 
calculated using the GraphPad Prism7© software. 
Western blot analysis: Protein analysis from cells was performed as described in our 
previous works [28-30]. Briefly, AN-3-Ca and SKUT-1 cells were plated in either 6-well 
plates or 35-mm2 dishes. Following treatments, cells were washed twice in phosphate 
buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4) 
and lysed in radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH 8.0, 
150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 1mM 
phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase Inhibitor 
Cocktails (Thermo Scientific). Cells were incubated while gently rocking at 4°C for five 
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minutes, and then transferred to a sterile micro-centrifuge tube. After two minutes on ice, 
cell disruption was completed using sonication. The lysate was cleared by centrifugation 
at 14,000 × g for 15 minutes. The protein in the cell lysates was quantified using a BCA 
kit (Pierce BCA Protein Assay Kit) in clear 96-well plates according to the manufacturer’s 
protocol using the Biotek Synergy H1 Microplate Reader. Proteins were then resolved by 
SDS-PAGE and transferred onto low fluorescence PVDF membranes. Membranes were 
placed in blocking buffer comprised of PBS supplemented with either 5% non-fat milk (for 
standard blots) or 5% bovine serum albumin (BSA; for phosphor-specific blots) and 
incubated for at least one hour at room temperature (RT) or overnight at 4°C. The 
membranes were incubated in PBS containing 0.1% Tween 20 (PBST) and either 5% non-
fat milk or BSA in the presence of primary antibodies for at least 2.5 hours (RT) or 
overnight (4oC) while gently rocking. Primary antibodies specific for Sab (Novus 
Biologics, #H00009467-M01), Bcl-2 (Cell Signaling Technologies (CST), 2870), Bcl-xL 
(CST, 2764), Mcl-1 (CST, 5453), Bad (CST, 9239), Bik (CST, 4592), Bim (CST, 2933), 
Bid (CST, 2002), PUMA (CST, 12450), Bax (CST, 5023), Bak (CST, 12105)Actin (CST, 
4970),and  α-tubulin (CST, 2144) were used at dilutions of 1:1000 for these studies. 
Membranes were washed three times for five minutes in PBST. Membranes were incubated 
with secondary antibodies in the appropriate blocking buffer at a ratio of 1:20,000 for one 
hour at RT gently rocking. The following secondary antibodies were used in the 
experiments below: IRDye 680RD Goat anti-Rabbit (926-32211) and IRDye 800CW Goat 
anti-Mouse (926-68070) (Licor Biosciences). Membranes were again washed three times 
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for five minutes in PBST. Membranes were analyzed using fluorescence detection using 
the Odyssey CLx near infrared scanner (Licor Biosciences). The corresponding bands on 
the western blots were quantified and normalized using the Image Studio 2.0 software 
(Licor Biosciences). The fluorescence of specific bands of interest were divided by the 
fluorescence of the loading control band to equilibrate signal strength and loading. The 
resulting signal was then normalized by dividing the signals from treated samples by 
respective untreated or normal tissue control signals for each experiment. 
Metabolic Analysis: Cellular metabolism was assessed by measuring the extracellular 
acidification rate (ECAR) and the oxygen consumption rate (OCR) of UC cells using the 
Seahorse Biosciences XF-96 extracellular flux analyzer [52]. Cells were plated in XF-96 
analyzer plates at 1.0 x104 cells per well and treated as described below. Basal glycolysis 
rates (ECAR) were achieved by supplementing glucose-free assay with 10mM glucose 
(Glc). After 10 minutes, the ECAR was measured; simultaneously, OCR was measured to 
determine the amount of glucose oxidation in each treatment group. Then 1.0M 
oligomycin was added to inhibit ATP-dependent respiration and induce maximum 
glycolysis (or ECAR). While treatment with 100M 2-DOG was used to impair glucose 
utilization and oxidation. For assessing oxygen consumption and substrate oxidation, cells 
were placed in nutrient-free media, and OCR was measured before injection of either 
10mM glucose or 5mM glutamine. Then, a mitochondrial respiratory profile was created. 
Briefly, basal OCR was measured for 20 minutes; next, cells were treated with 1M 
oligomycin for 10 minutes, and then OCR was measured again to determine ATP-
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independent respiration rates. Following that measurement, 1M uncoupler (FCCP) was 
added for 10 minutes, and then maximum OCR was measured. Finally, 1M of rotenone 
and antimycin A was added for 10 minutes to completely inhibit mitochondrial respiration, 
and OCR was measured to assess the amount of non-mitochondrial respiration. From these 
measurements, we derived respiratory parameters, including spare respiratory capacity as 
previously described. All rates were calculated from a minimum of six wells per 
experiment. Data were either normalized to cell number.  
Manipulation of Sab Expression: We transiently transfected UC cells with plasmids 
designed to express Sab (pLOC:Sab), red fluorescent protein (RFP; pLOC:RFP), or a Sab 
mutant lacking MAPK binding motifs (pLOC:SabKIML/A) to evaluate the impact of 
increasing Sab levels. Plasmid DNA and FugeneHD (Promega) were combined in 
Optimem (Invitrogen) at a ratio of 1:6 and incubated for 15 minutes at RT before addition 
to culture. Eight hours after the addition of the transfection complex to media, the media 
was exchanged. Protein levels were assessed by western blot analysis at 72 hours post-
transfection only cells demonstrating more than four-fold increases in Sab levels were used. 
To decrease Sab expression, SKUT-1 cells were transiently transfected with pLKO.1 
plasmids containing shRNAs either a luciferase-specific shRNA (control) or a shRNA for 
Sab that demonstrated over 85% silencing in 72 hours. Ectopic expression of a shRNA-
resistant form of Sab (previously described in (Chambers, TP, 2015)) was used to rescue 
Sab levels in SKUT-1 cells silencing Sab. Briefly, 1.5x104 cells were plated in a 96-well 
plate, or 1.5x105 cells were plated a day before transfection in 35-mm dishes for 
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experiments. Plasmids were mixed with FugeneHD (Promega) at a 6:1 ratio per 
manufacturer’s recommendations and added to cells for up to 72 hours. Protein levels were 
determined by western blotting as described above. 
Replicates and Statistics: Biochemical and other cellular measures were done with a 
minimum of six experimental replicates. Mitochondrial and protein analysis experiments 
were performed on a minimum of three biological replicates. To determine statistical 
significance, Mann-Whitney analysis was employed for significance between treatments 
and a Wilcoxon match pairs test was used to compare groups. One-way analysis of variance 
(ANOVA) was used to compared data across studies. Statistical significance is indicated 
by an asterisk in figures in which the P-value is less than 0.05. Data are displayed in figures 
as means with error bars representing plus and minus one standard deviation. 
3. Results  
3.1. Sab expression is diminished in late-stage uterine cancer and recurrent disease.  
To determine if changes in Sab levels may occur in UC, we used existing studies of 
endometrial cancer gene expression from the Oncomine repository [51]. We segregated 
these data into clinical stage first to determine if Sab concentrations changed during 
progression of the disease. In Figure 4.1A, Sab expression is significantly decreased (nearly 
6-fold) in Stage 4 samples, but not in the other stages of the disease. Similarly, our analysis 
of recurrent tumors versus patient samples from non-recurrent disease, demonstrate that 
Sab levels are markedly decreased (approximately 4-fold) in recurrent tumors compared to 
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non-recurrent (Figure 5.1B). In long-term recurrent disease, Sab mRNA levels are even 
lower (Figure 5.1B) at five years. This data suggest that Sab expression is diminished in 
advanced and recurrent UC. 
 
Figure 4.1: Secondary analysis of Sab expression from uterine cancer microarray studies. (A) 
The amount of Sab mRNA was examined from previous studies, and the patient samples were 
segregated based on the reported stage of the cancer. The distinct types of uterine cancer were 
grouped into clinical classifications. An asterisk (*) indicates a difference as determined by one-
way Analysis of variance (ANOVA). (B) For samples with available data regarding the recurrence 
of disease, Sab expression levels were assessed in regards to disease recurrence at one and five 
years. An asterisk (*) indicates a difference between non-recurring and recurring tumors according 
to the Wilcoxon matched pairs test. Data are displayed as means with error bars representing plus 
and minus one standard deviation. 
3.2.Metastatic AN-3-Ca cells have reduced chemosusceptibility:  
Because of the difference in Sab expression observed in Stage 4 disease, we performed 
comparisons of primary site and metastatic UC cell types. We obtained SKUT-1 and AN-
3-Ca cells that were derived from primary site and metastatic tumors, respectively. First, 
we assessed the relative chemosensitivity of the two lines to observe potential differences 
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using a battery of chemotherapeutic agents. Each drug reflects a different mode of death 
induction in cancer cells providing insight into potential defects in cell death signaling. In 
Table 4.1, the IC50s for megestrol acetate, ABT-737, cisplatin, doxorubicin, mitomycin C, 
and paclitaxel are presented. The metastasis-derived AN-3-Ca cell line consistently 
required more drug to induce cell death compared to primary site-derived SKUT-1 cells.  
3.3. SKUT-1 cells and AN-3-Ca cells are metabolically distinct:  
Because the trend in the IC50 data may suggest a difference in the induction of apoptosis, a 
mitochondrial process, we examined whether mitochondrial function differed between the 
two lines. Using respirometry, we measured the respiratory profile of the two cell lines and 
found that AN-3-Ca cells had a greater oxygen consumption rate (OCR) than SKUT-1 cells 
(Figure 4.2A). This was reflected by higher basal respiration (Figure 4.2B) and a greater 
respiratory capacity (Figure 4.2C) when compared to SKUT-1 cells. Additionally, AN-3-
Ca cells had a higher incidence of uncoupling than SKUT-1 cells (Figure 4.2D), and 
overall, AN-3-Ca cells had a greater OCR/ECAR ratio (Figure 4.2E). Next, we analyzed 
the metabolic parameters related to glycolysis in the two cell lines by assessing the 
extracellular acidification rate (ECAR) (Figure 4.2F). We found that SKUT-1 cells had a 
greater rate of glycolysis than AN-3-Ca cells (Figure 4.2G). Additionally, when 1M 
oligomycin was added to achieve maximum glycolysis, it was found that the  
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Table 4.1: IC50 values for Common Chemotherapy agents for UC cell lines 
 
 
 
Figure 4.2: Mitochondrial metabolism differs between AN-3-Ca and SKUT1 cells. (A) 
Respiratory profile of AN-3-CA and SKUT-1 cells was measured using the Seahorse XF-96 
extracellular flux analyzer. B. Basal respiration, C. Spare respiratory capacity, D. Uncoupling, E. 
Oxidative ratio, F. Extracellular acidification rate, G. Glycolysis, H. Glycolytic Capacity, I. 
Glycolytic reserve, J. Proton leak were measured. Data are displayed as means with error bars 
representing plus and minus one standard deviation. 
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Figure 4.3: Sab concentrations differ between metastatic AN-3-Ca cells and primary site 
SKUT-1 cells. (A) A representative western blot analysis of AN-3-Ca and SKUT-1 cells to assess 
the relative levels of Sab on mitochondria. COX-IV was used as a mitochondrial loading control. 
(B) Quantification of four replicate analysis was performed using Image Studio 2.0. An asterisk (*) 
indicates a difference (P<0.05) between cell lines as determined by a Mann-Whitney test. Data are 
displayed as means with error bars representing plus and minus one standard deviation. 
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Figure 4.4: Increasing Sab concentrations restore chemosensitivity in AN-3-Ca cells. (A) 
Western blot analysis of AN-3-Ca and SKUT-1 cells to assess the relative levels of Bcl-2 protein 
levels. COX-IV was used as a mitochondrial loading control. (B) Ectopic expression of either RFP 
or Sab was assessed by western blot analysis. Additionally, Bcl-2 and Bim levels were measured 
with COX-IV serving as an organelle loading control. (C) Quantification of the changes in Sab, 
Bcl-2, Bim, and Bid were performed using Image Studio 2.0. Differences (P<0.05) between paired 
samples was determined with a Wilcoxon matched pairs test, which are indicated by an asterisk 
(*). Data are displayed as means with error bars representing plus and minus one standard deviation. 
 
two cell lines had a similar capacity for glycolysis (Figure 4.2H); however, SKUT-1 cells 
had a greater glycolytic reserve (Figure 4.2I).   
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Intriguingly, AN-3-Ca cells had a greater proton leak than SKUT-1 cells (Figure 4.2J). 
Taken together, the studies suggest that AN-3-Ca cells and SKUT-1 cells have distinct 
mitochondrial metabolic profiles. 
 3.4 AN-3-Ca cells have diminished Sab concentrations:  
Because our previous work demonstrated that Sab-mediated events could affect chemo-
responsiveness and metabolism in human cancers, we measured the relative abundance of 
Sab in the primary-site-derived SKUT-1 cells and metastatic AN-3-Ca cell lines. In Figure 
4.3A, western blot analyses revealed a significant increase in Sab concentrations in the 
SKUT-1 cells compared to AN-3-Ca cells. The relative Sab fluorescence in these cells was 
normalized to the mitochondrial loading control, cyclo-oxygenase IV (COX-IV), a 
component of respiratory complex IV. Using semi-quantitative analysis, we found that AN-
3-Ca cells had ~8-fold less Sab than SKUT-1 cells (Figure 4.3B). 
3.5 AN-3-Ca cells have increased anti-apoptotic Bcl-2 proteins resulting from 
diminished Sab levels:  
Because of the chemo-responsive and metabolic differences along with the distinct Sab 
concentrations between the two cells, we assessed the expression of hallmark Bcl-2 
proteins in AN-3-Ca and SKUT-1 cells. The specific apoptotic proteins we examined were 
the anti-apoptotic Bcl-2 family proteins: Bcl-2 and Bcl-xL. We also looked at pro-apoptotic 
BH3-only family proteins: Bid, Bim, Bad. In Figure 4A, AN-3-Ca have higher anti-
apoptotic Bcl-2 concentrations (Bcl-2, Bcl-XL) and lower pro-apoptotic Bcl-2 protein 
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levels (Bid, Bim, and Bad) compared to SKUT-1 cells (quantified in Figure 4.4C). To test 
whether the shift in Bcl-2 proteins in AN-3-Ca cells was due to diminished Sab 
concentrations, we overexpressed Sab or red fluorescent protein (RFP) in AN-3-Ca cells 
to determine the effect on Bcl-2 protein levels (Figure 4.4B). Increasing the relative 
abundance of Sab in AN-3-Ca cells resulted in a significant decrease in Bcl-2 protein levels 
that was not observed in cells expressing RFP (Figure 4.4B). Furthermore, elevating Sab 
concentrations in AN-3-Ca cells increased the relative abundance of Bim, an effect that 
was not found in RFP-expressing AN-3-Ca cells (Figure 4.3B). This occurred without a 
significant change in mitochondrial protein levels, as indicated by COX-IV detection 
(Figure 4.3B). To determine whether increasing Sab altered the susceptibility of AN-3-Ca 
cells to chemotherapeutic agents, we examined cell viability following treatment with the 
previously introduced chemotherapeutic agents (Table 5.2). AN-3-Ca cells overexpressing 
cells were significantly more susceptible to chemotherapy agents than cells expressing RFP 
or non-transfected AN-3-Ca cells (Table 4.2). Collectively, these results demonstrate that 
increasing Sab levels alters the chemosensitivity of UC cells by manipulating Bcl-2 family 
protein levels on mitochondria. 
3.6 Silencing Sab expression in SKUT-1 cells induces chemoresistance: 
To examine if altering Sab expression impacted the sensitivity of primary-site derived cells 
to chemotherapy agents, we introduced a plasmid into SKUT-1 cells that expressed either  
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Table 4.2: IC50 values for Chemotherapy agents in AN-3-Ca cells with increasing Sab 
expression.
 
a control (luciferase-specific) small-hairpin RNA (shRNA) or a Sab-specific shRNA. We 
assessed the ability of the shRNAs to affect Sab abundance after 72 hours; wherein, the 
Sab shRNA, but not the control shRNA, reduced Sab levels to a concentration comparable 
to AN-3-Ca cells (Figure 4.5A). These differences were quantified in Figure 4.5B. To 
determine if silencing Sab expression, impaired JNK translocation to mitochondria, we 
purified mitochondria from cells that were treated with 0.01% DMSO or 25M 
staurosporine (STS) to induce JNK translocation to mitochondria. In the presence of 
DMSO, JNK did not become activated or translocate to mitochondria in either cell line or 
the presence of the shRNAs  
We expressed a shRNA-resistant version of Sab as a potential rescue for Sab-mediated 
events (Figure 4.5C). However, the addition of STS triggered JNK translocation to 
mitochondria in SKUT-1cells, as well as in SKUT-1 cells expressing the control and Sab 
shRNAs (Figure 4.5C, bottom panel). The relative abundance of mitochondrial JNK (P-
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JNK) corresponded to the levels of Sab in each cell type (Figure 4.5C), which was 
quantified as (Figure 4.5C, top panel).  
 
Figure 4.5: Silencing Sab in SKUT-1 cells make them chemoresistant. (A) Western blot analysis 
of AN-3-Ca and SKUT-1 after silencing Sab in SKUT-1 cell to assess Sab levels. COX-IV was 
used as a mitochondrial loading control. (B) Quantification of Sab. (C) Western blot analysis of 
active JNK in SKUT-1 cells after silencing of Sab. (D) Quantification of P-JNK was performed 
using the Image Studio 2.0 Software. Differences (P<0.05) between paired samples were 
determined using a Wilcoxon matched pairs test, which are indicated by an asterisk (*). (E) Western 
blot analysis of Bcl-2 and Bim in SKUT-1 cells after silencing of Sab. (F) Relative cytososlic 
cytochrome C released. Data are displayed as means with error bars representing plus and minus 
one standard deviation. 
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well to demonstrate that there was significantly less mitochondrial JNK in SKUT-1 cells 
silencing Sab and rescued by expressing the shRNA-resistant Sab (Figure 4.5D). We also 
examined critical JNK-regulated Bcl-2 proteins, Bcl-2, Bim, and Bid, in the presence and 
absence of the Sab shRNA. Following STS-exposure, Bcl-2 levels decreased in SKUT-1 
cells, but not in cells expressing the Sab shRNA (Figure 4.5E). Mitochondrial Bcl-2 was 
restored by expressing the shRNA-resistant Sab (Figure 4.5E). Contrariwise, the 
concentrations of Bim and Bid increased following STS treatment in SKUT-1 cells, but 
not in cells with the shRNA for Sab (Figure 4.5E). Again, the matriculation of Bim and 
Bid to mitochondria was rescued by expressing the shRNA-resistant form of Sab in SKUT-
1 cells (Figure 4.5E). To determine if the changes in Sab levels affected the apoptotic 
potential in SKUT-1 cells, we measured the amount of cytosolic cytochrome c following 
treatment with STS in SKUT-1 cells with and without Sab-mediated signaling. Again, 
silencing Sab results in less cytosolic cytochrome c release into the cytosol following STS-
treatment, and introducing the shRNA-resistant Sab restores the induction of apoptosis in 
SKUT-1 cells (Figure 4.5F). These data reiterate that Sab is a crucial element of apoptotic 
signaling in UC cells. 
To determine if indeed reducing Sab levels corresponds to chemoresistance, we examined 
the toxicity of chemotherapeutic agents in SKUT-1 cells expressing either the control or 
Sab shRNAs. We found that silencing Sab made SKUT-1 cells significantly less sensitive 
to chemotherapeutic agents (Table 4.3). Thus, the defects in apoptosis corresponded to 
diminished chemo-responsiveness in SKUT-1 cells. These data demonstrate that Sab-
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mediated signaling is crucial to cell death induction in UC cells and decreased Sab levels 
may in part be responsible for the treatment-resistant disease.  
Table 4.3. IC50 values for chemotherapy agents in SKUT-1 cells with diminished Sab 
expression. 
 
4. Discussion 
Late-stage UCs are typified by a poor survival rate; specifically, metastatic UC has only a 
16.9% survival [1]. Because the risk factors are commonplace: obesity, high blood 
pressure, and diabetes mellitus, it’s important to address the low survival of metastatic 
cancer [7]. Our previous work has shown that mitochondrial JNK signaling on the scaffold 
protein Sab is a critical mediator of apoptosis in gynecological cancers cells [28, 29]. 
Furthermore, in Chapter 3, we showed that diminished Sab levels contribute to 
chemoresistance in ovarian cancer. Herein, we used patient-derived data and cellular 
studies to demonstrate the consequences of diminished Sab-mediated signaling in UC. Our 
results demonstrate that Sab expression is down-regulated in UC and restoring Sab levels 
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on mitochondria restores apoptotic induction. These studies provides unique insight into 
the mechanisms driving resistance in late-stage UC. 
Our secondary data analysis of Sab expression in UC patient samples revealed that Sab 
mRNA levels were decreased significantly in late-stage and recurrent disease (Figure 4.1). 
While this reflects our previous observation in ovarian cancer, we did not segregate the 
ovarian patient data into clinical stages nor did we consider recurrence. The late decrease 
in Sab transcripts in advanced disease suggests that the change in Sab expression is in 
response to the progressive pathology of the disease. Our previous work demonstrates that 
mitochondrial JNK signaling, and by extension the expression of Sab, is highly responsive 
to mitochondrial toxins [28, 53, 54]. Since mitochondrial dysfunction is necessary for 
oncogenesis [55], one can postulate that Sab expression may be diminished as cancer cells 
switch to glycolysis and minimize their reliance on mitochondria [56]. Additionally, it is 
possible that prolonged mitochondrial dysfunction could habituate stress signaling failing 
to recognize mitochondrial damage and activate stress responses like mitochondrial JNK 
signaling. Regardless, the transcriptional regulation of Sab in gynecological cancers 
remains a topic of active investigation in our group. 
To examine the role of Sab-mediated signaling in UC physiology, we employed a primary-
site derived cell line (SKUT-1) and a metastatic-derived cell line (AN-3-Ca) to investigate 
early and late-stage UC. Initially, we found that AN-3-Ca cells had greater mitochondrial 
metabolism than SKUT-1 (Figure 2), which would suggest greater integrity of 
mitochondrial membrane potential. This was realized when we discovered that AN-3-Ca 
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cells had a higher concentration of Bcl-2 on the mitochondrial surface [57, 58]. This would 
suggest that the outer membrane of the mitochondria was more intact than the SKUT-1 
cells, which may in part explain the higher levels of respiration. The greater oxidative 
potential of metastatic UC cells may also be necessary to generate ROS needed for invasion 
[59]. Although we have previously shown that Sab can contribute to ROS amplification 
[53], it is likely that the significant levels of uncoupling and proton leak in AN-3-Ca cells 
(Figure 2) suggest a level of mitochondrial dysfunction that may be sufficient to generate 
the levels of ROS needed for metastasis.  
SKUT-1 cells were found to be more glycolytic, which is the hallmark metabolic feature 
of cancers [55]. This may also be partly explained by the increased levels of Sab in older 
patients. Specifically, in the aging brain, mitochondrial JNK signaling has been shown to 
impair the activity of pyruvate dehydrogenase reducing the amount of glucose oxidation 
[60, 61]. Alternatively, JNK signaling has been shown to influence a myriad of metabolic 
signaling [62]. One mechanism JNK signaling could employ is to phosphorylate Bcl-2 
proteins and alter their functions. Bcl-2 proteins have been shown to contribute to 
metabolic flux in mammalian cells [63, 64], and altering their mitochondrial functions 
could contribute to this outcome. 
The predominant impact of diminished Sab levels appears to be on the induction of 
apoptosis. UC cells with low Sab levels had increased anti-apoptotic Bcl-2 proteins and 
were resistant to chemotherapeutic agents; alternatively, cells with high Sab levels or 
restoring Sab levels increased the levels of pro-apoptotic BH3-only proteins on 
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mitochondria resulting in greater sensitivity to chemotherapeutic drugs. The specific 
change was a decrease in Bcl-2 levels on mitochondria and an increase in Bim and Bid. 
These drugs are well-established JNK targets [38], and the manipulation of these proteins 
occurs either at mitochondria or via JNK activity on the common scaffold 14-3-3 [65]. 
Mitochondrial JNK is a potent inducer of apoptosis following cytosolic stress, so increasing 
the magnitude of mitochondrial JNK signaling could greatly enhance apoptotic responses 
in cancer cells. However, this should be considered with caution, since elevating 
mitochondrial JNK signaling can induce off-target effects such as cardiotoxicity of 
chemotherapy agents [30]. This is of particular concern in older patients, which is the 
largest population of UC patients [3].  
These studies demonstrate that diminished Sab-mediated signaling in advanced UC can 
contribute to apoptotic resistance. Consequently, the concentration of Sab in tumors could 
be used as a prognostic to determine the relative dose of chemotherapy needed to treat a 
UC patient; alternatively, therapeutic approaches aimed at increasing Sab-mediated 
signaling could be potent chemosensitizing agents if their actions can be limited to cancers 
cells. We propose that investigation of Sab in more cells lines and in patient-derived 
xenograft models are needed to validate Sab as a prognostic marker or therapeutic target. 
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Chapter 5 
A HIGH-THROUGHPUT ASSAY TO SCREEN FOR COMPOUNDS 
ELEVATING SAB CONCENTRATIONS IN CHEMO-RESISTANT HUMAN 
OVARIAN CANCER CELLS. 
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1. Introduction 
With a mortality rate of approximately 55%, ovarian cancer (OC) is the deadliest 
gynecological malignancy due to the high level of recurrent and therapeutic resistant 
disease. The risk of developing recurrent OC in a woman’s lifetime is 1 in 79 and risk of 
dying from invasive OC is 1 in 109, which highlights the seriousness of OC [1, 2]. Even 
though numerous treatments are available for OC, the recurrence and resistance to available 
therapies is a substantial problem for effectively treating patients.  Thus, there is a need for 
more advanced treatments that target the unique aspects of OC biology in recurrent and 
resistant cases for complete, efficacious management of OC. 
Sab (SH3-binding protein 5, SH3BP5) is an outer mitochondrial scaffold protein that 
facilitates signal transduction events at the organelle-cell interface [3, 4]. Specifically, the 
interaction between Sab and the c-Jun N-terminal kinase (JNK) leads to inhibition of 
mitochondrial respiration, generation of reactive oxygen species, and the onset of 
mitochondrial dysfunction [5-7]. The JNK-Sab interaction (Mito-JNK signaling) is a 
crucial component of the intrinsic-apoptotic cell death following many toxic insults 
including chemotherapy agents [8-11]. Furthermore, inhibiting JNK or selectively 
targeting the JNK-Sab interactions protects various cell types from mitochondrial 
dysfunction and cell death [5, 6, 12-17]. Chambers et al. demonstrated that interfering with 
the JNK-Sab interaction blocks JNK-mediated Bcl-2 phosphorylation and emigration from 
the outer mitochondrial membrane [5]. Lastly, in different models of human disease, Mito-
JNK signaling is essential for mitochondrial dysfunction and apoptosis [5, 6, 12-15, 17]. 
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Enhanced Mito-JNK signaling has been linked to an increased capacity to induce apoptosis 
in cells with elevated Sab concentrations on mitochondria [6, 18]. Thus, increasing Sab 
levels was exploited as a strategy to enhance the efficacy of chemotherapeutic agents in 
drug-resistant cancer cells. LY294002 is an inhibitor of the PI3K signaling pathway, and 
it is used to improve chemotherapeutic efficacy [6, 18]. We observed an increase in Sab 
concentrations on the outer mitochondrial membrane with sub-chronic low dose treatment 
of LY294002, which caused the increase in the mitochondrial JNK level during stress. 
Elevated Sab resulted in a decrease in IC50 values of commonly used chemotherapeutic 
drugs, cisplatin, and paclitaxel [18]. However, the concentration of LY294002 was higher 
than physiologically-relevant drug concentrations [19]. As discussed in Chapter 3, the level 
of Sab expression corresponded to apoptotic priming and drug efficacy in ovarian cancer 
(OC) cell lines. Furthermore, we observed that increasing Sab levels enhances pro-
apoptotic Mito-JNK signaling in OC (Chapter 3) and endometrial (Chapter 4) cells. 
Clinically, gene expression (microarray) data from the Oncomine repository shows that 
Sab expression is diminished significantly in OC tumors compared to normal tissue 
controls. The low levels of Sab in patients also corresponded to disease resistance and poor 
survival as well. Hence, we propose that therapeutics aimed at increasing Sab levels in 
gynecological cancers can be used to improve chemotherapeutic efficacy in treatment-
resistant gynecological cancers.  
Our studies in OC demonstrate that Sab may be a biomarker for apoptotic priming and 
chemo-sensitivity. Small molecules capable of increasing Sab levels in chemoresistant 
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cancer cells can render these cells sensitive to established therapies, which represents a 
new, innovative venue for treating gynecological malignancies.  Molecular target-based 
therapy is considered a new approach for designing and prioritizing OC treatments, and 
Sab may represent a potential target for these efforts. Moreover, small molecules affecting 
Sab expression will provide unique insight into mechanisms of OC resistance and 
regulation of mitochondrial physiology and JNK signaling. 
To determine if Sab expression could be modulated by small molecules, we developed a 
highly-specific and reproducible In-cell western (ICW) assay, a quantitative 
immunofluorescence-based technique used to detect protein levels [20], to detect the 
relative levels of Sab in chemoresistant OC cells. After determining antibody specificity, a 
small panel of 80 compounds was used to identify compounds that induced Sab expression 
over 72 hours. We found that mitochondrial toxins and estrogens were the most potent 
inducers of Sab expression, while cyclic AMP analogs and inducers of protein kinase A 
(PKA) signaling significantly impaired Sab levels. Each compound class was verified in 
cell culture with conventional western blot analysis; RT-PCR analysis of Sab expression 
did not always correlate to Sab levels. After validation, the ICW was used to screen a 
scaffold ranking plate (over 50 compound classes) and a positional scanning library (over 
3,000 individual compounds) from the Torrey Pines Institute for Molecular Studies. We 
identified seven (7) distinct scaffolds that significantly elevated Sab expression in 
chemoresistant SK-OV-3 cells. From the two best scaffold families, we screened over 900 
compounds, and more than forty of those compounds increased Sab-expression. Also, 
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greater than 20 compounds were robustly lethal to SK-OV-3 and may represent new 
therapeutic classes to treat resistant diseases. We propose that the Sab ICW is a robust 
approach to survey small molecules for impacts on Sab protein levels in cells.  
2. Methods 
2.1. Cells and Tissue Culture  
Human HeLa, Hek-293T, and HepG2 cells were cultured in Dulbucco’s Minimal Essental 
Media (DMEM) containing 10% fetal bovine serum (FBS), 100U/ml Penicillin, 10g/ml 
streptomycin and 5g/ml plasmocin. Human SK-OV-3 (ATCC HTB-77) ovarian 
carcinoma cells were grown in McCoy’s 5A (Thermo-Fisher Scientific #SH30200.01) 
media supplemented with 10% fetal bovine serum (FBS), 100U/ml Penicillin, 100g/ml 
streptomycin and 5g/ml plasmocin under normal cell culture conditions (at 37˚C and 5% 
CO2). Cells were grown to approximately 80% confluency were trypsinized using TrypLE 
Express (Life Technologies #12604-013) and counted with the TC10 cell counter (Bio-
Rad) using trypan blue exclusion dye.  
2.2 Antibody Validation and Optimization 
The Sab monoclonal antibody (Novus Biologics #H00009467-M01) was validated using 
cell lines with varying levels of Sab expression. We isolated a HEK-293T clone that did 
not express Sab (based on RT-PCR for Sab transcripts), and this line, called HEK-293T-
381 (“Sab null”), was used as a negative control. Additionally, we used shRNAs (described 
in Chapter 3) to reduce Sab-expression; meanwhile, pLOC:Sab was used to increase Sab 
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levels in HeLa cells. Western blots were performed on these cell lines to make sure that 
the Sab antibody only detected Sab protein in human cells [5, 6, 18]. 
2.3 In-Cell Western  
After optimization of cell number, reagent concentrations, and assay volumes, we 
developed the following protocol for the Sab ICW. Black walled clear bottom 96 well plate 
(Thermo Scientific #H2861653050) was seeded with a 200l mixture of trypsinized cells 
and media, with a count of 20,000 cells per well. Three hours after plating cells were treated 
with either 1M of known compounds for 72 hours or 50g/ml for compounds in scaffold 
ranking and lead discovery for 16 hours at normal cell culture conditions. Cells were fixed 
with 4% paraformaldehyde (Santa Cruz Biotechnology #SC-281692) for 20 minutes at 
room temperature (RT). 
The cells were quenched with 100mM glycine for 5 minutes at RT. Cells were 
permeabilized using phosphate-buffered saline (PBS) with 0.2% Triton X-100, gently 
rocking for 20 minutes at RT. After permeabilization, the cells were blocked with 150l of 
LI-COR blocking buffer (LI-COR Biosciences, 927-40100), gently rocking the plate for 
90 minutes at RT. Sab antibody was diluted in blocking buffer at a ratio of 1:1000 and 
100l of this solution was added to each well. The plate was incubated on a rocker for 2.5 
hours at RT and then washed with 100l of PBST (PBS+0.1% Tween-20) for 5 minutes 
rocking at RT. This was repeated five times. A 1:800 ratio of anti-mouse secondary 
antibody (IRDye 800CW anti-mouse, LI-COR Biosciences, 926-32210) and 1:1000 ratio 
of 1mM of TO-PRO-3 (Invitrogen) were diluted in blocking buffer to make the secondary 
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antibody solution. Cells were incubated with 100l of secondary antibody solution in each 
well for 45 minutes gently rocking at RT. The plate was washed five times with PBST. The 
wash buffer was removed, and the plate was scanned in Odyssey scanner, and the protein 
expression was quantified using the LI-COR In-cell western analysis in the Image Studio 
2.0 (LI-Cor). Compounds that induced robust cell death, as indicated by a complete loss of 
TO-PRO-3 fluorescence, were noted, but these compounds were not included in our 
analysis of Sab expression. Instead, lethal compounds were checked for toxicity in HEK-
293T cells to determine if the cell death was selective towards SK-OV-3 cells. A list of 
known compounds (and their classifications) used for optimization and primary testing can 
be found in Table 5.1.  
2.4 Drug Treatments for Validation 
To determine if drugs identified in the ICW screen did indeed affect Sab levels in SK-OV-
3 cells, we plated 2.5x106 SK-OV-3 cells in the wells of two replicate six-well plate. Each 
well of the plate was then either left untreated or treated with 0.1% dimethylsulfoxide 
(DMSO) or 0.01M, 0.1M, 1M, or 10M of the identified compound. The cells grew in 
these conditions for 72 hours.  
2.5 Validation of Sab Levels 
From the cell cultures described above, one plate was used to harvest RNA according to 
the Qiagen RNEasy Kit protocol, and a second plate was lysed and used for traditional 
western blot analysis. Cells were lysed, and proteins were quantified according to our 
previous studies (see Chapter 3). The RNA was used for RT-PCR analysis to evaluate if 
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the compound affected Sab expression, while the cell lysates samples were used to assess 
the impact of Sab protein levels. RT-PCR data were normalized to the relative levels of 
housekeeping genes, actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
pyruvate kinase (PK), lactate dehydrogenase (LDH), and ATP synthase subunit F1. 
Protein levels were normalized to tubulin for cellular analyses, while VDAC was used as 
a mitochondrial normalization control. In the absence of another Sab antibody recognizing 
a distinct epitope, we used relative JNK translocation to mitochondria to determine if JNK 
levels were increased or decreased following particular drug treatments in response to 
cytotoxic stress. Briefly, cells were grown in three (3) 150mm2 plates and exposed to 
candidate compounds at a non-toxic dose for 72 hours. The cells were then exposed to 
25M Anisomycin for 45 minutes. Mitochondria were isolated using our established 
protocol (see references). Mitochondria were lysed using RIPA and analyzed for western 
blot analysis for the relative levels of JNK. Results were quantified using the Image Studio 
2.0 software.   
2.6 Assessment of Cell Viability and Chemotherapeutic Efficacy 
We performed dynamic BH3-profiling, determined the IC50 values for cisplatin and 
paclitaxel, and assessed relative cell viability using a panel of assays in the presence of 
cisplatin/paclitaxel after 72 hours of exposure to the identified compounds to evaluate the 
impact on drug efficacy. The methods for measuring IC50 values and cytotoxicity 
assessments were described in the previous chapters.  
2.7 Statistics 
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Cell-based measures and traditional western blotting data were analyzed by performing 
Mann-Whitney U Tests for direct comparisons, and analysis of variance was performed to 
compared multiple compounds. For studies involving cell-based screening, assay quality 
was determined using a Z’ calculation of positive (Sab-overexpressing cells) and negative 
controls (Sab-silenced cells) using the equation described in [21]. The Z’ was interpreted 
in regards to the coefficient of variation (CV) for specific cells. Only measures with >15% 
between basal measures and positive and negative controls were considered for used. Valid 
assays parameters were considered those that had a Z’ score >0.675 and CV greater than 
50%. Reproducibility was determined between measures using a Tukey post-hoc analysis. 
3. Results 
3.1 Development of a reliable ICW to detect Sab levels in human cell lines and OC 
cells.  
To develop our in-cell western (ICW) approach, we selected an antibody previously used 
in our lab to monitor Sab levels in cell lysates and tissue homogenates. To be sure that the 
antibody would be selective enough for use in a high-throughput screening assay, we 
measured the antibodies specificity in cell lines that did not express Sab (HEK-293T-381 
– Sab-null), HEK-293T, and HEK-293 cells overexpressing Sab (pLOC:Sab) and silencing 
Sab (pLKO.1:shSab). Accordingly, the antibody did not detect the anticipated Sab band 
nor any additional bands in the Sab null cells (Figure 5.1). While different levels of Sab 
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were found in HEK-293T, and HEK-293T cells with increased and decreased Sab 
expression (Figure 5.1). COX-IV was used to demonstrate equal loading  
of mitochondrial  
Figure 5.1: Validation of the Sab-specific antibody for assay development A western blot 
analysis of HEK-293T cells was performed with an antibody (Novus Biologicals) specific for 
human Sab. The HEK-293T cells were transfected with plasmids for silencing Sab (pLKO:shSab), 
which expressed a Sab shRNA, and pLOC:Sab, a plasmid that over-expressed Sab. A HEK-293T 
clone that did not express Sab (Sab null) was used as a negative control. An extended membrane 
image is presented to demonstrate the minimal non-specific binding of the antibody. COX-IV was 
used as a mitochondrial loading control, while Ponceau S was used to demonstrate equal loading 
among cell types. 
 
Proteins and Ponceau staining of membranes were used as a loading control (Figure 5.1).  
After validating the reliability of the antibody, we optimized cell conditions to develop an 
assay that provided a sufficient dynamic range between Sab null and Sab overexpressing 
HEK-293T cells. In Figure 5.2, we demonstrate the signal distribution of the in-cell western 
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in the different HEK-293T types. The assay has a dynamic range of 10-fold on a log scale 
which is a large dynamic range for a high-throughput assay.  
 
Figure 5.2: Optimizing the ICW for detection of distinct levels of Sab in cells. (top panel) The 
ICW was performed in a 96-well plate, and the Sab-related fluorescence was determined using the 
Odyssey CLx imager. Repeated measures (20) were performed for each cell type with 16 blank 
wells. (Bottom panel) Sab fluorescence distributions were plotted for each condition, and a Z’ score 
was calculate to be 0.76 between Sab-null and normal HEK-293T cells suggesting a strong assay. 
 
3.2 Pilot studies reveal that mitochondrial toxins and estrogens increase Sab 
expression. 
To determine if Sab levels could be manipulated by pharmacological agents, we used a 
small pool (62) of compounds from the LOPAC 1280 library that were known to impact 
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mitochondrial physiology and cellular kinase cascades to examine to impact on Sab levels. 
We plated 12,000 HEK-293T cells in a 96-well plate and treated with compounds at a 10-
fold dilution from manufacturer’s preparation. We performed the ICW at 72 hours post-
treatment. The data were analyzed, and Sab-fluorescence was normalized to viable cells 
 
Figure 5.3: A preliminary screen to examine Sab levels following pharmacological 
treatments. (left) Normalized Sab fluorescence was plotted, and the relative change with respect 
to controls was plotted on a volcano plot. Assay controls for Sab-expression, such as over-
expression, silencing, and JNK inhibitors are highlighted. (right) A table summarizing the 
compounds that increased and decreased Sab levels in HEK-293T cells. The P-value and pathways 
are noted to the right of the compound effect ratio. 
 
by TO-PRO-3 staining. The data were plotted on a volcano plot to observe Sab 
concentration trends  (Figure 5.3).  
The compounds responsible for the accumulation of Sab in cells were mitochondrial toxins, 
such as antimycin and benzo[]pyrene, and inflammatory compounds, like TNF-. 
Alternatively, antioxidants were found to decrease Sab levels in cells. Intriguingly, 
estrogen metabolites were also found to decrease Sab levels. Intriguingly, PKA modulators 
were potent effectors of Sab levels; wherein, inhibition of PKA by H89 increased Sab 
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concentrations, while activation of PKA by forskolin decreased Sab levels. This 
preliminary screen indicated that the ICW is a valid tool to detect changes in Sab abundance 
in cells and identify compounds that affect Sab concentrations. 
 
 
Figure 5.4: A redeveloped ICW for Sab detection in chemoresistant SK-OV-3 cells. (left) A 
representative validation assay for SK-OV-3 cells. (right) The Z’ score calculation for four (4) 
replicate assay. A high Z’ score of 0.8156 was achieved indicating a strong assay. 
3.3 Examination of the scaffold ranking library from Torrey Pines Institute for 
Molecular Studies (TPIMS). To identify compounds that could increase Sab levels in 
chemoresistant OC cells, we re-optimized the assay for SK-OV-3 cells (see Chapter 3). 
The redeveloped assay is shown in Figure 5.4.  
To determine if pharmacological agents could increase Sab levels in SK-OV-3 cells, we 
took the most potent Sab enhancers from our preliminary screen and used those molecules 
to assess the feasibility of elevating Sab in resistant OC cells. In Figure 5.5, H89, 
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LY294002, antimycin, rotenone, oligomycin, and hydrogen peroxide (H2O2) were exposed 
to SK-OV-3 cells at increasing doses for up to 72 hours, and the Sab ICW was performed. 
All of the compounds except oligomycin increased Sab expression in SK-OV-3 cells 
(Figure 5.5). This result confirms that Sab levels can be increased by pharmacological 
agents in SK-OV-3 cells. 
 
Figure 5.5: A feasibility screen for detecting changes in Sab levels in SK-OV-3 cells. (left) A 
representative assay in SK-OV-3 cells using compounds known to enhance Sab levels in HEK-
293T cells. We plated 15,000 cells per well and treated them with increasing concentrations of 
drugs for up to 72 hours. The Sab ICW was performed after treatment. (right) The quantification 
of three replicate assays was performed with Sab fluorescence normalized to TO-PRO-3 staining. 
One-way ANOVAs were performed to identify significant differences as indicated by an * 
(P<0.05). Data are displayed as means with error bars representing plus and minus one standard 
deviation. 
Next, we utilized a scaffold-ranking and positional-scanning library from the Torrey Pines 
Institute for Molecular Studies (TPIMS, Port St. Lucie, FL) to identify new compounds 
that could increase Sab concentrations in chemoresistant OC cells. We screened ~50 
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scaffold families in a randomized plate from TPIMS. We plated the cells and treated with 
compound families from TPIMS for 48 hours and applied the Sab ICW. Two separate 
screens were performed per batch (Figure 5.6A), and after the assay we applied our 
statistical parameters to identify prospective compound families (Figure 5.6B & 5.6C). 
  
 
Figure 5.6: A scaffold ranking screen and compound criteria for the TPIMS library. (A) A 
representative screen in SK-OV-3 cells using compounds from TPIMS. We plated 15,000 cells per 
well and treated them with increasing concentrations of drugs for 48 hours. The Sab ICW was 
performed after treatment. (B) The quantification criteria for assessing Sab levels and (C) viability 
by TO-PRO-3 staining. 
The screen netted seven (7) compound families that could be viable compounds for 
elevating Sab expression in chemoresistant OC cells. We took those compounds and we 
assayed the compounds in the ICW to validate the compounds as Sab inducers. In Figure 
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5.7, the secondary screen is shown, and a spaghetti plot shows that one group elevated Sab 
expression significantly, and that family was 1661, suggesting it may be a useful 
chemosensitizer.  
 
Figure 5.7: A positional scanning screen to identify best-in-class compounds from the TPIMS 
library. (left) A representative screen in SK-OV-3 cells using compound families from TPIMS. 
We plated 15,000 cells per well and treated them with increasing concentrations of drugs for 48 
hours. The Sab ICW was performed after treatment. (right) Quantification of the assay illustrates 
the increase with Sab fluorescence in response drug dose. 
Lastly, we evaluated family 1661 in SK-OV-3 cells to determine if the compound elevated 
Sab and to assess the impact on viability. We performed a dose-dependent ICW for 
compound family 1661, and we found that the compound family did increase Sab 
expression in a dose-dependent manner and had limited impact on viability in a 
physiologically relevant dose range (Figure 5.8A). These measures are quantified in Figure 
5.8B. We then treated SK-OV-3 with 1661 at increasing concentrations in two replicate 
preparation from TPIMS. In these studies (Figure 5.8C), Sab levels increase in a dose-
dependent manner without impacting mitochondrial protein concentration (indicated by 
COX-IV levels). Ponceau staining was used as a loading control. These results demonstrate 
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that family 1661 could be a potent enhancer of Sab protein levels in chemoresistant OC 
cells or OC tumors. 
 
Figure 5.8: Evaluation of family 1661 in SK-OV-3 cells. A. Dose-dependent ICW for family 
1661. B. Quantification of A. C. SK-OV-3 cells were treated with increasing dose of compound 
family 166. Sab level increases in a dose-dependent manner. Data are displayed as means with error 
bars representing plus and minus one standard deviation. 
4. Discussion 
The ability to predict tumor-specific vulnerabilities to therapeutic regimes will be an 
invaluable resource aiding personalized medical efforts, and such technologies will 
improve patient outcomes associated with ovarian cancer. In the current work, we describe 
a high-throughput technique to quantify the Sab concentrations in human cell lines with 
the aim of identifying compounds capable of increasing Sab levels to improve 
chemotherapeutic efficacy. This approach has many advantages over traditional way to 
quantify protein expression. Western blotting has been used as a major approach to 
quantify protein expression; however, this high-throughput ICW is advantageous over low-
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throughput WB. WB is labor-intensive and time-consuming. There is a requirement of 
more resources, i.e., more cells and more compounds or drugs, however, with this 
approach, the experiment can be done in one well of a microplate, which saves time and 
resources. There is a 100-fold decrease in volume in micro-plate compared to the 
experiment done in Petri-dishes [20]. As we have screened scaffold of compounds, this 
approach was very useful for detection of Sab-level. During western blotting, while lysing 
the cells, we use different detergents, and this might interfere with the protein detection, 
however, in ICW assay we detect the protein within the cell without interfering with its 
expression. With the fixation step, there might be a change in fluorescence signal. We used 
4% PFA in PBS with less fluorescence property [20]. We also experimented without using 
the fixation agent and didn’t observe a significant difference in fluorescence signal with or 
without fixation. The approach that we developed uses TO-PRO-3 for antibody 
normalization which is a preferred method [22]. TO-PRO-3 is a DNA staining dye and is 
used to normalize the number of cells. TO-PRO-3 stains the live cells, hence it also detects 
the cytotoxicity of the compound under screening. Because of the availability of two 
separate lasers and two different fluorescence channel in Odyssey Imager, we could detect 
two different targets, the antigen of our interest (Sab) and TO-PRO-3 dye. The fluorescent 
antibody is detected at 800nm channel while the TO-PRO-3 stain is detected at 700nm 
channel. The emission spectra are separated by 100nm, showing minimum interference in 
the signal. 
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As suggested by Chen et al., antibody specificity is critical for validation of ICW assay. 
We observed a single band of Sab in western blotting, showing the specificity of Sab in 
SKOV-3 cells [22]. The antibody is highly specific, as we do not see any alternate bands 
(Figure 5.1), which makes it an ideal candidate for assay development. More importantly, 
the specificity of the antibody provided an opportunity for a large dynamic range (Figure 
5.2). This 10-fold change will permit the identification of robust as well as modest 
modulation of Sab concentrations in cells, which will be essential to elucidate the 
regulation of Sab in different tissues and cell types. More importantly, a range of effective 
compounds can be identified for use in OC studies; whereby, a modest, non-toxic 
adjustment in Sab levels may be required to restore apoptotic capacity. 
The demonstration that Sab levels could be altered by pharmacological agents was crucial 
to establishing our assay (Figures 5.3 and 5.5) because if we could not manipulate Sab with 
chemicals, the only other option would be through gene therapy approaches, which are not 
ready for clinical use. It was interesting that manipulation of PKA signaling had such a 
profound effect on Sab levels. This observation is interesting in part because mitochondrial 
PKA signaling has been shown to sustain mitochondrial health and improve cell survival 
[23-28]. These are the opposite effects of mitochondrial JNK signaling. It is interesting to 
conjecture that protective PKA signaling may post-translationally impair detrimental Sab-
mediated events in human cells. Alternatively, enhanced Sab mediated signaling may be 
required to disengage the protection of PKA in apoptotic cells. The relationship of these 
two signaling pathways is ongoing in our lab. 
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A potent enhancer of Sab levels were mitochondrial toxins. Indeed, we have shown that 
mitochondrial JNK signaling is responsive to mitochondrial stress and JNK signaling 
regulates Sab expression [7, 18]. This data suggests that the upregulation of Sab following 
mitochondrial damage may be a stress response rather than an abortive mechanism. 
Similarly, TNF-a is a potent activator of JNK signaling during inflammation, and JNK is 
responsible for activation transcriptional responses in immune responses; however, the role 
of mitochondrial JNK is this regard is still unknown [29]. Further studies will be needed to 
determine the physiological role of mitochondrial JNK signaling on Sab. 
The presence of estradiol as a negative regulator of Sab levels was equally interesting 
because estrogen has been shown to regulate AP-1 transcription, a target activated by JNK. 
Also, estrogen has been shown to prevent neurodegeneration in Parkinson’s models where 
our work has demonstrated that Sab-mediated JNK signaling drives neuron loss in the 
substantia nigra [15, 30-32]. Alternatively, estrogen has been shown to induce JNK-
mediated apoptosis in cancer cells [33, 34]. It is likely the impact of estrogen signaling on 
JNK-mediated processes will be cell type and tissue-specific; thus, elucidating the impact 
of estrogen signaling on Sab levels in OC cells will be important since estrogen can be used 
as hormone therapy in gynecological cancers [35-37]. 
We used this technique to screen the compounds that could increase Sab expression in 
SKOV-3 cells. As mentioned previously, increasing Sab expression sensitizes the cancer 
cells for chemotherapeutic agents [18]. We were looking for compounds that would 
increase the Sab expression with less cytotoxic effect, eventually causing less harm to 
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normal cells (Figure 7). Our screening strategy was to find the compounds that would 
increase the Sab expression by 30% with least effect on the viability of the cells. As shown 
in Figure 5.4, the assay was highly reproducible with the screening of same compounds. 
We identified a compound family 1661 that will be the topic of ongoing development for 
use in preclinical OC models. Regardless of the outcome of 1661, we have developed an 
assay that can be used to screen existing chemical as possible agents to improve 
chemotherapeutic efficacy in chemoresistant OC cells. 
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Chapter 6 
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The goal of this research project was to identify and characterize molecular events 
responsible for therapeutic resistance in gynecological cancers. Our rationale was that once 
mechanisms driving resistance and recurrence are known therapeutic approaches can be 
developed to target these events. Our previous research has focused on how changes in 
mitochondrial signaling influence the susceptibility of mammalian cells toward cytotoxic 
stimuli. Specifically, we have reported that increasing Sab-mediated signaling sensitizes 
cells to stressors in a JNK dependent manner. The result of this change in mitochondrial 
signaling is a lower threshold for the induction of apoptosis. Thus, we hypothesized that 
diminished Sab expression in gynecological cancers might contribute to chemotherapeutic 
resistance in late-stage disease. To see if this was the case, we examined gene expression 
data from patients and manipulated Sab expression in ovarian and uterine cancer cells to 
determine how Sab-mediated events impacted the chemoresponsiveness of cancer cells. 
Ultimately, we found that decreased Sab levels in gynecological cancer cell lines prevent 
proper induction of apoptosis, and restoring Sab levels resulting in improved 
chemosensitization. Finally, we used a high-throughput approach to identify 
pharmacological agents capable of increasing Sab levels in chemoresistant ovarian cancer 
cells. Future studies will revolve around elucidating the impact of Sab levels on 
gynecological cancers in preclinical models. 
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A summary of the primary findings from each of the project aims can be found below. 
 
First, we identified a decrease in Sab expression using microarray data obtained from 
ovarian cancer patient tumors. Ovarian cancer cell lines were obtained and characterized 
based on the relative abundance of Sab and the relative responsiveness to chemotherapeutic 
drugs. We found that the cell lines expressing low levels of Sab were resistant to these 
chemotherapeutic drugs while the cell lines with a high level of Sab showed responsiveness 
to chemotherapeutic drugs. Sab levels were then manipulated by ectopic expression or gene 
silencing, which changes the magnitude of mitochondrial JNK signaling in ovarian cancer 
cells. Cells expressing a high level of Sab are primed for apoptosis, which means these 
cells have a higher level of pro-apoptotic BH3-only proteins and low level of anti-apoptotic 
Bcl-2 proteins. Hence our result suggests, Sab level reflects the concentration of BH3 only 
proteins. Dynamic BH3-profiling can determine chemoresponsiveness in cancer cells. Sab 
profiling along with dynamic BH3-profiling can be used as a combined approach to predict 
chemoresponsiveness in the ovarian cancer patient. 
 
Second, we examined the impact of Sab levels on chemosusceptibility in uterine cancer. 
Analysis of patient samples revealed that Sab expression was diminished in advanced and 
recurrent uterine cancers. We used two different cell lines; a primary-site derived cell line 
with high Sab levels and a metastatic-derived cell line with low Sab expression. We 
assessed mitochondrial physiology and apoptotic capacity in these cells and found that low 
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Sab concentrations in the metastatic cell line corresponded to elevated respiration and 
proton leak, which was accompanied by elevated levels of anti-apoptotic Bcl-2 proteins. 
Uterine cancer cells with elevated Sab concentrations were more glycolytic and had a 
greater abundance of pro-apoptotic BH3-only proteins.  Like ovarian cancer cells, uterine 
cancer cells with a higher level of Sab were sensitive to chemotherapeutic drugs and had 
higher expression of pro-apoptotic BH3 only proteins.  
 
Finally, we surmised that pharmacological agents capable of elevating Sab concentrations 
could be used to prime gynecological cancer cells for apoptosis and lower the dose of 
chemotherapy. Not only could this approach improve the effectiveness of existing drugs, 
but the lower dose would mean that there would be less of a chance for off-target toxicity. 
To identify chemicals capable of increasing Sab in resistant cancer cells, we developed an 
in-cell western method to detect the relative abundance of Sab cancer cells. The approach 
was validated in HEK-293T cells where it was found that mitochondrial toxins and 
inhibitors of PKA were potent enhancers of Sab levels. The in-cell western was then 
applied to chemoresistant ovarian cancer cells and screened against a scaffold ranking 
library from the Torrey Pines Institute for Molecular Studies. We found promising 
compounds capable of increasing Sab levels in SK-OV-3 cells. Thus, the Sab in-cell 
western can be used as a method of screening compounds for novel therapies or to 
determine the relative responsiveness of patient cancers to specific therapies. Detecting the 
level of Sab in patients’ tumor would help to determine the dose and efficacy of 
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chemotherapeutic drugs. We propose this technique can be a useful tool in personalized 
medicine. 
 
The main limitation of our study is the use of cell lines instead of patient-derived tumors. 
The cell lines might not be representative of tumor cells from patients. Cell lines may 
develop additional mutations during adaptation to culture conditions, and additional 
genetic variations (i.e., epigenetic changes) not representative of the real cancer cells. 
Additionally, the cell lines used in our studies were from different patients and distinct 
genetic backgrounds. These difference may also explain the differences in Sab-levels rather 
than mechanisms responsible for oncogenesis; likewise, these discrete differences among 
cell lines may also explain the susceptibility to chemotherapeutic agents. Thus, increasing 
Sab levels may be a means to lower the chemosensitivity of all cells and the phenomenon 
may not be specific to gynecological cancers. Further, recent studies preliminarily conclude 
that stem cells within tumors may be responsible for chemoresistance. Because we did not 
use stem cells from gynecological tumors, we may have missed other factors contributing 
to chemoresistance. Thus, future studies will focus on the isolation and characterization of 
chemoresponsiveness from patient-derived samples. 
 
Another concern is that increasing Sab levels in cells of distinct genetic background all 
enhanced the responsiveness of cells to chemotherapy agents. When viewed in light of our 
studies in cardiomyocytes demonstrating that increasing the levels of Sab enhances the 
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effect of toxic exposures, it appears as though increasing Sab levels could lower the 
apoptotic threshold for all cell types. This means that, if compounds were found that could 
increase Sab levels in gynecological cancers, the drugs would have to be selectively 
targeted to cancer cells to avoid off-target toxicities. This highlights the importance of 
characterizing Sab-mediated signaling in many tissues before delivering potential therapies 
to patients. 
 
Another pitfall of our study is the sample size, for ovarian cancer study we have used four 
cell lines while for uterine cancer study only two cell lines. The number of cell lines is too 
small to derive any true conclusions regarding Sab-mediated signaling and 
chemoresistance in gynecological cancers. Again, future studies with more cell types of 
appropriate origins will be needed to ascertain the true relevance of Sab-mediated signaling 
changes in gynecological cancers.  
 
Despite the limitations of the current study, our study opens a new avenue for connecting 
Sab-mediated OMM signaling to the physiology, prognosis, and treatment of 
gynecological cancers. 
 
In closing, we have found that Sab levels indicate the relative apoptotic capacity in 
gynecological cancer cells and increasing Sab levels represents a unique approach to 
improve therapeutic outcomes in patients.  
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Supplementary Information for Chapter 3  
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SUPPLEMENTAL FIGURE 1: Sab is not present in non-mitochondrial subcellular 
fractions from OC cell lines.  
 
SUPPLEMENTAL FIGURE 2: Quantification of Phospho-JNK and JNK levels on 
untreated and STS-treated OC cell lines. 
 
SUPPLEMENTAL FIGURE 3: Anisomycin stress induces mitochondrial JNK 
translocation, and demonstrates differences in mitochondrial JNK signaling among 
the four OC cell lines. 
 
SUPPLEMENTAL FIGURE 4: TO-PRO-3 Assays were used to determine cellular 
IC50 values for chemotherapeutic drugs. 
 
SUPPLEMENTAL FIGURE 5: Correlation plots of IC50 values for the four OC cell 
lines. 
 
SUPPLEMENTAL FIGURE 6: Quantification of Bcl-2 and BH3-only western 
analysis of OC Cell Lines. 
 
SUPPLEMENTAL FIGURE 7: Ectopic Expression of Sab in SK-OV-3 cells does 
not impact the cellular apoptosis profile. 
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